decitabine profile

ID Source	ID
PubMed CID	451668
CHEMBL ID	1201129
CHEBI ID	50131
SCHEMBL ID	4006
MeSH ID	M0062824

Synonym
AC-1135
HY-A0004
AB00918337-07
5-aza-2'-deoxycytidine ,
2353-33-5
2'-deoxy-5-azacytidine
nsc-127716
decitabine ,
dezocitidine
azadc
5-aza-cdr
dacogen
e-7373
CHEBI:50131 ,
DAC ,
decitabine (usan/inn)
D03665
dacogen (tn)
MOLMAP_000063
5-azadeoxycytidine
NCGC_5ADOC ,
MLS001332588
1,3, 5-triazin-2(1h)-one, 4-amino-1-(2-deoxy--d-erythro-pentofuranosyl)-
4-amino-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,3,5-triazin-2-one
5-azadc
5-aza-dc
nsc 127716
einecs 219-089-4
2-desoxy-5-azacytidine
c8h12n4o4
s-triazin-2(1h)-one, 4-amino-1-(2-deoxy-beta-d-erythro-pentofuranosyl)-
brn 0617982
decitabine [usan:inn:ban]
5-aza-2'-deoxycytidine, >=97%
DB01262
4-amino-1-(2-deoxy-beta-d-erythro-pentofuranosyl)-s-triazin-2(1h)-one
4-amino-1-(2-deoxy-beta-d-erythro-pentofuranosyl)-1,3,5-triazin-2(1h)-one
azadc compound
5a2dc
5-aza-2-deoxycytidine
smr000857076
MLS001332587 ,
4-amino-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one
CHEMBL1201129
4-amino-1-[(2s,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one
776b62cq27 ,
ccris 8227
jnj 30979754
unii-776b62cq27
2-deoxyazacytidine
jnj-30979754
5-aza-deoxycytidine
dtxcid5010432
dtxsid7030432 ,
cas-2353-33-5
tox21_112311
BCP9000593
HMS2235O03
BCP0726000271
NCGC00166088-05
cid_451668
bdbm96274
1,3,5-triazin-2(1h)-one, 4-amino-1-(2-deoxy-.beta.-d-erythro-pentofuranosyl)-
decitabine [mart.]
decitabine [inn]
decitabine [vandf]
decitabine [orange book]
decitabine [mi]
astx-727 component decitabine
inqovi component decitabine
decitabine [who-dd]
decitabine component of inqovi
astx727 component decitabine
decitabine [usan]
4-amino-1-(2-deoxy-.beta.-d-erythro-pentofuranosyl)-s-triazin-2(1h)-one
CS-0372
S1200
AKOS015895047
gtpl6805
astx-727
inqovi (decitabine + cedazuridine)
astx727 (decitabine + cedazuridine)
CCG-208143
MLS006010136
SCHEMBL4006
tox21_112311_1
NCGC00166088-02
J-700084
XAUDJQYHKZQPEU-KVQBGUIXSA-N
4-amino-1-(2-deoxy-?-d-erythro-pentofuranosyl)-1,3,5-triazin-2(1h)-one
4-amino-1-((2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1,3,5-triazin-2(1h)-one
5-aza-2'-deoxycytidine (decitabine)
HB1356
4-amino-1-(2-deoxy-beta-d-erythro-pento furanosyl)-1,3,5-triazin-2(1h)-one
AB00918337_08
mfcd00043011
4-amino-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydro-1,3,5-triazin-2-one
EX-A961
sr-01000838879
SR-01000838879-4
deoxy-5-azacytidine
SW218076-2
decitabine (2 inverted exclamation marka-deoxy-5-azacytidine).cd
HMS3677L07
AS-17558
BCP02870
HMS3413L07
Q1181878
decitabine (nsc127716; 5aza-cdr)
decitabine, free base
AMY33354
compound, azadc
2' deoxy 5 azacytidine
5 aza 2' deoxycytidine
5azadc
5 azadeoxycytidine
decitabine- bio-x
BA164359
EN300-269341
decitabinum
2'-desoxy-5-azacytidine
l01bc08
decitabina
decitabine (mart.)
Z2467077030

Excerpt	Reference	Relevance
"Decitabine (DAC) is an inhibitor of DNA methyltransferase used to treat leukemia, but primary or secondary resistance to DAC may develop during therapy. "	( Abnormal regulation of miR-29b-ID1 signaling is involved in the process of decitabine resistance in leukemia cells. Jin, Y; Lin, J; Ma, J; Qian, J; Wen, X; Xia, P; Xu, Z, 2023)	2.58
"Decitabine is a DNA-hypomethylating agent that has been widely applied for the treatment of acute myeloid leukaemia (AML) patients who are elderly or unfit for intensive therapy. "	( Multi-dimensional analysis identifies an immune signature predicting response to decitabine treatment in elderly patients with AML. Claxton, DF; Ehmann, WC; Hohl, RJ; Jia, B; Mineishi, S; Naik, S; Rybka, WB; Schell, TD; Sivik, JM; Songdej, N; Wang, M; Zeng, H; Zhao, C; Zheng, H, 2020)	2.23
"Decitabine (DAC) is an FDA-approved DNA methyltransferase (DNMT) inhibitor that is used in the treatment of patients with myelodysplastic syndromes. "	( TERT and DNMT1 expression predict sensitivity to decitabine in gliomas. Arrillaga-Romany, I; Cahill, D; Herold-Mende, C; Monje, M; Park, JW; Sahm, F; Steffl, B; Turcan, Ş; Wick, W, 2021)	2.32
"Decitabine (DAC) is a pyrimidine analogue of the nucleoside cytidine, which can lead to injury to endothelium."	( Decitabine-induced kidney thrombotic microangiopathy with glomerular crescents formation and tubular necrosis: A case report. Qin, AB; Su, T; Tan, Y, 2020)	2.72
"Decitabine (DAC) is a well-known DNA methyltransferase inhibitor, which has been widely used for the treatment of acute myeloid leukemia (AML). "	( Decitabine Downregulates TIGAR to Induce Apoptosis and Autophagy in Myeloid Leukemia Cells. Hong, M; Li, L; Liu, W; Qian, S; Sun, Q; Zhu, H, 2021)	3.51
"Decitabine is an approved hypomethylating agent used for treating hematological malignancies. "	( Decitabine Promotes Modulation in Phenotype and Function of Monocytes and Macrophages That Drive Immune Response Regulation. Cardoso-Silva, PM; Castro, RC; Emery, FDS; Fontanari, C; Frantz, FG; Zambuzi, FA, 2021)	3.51
"Decitabine is a deoxycytidine nucleoside derivative inhibitor of DNA-methyltransferases, which has been studied extensively and is approved for myelodysplastic syndrome in adults but with less focus in children. "	( A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML. Alvaro, F; Arceci, RJ; Arndt, C; Barnette, P; Boklan, J; Carpten, J; Cooper, T; Farrar, JE; Gooden, GC; Gore, L; Lee, D; Legendre, C; Liang, WS; Macy, ME; Martin, L; Meshinchi, S; Narendran, A; Pollard, J; Salhia, B; Triche, TJ; Wai, D, 2017)	2.17
"Decitabine (DAC) is a hypomethylating drug used in myelodisplastic syndrome, that has been shown to exert immunomodulatory effects."	( Decitabine induces regulatory T cells, inhibits the production of IFN-gamma and IL-17 and exerts preventive and therapeutic efficacy in rodent experimental autoimmune neuritis. Bramanti, P; Chikovani, T; Colletti, G; Fagone, P; Mammana, S; Mangano, K; Mazzon, E; Nicoletti, F; Saraceno, A, 2018)	2.64
"Decitabine bridge is a safe regimen before allo-HSCT in children with refractory hematological malignancies."	( [The safety of decitabine as bridging pretreatment regimen before hematopoietic stem cell transplantation in pediatric hematological malignancies]. Bian, XN; Fan, LY; Hu, SY; Kong, LJ; Li, J; Ling, J; Liu, H; Lu, J; Xiao, PF; Yao, YH, 2018)	1.56
"Decitabine (DAC) is an epigenetic modulating agent that induces tumor suppressor gene reexpression based on its gene-specific DNA hypomethylation."	( Synergistic Efficacy of the Demethylation Agent Decitabine in Combination With the Protease Inhibitor Bortezomib for Treating Multiple Myeloma Through the Wnt/β-Catenin Pathway. Chen, X; Dong, B; Feng, J; Gao, G; Gu, H; Jin, Y; Shu, M; Wu, X; Xu, L; Zhang, J, 2019)	1.49
"Decitabine is a DNA methyltransferase inhibitor and is considered a promising drug to treat myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) with p53 mutations. "	( Opposing effects of acute versus chronic inhibition of p53 on decitabine's efficacy in myeloid neoplasms. Asada, S; Fukuyama, T; Goyama, S; Hayashi, Y; Kitamura, T; Liu, X; Tamura, M; Tanaka, Y; Yonezawa, T, 2019)	2.2
"Decitabine (Dacogen(®)) is a deoxynucleoside analogue of cytidine that selectively inhibits DNA methyltransferases. "	( Decitabine: a review of its use in older patients with acute myeloid leukaemia. Curran, MP, 2013)	3.28
"Decitabine is a methylation inhibitor, which has different action mechanism and targeting characteristics from the traditional chemotherapy, representing a new therapeutic strategy."	( [Research progress of epigenetic drug decitabine in AML]. Li, HM; Zhang, R, 2014)	1.39
"Decitabine is a hypomethylating agent that irreversibly inhibits DNA methyltransferase I, inducing leukemic differentiation and re-expression of epigenetically silenced putative tumor antigens. "	( Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome. Abboud, CN; Cashen, AF; Choi, J; DiPersio, JF; Fiala, MA; Gao, F; Holt, M; Jacoby, MA; Pusic, I; Stockerl-Goldstein, KE; Uy, GL; Vij, R; Westervelt, P, 2015)	2.16
"Thus decitabine is an effective therapy during bridge time to HSCT in patients with MDS and AML."	( [Therapeutic efficacies of decitabine application prior to hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia]. Fu, C; Han, Y; Jin, Z; Liu, H; Ma, L; Miao, M; Qiu, H; Tang, X; Wang, J; Wang, P; Wu, D; Yan, S; Zheng, H; Zhou, J, 2015)	1.23
"Decitabine is a viable therapeutic option for patients with MPN-AML, MP-AP and high-risk PMF."	( Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase. Badar, T; Borthakur, G; Cortes, JE; Daver, N; Jabbour, E; Kantarjian, HM; Newberry, KJ; Pemmaraju, N; Pierce, SR; Ravandi, F; Verstovsek, S, 2015)	1.45
"Guadecitabine (SGI-110) is a novel hypomethylating dinucleotide of decitabine and deoxyguanosine resistant to degradation by cytidine deaminase."	( Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. Azab, M; Chung, W; Daver, N; Griffiths, EA; Hao, Y; Issa, JJ; Jabbour, E; Kantarjian, H; Lowder, JN; Naim, S; O'Connell, C; Oganesian, A; Rizzieri, D; Roboz, G; Stock, W; Taverna, P; Tibes, R; Walsh, K; Yee, K, 2015)	1.22
"Decitabine is a pyrimidine analog incorporated into DNA, where it irreversibly inhibits DNA methyltransferases through covalent adduct formation with the enzyme."	( The European Medicines Agency Review of Decitabine (Dacogen) for the Treatment of Adult Patients With Acute Myeloid Leukemia: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use. Béhanzin, E; Bowen, D; Demolis, P; Flores, B; Gisselbrecht, C; Hudson, I; Moreau, A; Nieto, M; Pignatti, F; Salmonson, T; Stemplewski, H, 2016)	1.42
"Decitabine is an effective therapy for patients with lower risk myelodysplastic syndrome (MDS). "	( Increased PD-1/STAT1 ratio may account for the survival benefit in decitabine therapy for lower risk myelodysplastic syndrome. Chang, CK; Guo, J; He, Q; Li, X; Song, LX; Su, JY; Tao, Y; Wu, D; Wu, LY; Xiao, C; Xu, F; Zhang, Z; Zhou, LY, 2017)	2.13
"Decitabine is a hypomethylating agent with activity in myelodysplastic syndrome (MDS). "	( Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome. Champlin, R; Davisson, J; de Lima, M; De Padua Silva, L; Faderl, S; Garcia-Manero, G; Giralt, S; Issa, JP; Kantarjian, H; Kebriaei, P; Ravandi, F, 2009)	2.04
"Decitabine is a cytidine analogue that has activity as a hypomethylating agent and has been evaluated in the therapy of patients with high-risk MDS."	( Decitabine in the treatment of myelodysplastic syndromes. Garcia-Manero, G; Issa, JP; Kantarjian, H; Ravandi, F; Santos, FP, 2010)	2.52
"Decitabine is a synthesized cytosine analog that is a potent inhibitor of DNA methylation. "	( Decitabine, independent of apoptosis, exerts its cytotoxic effects on cell growth in melanoma cells. Chen, DW; Liu, QY; Wang, HZ; Xie, LP; Zhang, RQ, 2011)	3.25
"Decitabine is a nucleoside analog used in the treatment for myelodysplastic syndrome. "	( Decitabine triphosphate levels in peripheral blood mononuclear cells from patients receiving prolonged low-dose decitabine administration: a pilot study. Beijnen, JH; Jansen, RS; Keizer, RJ; Rosing, H; Schellens, JH; Wijermans, PW, 2012)	3.26
"Decitabine is a hypomethylating agent with proven clinical efficacy in myelodysplastic syndrome (MDS). "	( Genome-wide single-nucleotide polymorphism array-based karyotyping in myelodysplastic syndrome and chronic myelomonocytic leukemia and its impact on treatment outcomes following decitabine treatment. Do, YR; Huh, J; Kim, DD; Kim, H; Kim, HJ; Kim, KH; Kim, MK; Kim, SH; Kim, T; Mun, YC; Yi, JH, 2013)	2.03
"Decitabine is a hypomethylating agent that has activity in patients with leukemia. "	( Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias. Andersson, B; Champlin, R; Couriel, D; de Lima, M; Donato, M; Gajewski, J; Giralt, S; Kantarjian, H; Khouri, I; Ravandi, F; Shahjahan, M; van Besien, K, 2003)	2.01
"Decitabine is a hypomethylating agent that has shown encouraging preliminary anti-CML activity."	( Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Andreeff, M; Cortes, J; Faderl, S; Garcia-Manero, G; Giles, FJ; Issa, JP; Kantarjian, HM; Keating, M; O'Brien, S; Rios, MB; Shan, J; Talpaz, M, 2003)	1.43
"Decitabine is a cytosine analogue synthesized in the 1960s that is currently enjoying a revival of interest prompted by the elucidation of DNA methylation inhibition as its major mechanism of action, along with increased understanding of the role of DNA methylation in epigenetic dysregulation in cancer. "	( Decitabine. Issa, JP, 2003)	3.2
"Decitabine (DAC) is a small molecule nucleotide analog that is incorporated into DNA and traps human DNA methyltransferases. "	( Decitabine: development of a DNA methyltransferase inhibitor for hematological malignancies. Bayar, E; Fine, G; Lyons, J; McCullar, M; Rolens, R; Rosenfeld, C; Rubinfeld, J, 2003)	3.2
"Decitabine is a DNA methyltransferase inhibitor under development by SuperGen Inc and MGI Pharma Inc for the potential treatment of a range of hematological malignancies, including myelodysplastic syndrome, solid tumors and sickle cell disease."	( Decitabine. MGI Pharma Inc/SuperGen Inc. Arthur, C, 2004)	3.21
"Decitabine appears to be a promising new therapy for the treatment of MDS; however, defining the optimal dosing schedule and exploring the possible use in combination with other agents such as the histone deacetylase inhibitors need further evaluation."	( Decitabine in myelodysplastic syndromes. Saba, HI; Wijermans, PW, 2005)	2.49
"Decitabine is a potent demethylating agent that exhibits clinical activity against myeloid malignancies. "	( 5-Aza-2'-deoxycytidine (decitabine) can relieve p21WAF1 repression in human acute myeloid leukemia by a mechanism involving release of histone deacetylase 1 (HDAC1) without requiring p21WAF1 promoter demethylation. Decoteau, JF; Dong, WF; Geyer, CR; Hirsch, C; Ichinohasama, R; Sanche, SE; Scott, SA; Sheridan, D, 2006)	2.08
"Decitabine is a hypomethylating agent. "	( Decitabine: in myelodysplastic syndromes. Croom, KF; McKeage, K, 2006)	3.22
"Decitabine is a hypomethylating agent that is incorporated into DNA and forms irreversible covalent adducts with DNA-methyltransferases."	( The role of decitabine in the treatment of myelodysplastic syndromes. Atallah, E; Garcia-Manero, G; Kantarjian, H, 2007)	1.44

Excerpt	Reference	Relevance
"Decitabine has a short serum half-life and limited stability in tissue culture."	( Recurrent transcriptional responses in AML and MDS patients treated with decitabine. Beales, J; Gruszczynska, A; Ley, TJ; Link, DC; Miller, CA; Petti, AA; Ramakrishnan, SM; Shah, NM; Upadhyay, P; Welch, JS, 2022)	1.67
"Decitabine has a short serum half-life and limited stability in tissue culture."	( Recurrent transcriptional responses in AML and MDS patients treated with decitabine. Beales, J; Gruszczynska, A; Ley, TJ; Link, DC; Miller, CA; Petti, AA; Ramakrishnan, SM; Shah, NM; Upadhyay, P; Welch, JS, 2022)	1.67
"Decitabine has frequently been deployed but its efficacy and safety profile are not well described in this population."	( Clinical Benefit Derived from Decitabine Therapy for Advanced Phases of Myeloproliferative Neoplasms. Hoffman, R; Kremyanskaya, M; Li, L; Mascarenhas, J; Moshier, E; Najfeld, V; Tremblay, D; Zhou, S, 2021)	1.63
"Decitabine has been explored as a reduced-intensity therapy for older or unfit patients with acute myeloid leukemia (AML). "	( Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimen. Abboud, CN; Ali, AM; Cashen, AF; DiPersio, JF; Fehniger, TA; Gao, F; Ghobadi, A; Jacoby, MA; Oh, ST; Pusic, I; Romee, R; Schroeder, MA; Stockerl-Goldstein, KE; Uy, GL; Vij, R; Wartman, LD; Weisel, D; Welch, JS; Westervelt, P, 2017)	2.11
"Decitabine (DAC) has been reported to enhance the immunogenicity of tumor cells, thereby reinstating endogenous immune recognition and tumor lysis."	( Decitabine Inhibits Gamma Delta T Cell Cytotoxicity by Promoting KIR2DL2/3 Expression. Chen, J; Chen, Y; Cui, J; Li, M; Li, W; Liu, Y; Niu, C; Xu, D; Zhou, L; Zhu, S, 2018)	2.64
"Decitabine, which has been approved to treat MDS, cannot eliminate malignant clones of MDS."	( Successful treatment of high-risk myelodysplastic syndrome with decitabine-based chemotherapy followed by haploidentical lymphocyte infusion: A case report and literature review. Ma, Y; Shen, J; Wang, LX, 2018)	1.44
"Decitabine has shown clinical benefits in patients with intermediate (INT)-2 or high-risk myelodysplastic syndrome (MDS), determined according to the International Prognostic Scoring System (IPSS), but the benefits have not been well demonstrated in patients with lower-risk (IPSS low or INT-1) disease. "	( Clinical Outcomes of Decitabine Treatment for Patients With Lower-Risk Myelodysplastic Syndrome on the Basis of the International Prognostic Scoring System. Chang, MH; Choi, CW; Do, YR; Jang, JH; Jeong, SH; Jung, KS; Kim, HG; Kim, I; Kim, MK; Kim, SJ; Kim, SY; Kim, YJ; Kim, YK; Lee, JH; Mun, YC; Park, J; Park, S; Park, SK; Yi, HG, 2019)	2.28
"Decitabine has been approved for the treatment of all subtypes of myelodysplastic syndrome (MDS). "	( Decitabine of reduced dosage in Chinese patients with myelodysplastic syndrome: a retrospective analysis. Chang, C; Chen, Y; Hou, M; Li, X; Song, L; Song, Q; Su, J; Wu, D; Wu, L; Xu, F; Zhang, X; Zhang, Z; Zhou, L, 2014)	3.29
"Decitabine has previously been shown to induce lethal mutagenesis of human immunodeficiency virus type 1 (HIV-1). "	( Lack of mutational hot spots during decitabine-mediated HIV-1 mutagenesis. Bonnac, L; Landman, SR; Mansky, LM; Patterson, SE; Rawson, JM; Reilly, CS, 2015)	2.13
"Decitabine has favorable effects in terms of overall survival, which were considered clinically meaningful in the context of a manageable toxicity profile and after consideration of the lack of therapeutic alternatives for these patients."	( The European Medicines Agency Review of Decitabine (Dacogen) for the Treatment of Adult Patients With Acute Myeloid Leukemia: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use. Béhanzin, E; Bowen, D; Demolis, P; Flores, B; Gisselbrecht, C; Hudson, I; Moreau, A; Nieto, M; Pignatti, F; Salmonson, T; Stemplewski, H, 2016)	1.42
"Decitabine has the synergistic effect with TSA."	( [Effect of decitabine combined with Trichostatin A on MDS cell line SKM-1 in vitro]. Ding, XS; Hang, HM; Jiang, SH; Liu, H; Song, GQ; Wang, XF; Xu, RR; Yang, L, 2008)	1.46
"Decitabine has established efficacy in MDS and shown promising activity in AML at low doses. "	( Pharmacokinetic evaluation of decitabine for the treatment of leukemia. Bryan, J; Garcia-Manero, G; Jabbour, E; Kantarjian, H, 2011)	2.1
"Decitabine has been shown to be active in numerous studies including International Prognostic Scoring System (IPSS) intermediate-1 to high risk patients, in secondary acute myeloid leukemia (AML) arising from MDS, and in MDS with poor-risk cytogenetics."	( Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update. Joeckel, TE; Lübbert, M, 2012)	1.33
"Decitabine has demethylating effect on the FHIT gene hypermethylation of plasma from MDS patients."	( [Methylation of FHIT gene promoter region in DNA from plasma of patients with myelodysplastic syndromes and demethylating effect of decitabine]. Dai, D; Deng, YF; Hu, MQ; Xu, YL; Zhang, L; Zhang, XQ; Zhang, XZ, 2012)	1.3
"Decitabine has been evaluated for the treatment of AML in several different settings. "	( The role of decitabine for the treatment of acute myeloid leukemia. Ganetsky, A, 2012)	2.2
"Decitabine has also received orphan drug status in the US as a host-protective agent in the treatment of AML."	( Decitabine: 2'-deoxy-5-azacytidine, Aza dC, DAC, dezocitidine, NSC 127716. , 2003)	2.48
"Decitabine has been studied in several phase II trials for solid tumours as well as in different types of leukaemia."	( Decitabine: 2'-deoxy-5-azacytidine, Aza dC, DAC, dezocitidine, NSC 127716. , 2003)	2.48
"Decitabine, an old drug, has now made a comeback as a targeted agent and a prototype for epigenetic therapy in cancer. "	( Decitabine. Issa, JP, 2003)	3.2
"Decitabine has been shown to have a broad range of antineoplastic activity in preclinical studies."	( DNA methylation in haematological malignancies: the role of decitabine. Garcia-Manero, G; Giles, FJ; Hennessy, BT; Kantarjian, HM, 2003)	1.28
"Decitabine has response rates of 17-49% in myelodysplastic syndrome in multiple phase II and III studies and also activity in acute and chronic myelogenous leukemia."	( Review: recent clinical trials in epigenetic therapy. Issa, JP; Oki, Y, 2006)	1.06
"Decitabine has promising activity in CML."	( Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia. Beran, M; de Vos, D; Estey, E; Giralt, S; Kantarjian, HM; Keating, M; Kornblau, S; O'Brien, SM; Rios, MB; Talpaz, M, 1997)	1.41

Excerpt	Reference	Relevance
"Decitabine promotes p27 gene expression possibly by inhibiting its DNA methylation, thereby decreases the proliferation of astrocytes, neuronal death and infarct volume after ischemic stroke."	( Decitabine attenuates ischemic stroke by reducing astrocytes proliferation in rats. Li, D; Zhang, Q; Zhang, X; Zhao, H, 2022)	2.89
"Decitabine can inhibit the proliferation of KMS-18 cells and induce their apoptosis, its mechanism ralates with partially reversing the methylation of P53 gene promoter in KMS-18 cells."	( [Inducing Effect of Decitabine on Apoptosis of KMS-18 Myeloma Cells and Its Mechanism]. He, PC; Wang, XN; Zhang, M, 2019)	2.28
"Decitabine was shown to suppress the growth of RCC cells via G2/M cell cycle arrest and the p38-NF-κB signaling pathway may play a role in the anti-neoplastic effect of decitabine in RCC cells."	( Decitabine induces G2/M cell cycle arrest by suppressing p38/NF-κB signaling in human renal clear cell carcinoma. Han, T; Liu, Y; Shang, D; Xu, X, 2015)	2.58
"Decitabine may enhance the allo-NK cell-mediated killing effects on LSC by up-regulation of the expressions of NKG2D ligands on LSC."	( [Decitabine Enhances the Sensitivity of Leukemia Stem Cell to Allo-NK Cell-Mediated Killing]. Chen, J; Chen, SX; Huang, HT; Li, JG; Li, Q; Peng, Q; She, MR; Wei, SS; Xia, PF, 2017)	2.81

Excerpt	Reference	Relevance
"Decitabine treatment restored TET2 methylation and EZH2 transcription and ameliorated CIN in AML."	( Analysis of TET2 and EZH2 gene functions in chromosome instability in acute myeloid leukemia. Han, F; He, N; Hua, M; Ji, C; Ma, D; Tian, T; Wang, J; Wang, R; Zhang, C; Zhong, C, 2020)	1.28
"Decitabine treatment of latency I EBV+ Burkitt lymphoma (BL) sensitized cells to lysis by EBV-specific cytotoxic T cells (EBV-CTLs)."	( Epigenetic reprogramming sensitizes immunologically silent EBV+ lymphomas to virus-directed immunotherapy. Alonso, A; Cesarman, E; Dalton, T; Doubrovina, E; Dyomin, V; Elemento, O; Gewurz, BE; Giulino-Roth, L; O'Reilly, RJ; Oakes, CC; Pan, H; Pankov, D; Phillip, JM; Reynolds, R; Savalia, B; Scholze, H; Selvakumar, A; Vizconde, T; Weigel, C, 2020)	1.28
"Decitabine treatment was also associated with higher incidence of transfusion independence (42% vs."	( Hypomethylating agents in the treatment of chronic myelomonocytic leukemia: a meta-analysis and systematic review. Deng, C; Du, X; Geng, S; Huang, X; Li, M; Weng, J; Wu, P; Xu, R, 2021)	1.34
"Decitabine treatment of different cell lines showed that induced loss of methylation at the MN1 locus can result in an increase of MN1 expression, indicating that MN1 expression is coregulated by DNA methylation."	( MN1 overexpression is driven by loss of DNMT3B methylation activity in inv(16) pediatric AML. Arentsen-Peters, TCJM; Baruchel, A; Danen-van Oorschot, AA; de Haas, V; Fornerod, M; Larmonie, NSD; Obulkasim, A; Pieters, R; Reinhardt, D; Sonneveld, E; Trka, J; Valerio, D; van den Heuvel-Eibrink, MM; Zimmermann, M; Zwaan, CM, 2018)	1.2
"Decitabine treatment leads to restoration of RASSF1A, activation of hippo pathway followed by decreased expression of its oncogenic downstream targets (CTGF & CYR61)."	( Decitabine augments cytotoxicity of cisplatin and doxorubicin to bladder cancer cells by activating hippo pathway through RASSF1A. Anand, V; Appunni, S; Khandelwal, M; Mathur, S; Seth, A; Sharma, A; Singh, P, 2018)	2.64
"Decitabine treatment showed a survival benefit in the higher-risk group of IPSS lower-risk MDS patients who responded to treatment, and classification using the LR-PSS category was helpful for this subgroup, indicating that decitabine treatment might alter the natural course of disease in these patients."	( Clinical Outcomes of Decitabine Treatment for Patients With Lower-Risk Myelodysplastic Syndrome on the Basis of the International Prognostic Scoring System. Chang, MH; Choi, CW; Do, YR; Jang, JH; Jeong, SH; Jung, KS; Kim, HG; Kim, I; Kim, MK; Kim, SJ; Kim, SY; Kim, YJ; Kim, YK; Lee, JH; Mun, YC; Park, J; Park, S; Park, SK; Yi, HG, 2019)	2.28
"Decitabine treatment brought the peripheral blood and bone marrow cell counts of SSAT mice to the level of wild-type mice."	( Spermidine/spermine N(1)-acetyltransferase activity associates with white blood cell count in myeloid leukemias. Alhonen, L; Jantunen, E; Mäntymaa, P; Mustjoki, S; Pirnes-Karhu, S; Uimari, A, 2014)	1.12
"Decitabine treatment induced CT45 mRNA and protein expression in EOC cells, and promoter transgene analyses indicated that DNA methylation directly represses CT45 promoter activity."	( DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer. Akers, SN; Barger, CJ; Karpf, AR; Link, PA; Mhawech-Fauceglia, P; Miller, A; Odunsi, K; Zhang, W, 2015)	1.14
"Decitabine treatment was efficacious in Chinese patients with MDS with its safety profile comparable to the global studies of decitabine conducted to date."	( Decitabine for Treatment of Myelodysplastic Syndromes in Chinese Patients: An Open-Label, Phase-3b Study. Cai, Z; Chen, B; Du, X; He, G; Huang, X; Jin, J; Li, J; Li, X; Liang, H; Liu, T; Ruan, C; Shao, Z; Shen, Z; Wu, D; Xiao, Z; Yu, L, 2015)	3.3
"Decitabine-treated 4T1 cells stimulated greater IFN-gamma release from tumor-sensitized lymphocytes, implying increased immunogenicity."	( DNA methyltransferase inhibition increases efficacy of adoptive cellular immunotherapy of murine breast cancer. Baek, A; Bear, HD; Damle, SR; Graham, LJ; Manjili, MH; Payne, KK; Terracina, KP, 2016)	1.16
"Decitabine treatment decreased global methylation, DNMT activity and DNMT1, DNMT3a and DNMT3b mRNA expression in MDA-MB-231 docetaxel-resistant cells."	( Altered DNA methylation is associated with docetaxel resistance in human breast cancer cells. Brown, I; Kastl, L; Schofield, AC, 2010)	1.08
"Decitabine treatment of normal, nonanemic baboons induced similar increases in the γ/γ+β chain synthetic ratio and the γ/total β-like globin RNA ratio and also increased expression of ɛ-globin transcripts. "	( Decitabine increases fetal hemoglobin in Papio anubis by increasing γ-globin gene transcription. Akpan, I; Banzon, V; DeSimone, J; Ibanez, V; Lavelle, D; Vaitkus, K, 2010)	3.25
"Decitabine treatment resulted in a decrease in global DNA methylation, corresponding to 4876 probeset IDs with significantly reduced methylation levels, while the expression of 2583 IDs was modified."	( Analysis of genome-wide methylation and gene expression induced by 5-aza-2'-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia. Criscuolo, M; D'alo', F; Fabiani, E; Giachelia, M; Greco, M; Guidi, F; Hohaus, S; Leone, G; Rutella, S; Voso, MT, 2010)	1.08
"Decitabine treatment was associated with improvements in patient-reported quality-of-life (QOL) parameters."	( Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Rese Aul, C; Baila, L; Beeldens, F; Coens, C; de Witte, T; Eckart Schaefer, H; Ganser, A; Germing, U; Giagounidis, A; Hagemeijer, A; Labar, B; Lübbert, M; Muus, P; Pflüger, KH; Platzbecker, U; Rüter, BH; Salih, HR; Selleslag, D; Suciu, S; Wijermans, PW, 2011)	1.51
"Decitabine treatment was feasible and effective in Korean patients with myelodysplastic syndrome, and the overall survival was significantly longer in patients showing hematologic improvement."	( A prospective multicenter observational study of decitabine treatment in Korean patients with myelodysplastic syndrome. Choi, CW; Jang, JH; Joo, YD; Kim, HG; Kim, SH; Kim, YK; Lee, JH; Min, YH; Park, E; Park, J; Park, S; Park, SK, 2011)	2.07
"Decitabine-treated keratinocytes also show increased mir-302c and proliferation similar to other Oct4(+) cells."	( Treatment with the cancer drugs decitabine and doxorubicin induces human skin keratinocytes to express Oct4 and the OCT4 regulator mir-145. Bickenbach, JR; Chinnathambi, S; Tomanek-Chalkley, A; Wiechert, S; Winter, MC, 2012)	1.38
"Decitabine treatment of H1299 cells resulted in reduced methylation levels in gene promoters, elevated transcript levels of CHRNB4 and CHRNA3, and a slight downregulation of TERT demonstrating epigenetic regulation of lung cancer cells."	( Epigenetic screen identifies genotype-specific promoter DNA methylation and oncogenic potential of CHRNB4. Bermejo, JL; Claus, R; Dienemann, H; Gu, L; Jacobsson, H; Meister, M; Muley, T; Peil, B; Plass, C; Risch, A; Sarkisyan, N; Scherf, DB, 2013)	1.11
"Decitabine treatment results in a biphasic effect in overall NK cell lytic function, which correlates with a biphasic pattern of global hypomethylation."	( Decitabine has a biphasic effect on natural killer cell viability, phenotype, and function under proliferative conditions. Denman, CJ; Kopp, LM; Lee, DA; Ray, A; Senyukov, VS; Somanchi, SS; Zhu, S, 2013)	2.55
"Decitabine treatment is associated with a response rate that is higher in patients with high-risk cytogenetics (i.e., complex karyotype and/or abnormalities of chromosome 7) than in patients with intermediate-risk cytogenetics (two abnormalities or single abnormalities excluding 5q-, 20q-, and -Y)."	( In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies. Hackanson, B; Lübbert, M; Robbel, C; Wijermans, P, 2005)	1.38
"Decitabine-treated MDS patients can be managed as outpatients after completion of a 3-day infusion schedule."	( Quantification of outpatient management and hospitalization of patients with high-risk myelodysplastic syndrome treated with low-dose decitabine. Germing, U; Haas, PS; Kündgen, A; Lübbert, M; Müller-Berndorff, H; Pitako, JA; Van den Bosch, J; Wijermans, PW, 2005)	1.25
"Co-treatment with decitabine reversed TETs' levels and modulated immune response after repeated cocaine exposure."	( Psychostimulant-induced aberrant DNA methylation in an in vitro model of human peripheral blood mononuclear cells. Alttoa, M; Anier, K; Jaako, K; Kalda, A; Kisand, K; Kokassaar, R; Sikk, K; Somelar, K, 2022)	1.04
"Rats treated with decitabine showed hypomethylation and reduced infarct volume in the cortex."	( Decitabine attenuates ischemic stroke by reducing astrocytes proliferation in rats. Li, D; Zhang, Q; Zhang, X; Zhao, H, 2022)	2.49
"Treatment with decitabine plus anti-PD-1 promoted the activation and expansion of tumor-infiltrated CD8+ progenitor Tex and efficiently suppressed tumor growth in multiple tumor models."	( Decitabine priming increases anti-PD-1 antitumor efficacy by promoting CD8+ progenitor exhausted T cell expansion in tumor models. Bo, X; Chang, Y; Chen, H; Chen, M; Dong, L; Han, W; Li, X; Li, Y; Nie, J; Wang, C; Zhang, X, 2023)	2.69
"Treatment with decitabine also caused apoptosis of Th1 and Th17 cells in active arthritis in a highly selective manner."	( Pharmacological modulation of T cell immunity results in long-term remission of autoimmune arthritis. Chiang, NY; Clanchy, FIL; Ericsson, P; Huang, YS; Lin, HH; Luo, SF; McNamee, K; Ogbechi, J; Perocheau, D; Salford, LG; Sjögren, HO; Stone, TW; Sundstedt, A; Topping, LM; Tseng, WY; Williams, RO; Xue, ZT, 2021)	0.96
"Pre-treatment with decitabine may represent a newer therapeutic option for pediatric AML, especially as it appears to induce important epigenetic alterations."	( A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML. Alvaro, F; Arceci, RJ; Arndt, C; Barnette, P; Boklan, J; Carpten, J; Cooper, T; Farrar, JE; Gooden, GC; Gore, L; Lee, D; Legendre, C; Liang, WS; Macy, ME; Martin, L; Meshinchi, S; Narendran, A; Pollard, J; Salhia, B; Triche, TJ; Wai, D, 2017)	1.05
"The treatment of decitabine combined with modified CAG regimen for relapsed and refractory AML shows high response rate, low side effects, so it worthy to further clinical study."	( [Clinical resarch of decitabine combined with modified CAG regimen for treatment of relapsed or refractory acute myeloid leukemia]. Jing, Y; Liu, SY; Niu, JH; Yang, H; Yu, L; Zhang, Q; Zhu, CY; Zhu, HY, 2015)	1.08
"Treatment with decitabine after azacitidine failure yielded modest ORR (19.4%) with short response duration and poor OS."	( Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure. Adès, L; Berthon, C; Braun, T; Brechignac, S; Cherait, A; Fenaux, P; Gardin, C; Harel, S; Park, S; Quesnel, B; Rigal, M; Thépot, S; Willekens, C, 2015)	0.96
"Pretreatment with decitabine decreased the cytotoxic activity of MEK inhibitors in KRAS-mutant ovarian cancer cells, with reciprocal downregulation of DNMT1 and MEK/ERK phosphorylation."	( KRAS Genomic Status Predicts the Sensitivity of Ovarian Cancer Cells to Decitabine. Chang, YM; Khabele, D; Kim, JW; Schreiber, SL; Shamji, AF; Stewart, ML; Tamayo, P; Wang, S; Wilson, AJ, 2015)	0.97
"Treatment with decitabine or other epigenetic modulators could provide a means for more effective immunological targeting of CT45."	( DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer. Akers, SN; Barger, CJ; Karpf, AR; Link, PA; Mhawech-Fauceglia, P; Miller, A; Odunsi, K; Zhang, W, 2015)	0.76
"Co-treatment with decitabine and doxorubicin results first in increased OCT4 and mir-145, then a decrease in both, suggesting that OCT4 and mir-145 regulate each other."	( Treatment with the cancer drugs decitabine and doxorubicin induces human skin keratinocytes to express Oct4 and the OCT4 regulator mir-145. Bickenbach, JR; Chinnathambi, S; Tomanek-Chalkley, A; Wiechert, S; Winter, MC, 2012)	0.99
"Treatment with decitabine resulted in the reexpression of EGFR in CAMA1 and MB453."	( Epigenetic inactivation of EGFR by CpG island hypermethylation in cancer. Díaz-Montero, CM; Estecio, M; Issa, JP; Mao, L; Montero, AJ; Shen, L; Youssef, EM, 2006)	0.67
"Treatment with Decitabine resulted in a significant increase in circulating neutrophils, platelets, and hemoglobin with respect to pretreatment values in over 50% of patients."	( 5-Aza-2'-deoxycytidine (Decitabine) induces trilineage response in unfavourable myelodysplastic syndromes. Babare, R; De Angelis, V; Gattei, V; Lo Re, G; Marotta, G; Monfardini, S; Pinto, A; Sardeo, G; Zagonel, V, 1993)	0.93

Excerpt	Reference	Relevance
" 5-AzadCyd is highly toxic in cultured cells and animals and is utilized as a potent antitumor agent for treatment of certain human cancers."	( Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Jaenisch, R; Jüttermann, R; Li, E, 1994)	0.29
" The high recombinagenic activity of these two drugs suggests that--despite their therapeutic effects against cancer--a question is raised whether these drugs should be considered for adverse effects in cancer chemotherapy."	( Somatic recombination: a major genotoxic effect of two pyrimidine antimetabolitic chemotherapeutic drugs in Drosophila melanogaster. Cunha, KS; de Andrade, HH; Graf, U; Reguly, ML, 2002)	0.31
" Similar to previous studies, we show that mice that are heterozygous for a nonfunctional Dnmt1 gene are partially protected against the deleterious effects of 5-azaCdR; however, methylation levels are not restored in these mice, suggesting that adverse effects are due to another mechanism(s) in addition to DNA hypomethylation."	( Adverse effects of 5-aza-2'-deoxycytidine on spermatogenesis include reduced sperm function and selective inhibition of de novo DNA methylation. Kelly, TL; Oakes, CC; Robaire, B; Trasler, JM, 2007)	0.34
" In an attempt to design an efficacious and safe prehematopoietic stem cell transplantation conditioning regimen, we investigated the cytotoxicity of the combination of busulfan (B), melphalan (M), and gemcitabine (G) in lymphoma cell lines in the absence or presence of drugs that induce epigenetic changes."	( Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in lymphoma cell lines. Andersson, BS; Champlin, RE; Li, Y; Murray, D; Nieto, Y; Valdez, BC; Wang, G, 2012)	0.38
" Our findings suggest that 5'-aza-dC modulating DNA methylation could sensitize paraquat toxic effects on PC12 cell by oxidative stress increment and mitochondrial deficit."	( 5'-Aza-dC sensitizes paraquat toxic effects on PC12 cell. Ba, M; Kong, M; Liang, H; Ma, L; Wang, Y; Yu, Q; Yu, T, 2012)	0.38
" Decitabine was tolerated at all doses administered, and grade 3 or 4 toxic effects included non-life-threatening hepatotoxicity and hyperglycaemia."	( Safety and clinical activity of 5-aza-2'-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia. Benton, CB; Borthakur, G; Dara, S; Franklin, AR; Garcia-Manero, G; Jabbour, E; Kantarjian, H; Kwari, M; O'Brien, S; Pierce, SR; Ravandi, F; Rytting, M; Thomas, DA; Yang, H, 2014)	1.56
" The most common grade 3 or higher adverse events were febrile neutropenia (38 [41%] of 93 patients), pneumonia (27 [29%] of 93 patients), thrombocytopenia (23 [25%] of 93 patients), anaemia (23 [25%] of 93 patients), and sepsis (16 [17%] of 93 patients)."	( Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. Azab, M; Chung, W; Daver, N; Griffiths, EA; Hao, Y; Issa, JJ; Jabbour, E; Kantarjian, H; Lowder, JN; Naim, S; O'Connell, C; Oganesian, A; Rizzieri, D; Roboz, G; Stock, W; Taverna, P; Tibes, R; Walsh, K; Yee, K, 2015)	0.71
"1 nm) for 24 hours pretreatment with or without methyltransferase inhibitor 5-aza-2'-deoxycytidine and the reactive oxygen species (ROS) scavenger α-lipoic acid to assess the possible role of methylation and ROS in the toxic effect of TNPs."	( Cross talk between poly(ADP-ribose) polymerase 1 methylation and oxidative stress involved in the toxic effect of anatase titanium dioxide nanoparticles. Bai, W; Chen, Y; Gao, A, 2015)	0.42
" Safety was evaluated based on treatment related grades 3-4 adverse events (AEs) and early death (ED) rate."	( Efficacy and safety of decitabine in treatment of elderly patients with acute myeloid leukemia: A systematic review and meta-analysis. He, PF; Lian, XY; Lin, J; Ma, JC; Qian, J; Wen, XM; Xu, ZJ; Yao, DM; Zhang, ZH; Zhou, JD, 2017)	0.77
" In addressing key issues of reducing toxic side effects and improving pharmacokinetic profiles of the therapeutic agents, we have developed a new formulation by co-packaging DAC and ATO into alendronate-conjugated bone-targeting nanoparticles (BTNPs)."	( Bone-targeting nanoparticle to co-deliver decitabine and arsenic trioxide for effective therapy of myelodysplastic syndrome with low systemic toxicity. Ferrari, M; Hu, Z; Nizzero, S; Ramirez, MR; Shen, H; Shi, C; Wu, X; Zhang, G; Zhou, J, 2017)	0.72
" Grade 3 to 4 adverse events (AEs) were reported in 11 (24."	( Phase Ib/II study of safety and efficacy of low-dose decitabine-primed chemoimmunotherapy in patients with drug-resistant relapsed/refractory alimentary tract cancer. Brock, MV; Chen, M; Feng, K; Guo, M; Han, W; Li, S; Li, X; Liu, Y; Mei, Q; Nie, J; Shi, L; Wu, Z; Zhang, Y, 2018)	0.73
" The main adverse reaction was hematological toxicity."	( [The safety of decitabine as bridging pretreatment regimen before hematopoietic stem cell transplantation in pediatric hematological malignancies]. Bian, XN; Fan, LY; Hu, SY; Kong, LJ; Li, J; Ling, J; Liu, H; Lu, J; Xiao, PF; Yao, YH, 2018)	0.83
" In terms of adverse reactions, there was no statistically significant difference in the rates of myelosuppression, pulmonary infection, gastrointestinal reactions, and bleeding events between the 2 groups (P＞0."	( [Efficacy and Safety of Decitabine Combined with CAG (Cytarabine, Aclarubicin, G-CSF) for Patients with Intermediate or High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia: a Meta-Analysis]. Cao, YP; Li, JG; Zhang, JL, 2019)	0.82
" As compared with control group, there was no significant difference in adverse events."	( [Efficacy and Safety of Decitabine Combined with CAG (Cytarabine, Aclarubicin, G-CSF) for Patients with Intermediate or High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia: a Meta-Analysis]. Cao, YP; Li, JG; Zhang, JL, 2019)	0.82
" The anti-tumor effect and DNA demethylation effect of OR-2003 and OR-2100 were comparable to that of DAC with fewer adverse effects in vivo."	( Novel prodrugs of decitabine with greater metabolic stability and less toxicity. Hattori, N; Iida, N; Kimura, K; Kono, Y; Nakata, Y; Sako, M; Takeshima, H; Ushijima, T, 2019)	0.85
" These compounds are expected to overcome the difficulty in achieving stable pharmacokinetics in patients, leading to maximum DNA demethylation activity with minimum adverse effects."	( Novel prodrugs of decitabine with greater metabolic stability and less toxicity. Hattori, N; Iida, N; Kimura, K; Kono, Y; Nakata, Y; Sako, M; Takeshima, H; Ushijima, T, 2019)	0.85
"The CHG priming regimen provided a safe and effective salvage regimen for higher risk MDS patients who were resistant to decitabine."	( The efficacy and toxicity of the CHG priming regimen (low-dose cytarabine, homoharringtonine, and G-CSF) in higher risk MDS patients relapsed or refractory to decitabine. Chang, C; He, Q; Li, X; Song, L; Su, J; Tao, Y; Wu, D; Wu, L; Xiu, C; Xu, F; Zhang, Z; Zhao, Y; Zhou, L, 2019)	0.92
" The therapentic efficacy and adverse reactions during treatment were compared between 2 groups."	( [Efficacy and Safety of Decitabine Combined with Half-Course Pre-excitation for the Treatment of Elderly Patients with Acute Myeloid Leukemia]. Kong, R; Liu, Q; Qiu, HC; Wang, Y; Wu, DH; Wu, PF; Zhang, XL, 2019)	0.82
" The rate of adverse reactions of digestive tract in combined therapy group was 40."	( [Efficacy and Safety of Decitabine Combined with Half-Course Pre-excitation for the Treatment of Elderly Patients with Acute Myeloid Leukemia]. Kong, R; Liu, Q; Qiu, HC; Wang, Y; Wu, DH; Wu, PF; Zhang, XL, 2019)	0.82
"Combination of disitamine and half-course prestimulation treatmentis is a safe and effective and elderly patients with AML shown a good tolerance."	( [Efficacy and Safety of Decitabine Combined with Half-Course Pre-excitation for the Treatment of Elderly Patients with Acute Myeloid Leukemia]. Kong, R; Liu, Q; Qiu, HC; Wang, Y; Wu, DH; Wu, PF; Zhang, XL, 2019)	0.82
"Our data demonstrated that decitabine was effective and relatively safe in treating MDS and AML."	( Decitabine: An effective and safe treatment for myelodysplastic syndrome and acute myeloid leukemia. Chang, Y; Chen, X; Feng, X; Gao, Y; Huang, J; Li, T; Liu, S; Mao, C; Meng, F; Nie, S; Xiao, S; Yan, X; Zhou, J, 2019)	2.25
"Neonatal exposure to sevoflurane sensitizes rats to adverse effects of repeated exposure to the anesthetic."	( Neonatal exposure to sevoflurane expands the window of vulnerability to adverse effects of subsequent exposure to sevoflurane and alters hippocampal morphology via decitabine-sensitive mechanisms. Gravenstein, N; Ju, LS; Lei, L; Lin, Y; Martynyuk, AE; Morey, TE; Xu, N; Yang, J, 2020)	0.75
"D-CAG regimen is safe and effective in the treatment of AML patients ≥70 years old, and can partially improve the prognosis of elderly and high-risk patients."	( [Efficacy and Safety of Decitabine Combined with Modified CAG Regimen in Patients Aged ≥ 70 Years with Newly Diagnosed Acute Myeloid Leukemia]. Cao, L; Hong, M; Jiang, ZQ; Li, JY; Liu, WJ; Qian, SX; Sun, Q; Zhu, Y, 2023)	1.22

Excerpt	Reference	Relevance
"A phase I trial and pharmacokinetic study of 5-aza-2'-deoxycytidine (5-aza-dCyd) were conducted in 21 patients with advanced solid tumors."	( Phase I and pharmacokinetic study of 5-aza-2'-deoxycytidine (NSC 127716) in cancer patients. Gall, HE; Leyva, A; O'Brien, AM; Pinedo, HM; van Groeningen, CJ, 1986)	0.27
" This has greatly limited application of pharmacokinetic assays to clinical development of decitabine."	( Characterization of decomposition products and preclinical and low dose clinical pharmacokinetics of decitabine (5-aza-2'-deoxycytidine) by a new liquid chromatography/tandem mass spectrometry quantification method. Byrd, JC; Chan, KK; Grever, M; Liu, Z; Marcucci, G; Xiao, J, 2006)	0.77
" The mean values for terminal phase elimination half-life (0."	( Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Cashen, AF; DiPersio, J; Fisher, N; Shah, AK; Todt, L, 2008)	0.67
" Pharmacodynamic analyses included 5-methyl-2'-deoxycytidine levels, MAGE1A CpG island methylation, and fetal hemoglobin (HbF) expression."	( Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. Appleton, K; Barrett, S; Bellenger, K; Brown, R; Jadayel, D; Judson, I; Kaye, SB; Lee, C; Mackay, HJ; Mackay, L; McCormick, C; Plumb, JA; Reade, S; Schätzlein, A; Setanoians, A; Strathdee, G; Tang, A; Twelves, C, 2007)	0.57
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."	( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Lombardo, F; Obach, RS; Waters, NJ, 2008)	0.35
" The authors review the pharmacokinetic data gained from low-dose decitabine, as well as the clinical progress of decitabine in the treatment of hematologic malignancies."	( Pharmacokinetic evaluation of decitabine for the treatment of leukemia. Bryan, J; Garcia-Manero, G; Jabbour, E; Kantarjian, H, 2011)	0.89
" Pharmacodynamic analysis showed FLT3 down-regulation on day 26 of cycle 1 (P = ."	( Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia. Bloomfield, CD; Blum, W; Byrd, JC; Caligiuri, MA; Chan, KK; Curfman, JP; Devine, SM; Eisfeld, AK; Garr, C; Garzon, R; Geyer, S; Grever, MR; Jacob, S; Kefauver, C; Klisovic, R; Marcucci, G; Perrotti, D; Santhanam, R; Schwind, S; Tarighat, SS; Walker, A; Wang, H; Whitman, S, 2012)	0.63
" We developed a pharmacodynamic model to characterize the interaction between CLO and DEC on an AML cell line and down-regulated p53R2 protein to understand its role."	( Synergism between clofarabine and decitabine through p53R2: a pharmacodynamic drug-drug interaction modeling. Fetterly, GJ; Ghoshal, S; Haese, JP; Karpf, AR; Thudium, KE; Wetzler, M, 2012)	0.66
" A population pharmacokinetic model was developed by pooling decitabine concentration-time data from 5 adult (AML and MDS) and 2 pediatric (AML) studies."	( Population Pharmacokinetic Analysis of Decitabine in Pediatric Patients With Acute Myeloid Leukemia. Appiani, C; Massarella, J; Nakahara, S; Nemat, S; Parasrampuria, DA; Poggesi, I; Zhang, L; Zhou, W, 2019)	1.02

Excerpt	Reference	Relevance
" Because of the potentially large antigen load released by such a cell kill, the immune modulator pyran copolymer was also tested in combination with DAC."	( Effects of 5-aza-2'-deoxycytidine in combination with the biochemical modulator thymidine or the immune modulator pyran copolymer on L1210 leukemia-bearing mice. Covey, JM; Zaharko, DS, 1984)	0.27
" Since most clinical regimens for tumor therapy consist of several drugs, we investigated the antineoplastic action of Ado in combination with 5-aza-2'-deoxycytidine (5-Aza-CdR), a potent inhibitor of DNA methylation or cytosine arabinoside (Ara-C), a potent inhibitor of DNA synthesis."	( Evaluation of the antineoplastic activity of adozelesin alone and in combination with 5-aza-2'-deoxycytidine and cytosine arabinoside on DLD-1 human colon carcinoma cells. Côté, S; Momparler, RL, 1993)	0.29
"5-Aza-2'-deoxycytidine combined with either amsacrine or idarubicin has been applied in a treatment protocol for patients with a relapse of acute myeloid or lymphocytic leukemia."	( A randomized phase II study on the effects of 5-Aza-2'-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893). Archimbaud, E; Berneman, Z; Dardenne, M; Dohner, H; Jaksic, B; Jehn, U; Labar, B; Louwagie, EA; Muus, P; Stryckmans, P; Suciu, S; Tjean, M; Wijermans, P; Willemze, R; Zittoun, R, 1997)	0.3
" In this study, we show for the first time that VPA, in combination with RA and the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine (Aza-dC), can overcome the epigenetic barriers to transcription of a prototypical silenced tumor suppressor gene, RARbeta2, in human breast cancer cells."	( Valproic acid, in combination with all-trans retinoic acid and 5-aza-2'-deoxycytidine, restores expression of silenced RARbeta2 in breast cancer cells. Gudas, LJ; Mongan, NP, 2005)	0.33
" These findings suggest that 5-aza-CdR is a promising chemotherapeutical agent for gastric carcinomas, in combination with the anticancer drugs SN38 and GEM, in apoptosis signaling."	( Synergic antiproliferative effect of DNA methyltransferase inhibitor in combination with anticancer drugs in gastric carcinoma. Hirakawa, K; Ohira, M; Ren, J; Yashiro, M; Zhang, X, 2006)	0.33
" A Phase II study was performed on low-dose decitabine, a DNA methyltransferase inhibitor, in combination with imatinib in patients with CML in accelerated phase (AP) and myeloid blastic phase (BP)."	( Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. Cortes, J; Garcia-Manero, G; Gharibyan, V; Issa, JP; Jones, D; Kantarjian, HM; Morris, GM; O'brien, S; Oki, Y; Verstovsek, S, 2007)	0.9
"To determine an optimal biologic dose (OBD) of decitabine as a single agent and then the maximum-tolerated dose (MTD) of valproic acid (VA) combined with decitabine in acute myeloid leukemia (AML)."	( Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. Blum, W; Byrd, JC; Chan, KK; Devine, H; Devine, SM; Grever, MR; Hackanson, B; Heerema, NA; Huynh, L; Kefauver, C; Klisovic, RB; Liu, S; Liu, Z; Lozanski, G; Marcucci, G; Murgo, A; Plass, C; Vukosavljevic, T, 2007)	0.94
" HL-60 and T24 cancer cell lines were treated with azacitidine or decitabine in combination with HC and DNA methylation of LRE1, MAGEA1 and CDKN2A was quantitatively measured by bisulphite-polymerase chain reaction pyrosequencing."	( Hydroxycarbamide in combination with azacitidine or decitabine is antagonistic on DNA methylation inhibition. Byun, HM; Choi, SH; Issa, JP; Kwan, JM; Yang, AS, 2007)	0.83
" These results indicate that decitabine in combination with gemtuzumab is a regimen of promising efficacy worthy of further investigation in controlled trials."	( Decitabine combined with fractionated gemtuzumab ozogamicin therapy in patients with relapsed or refractory acute myeloid leukemia. Chowdhury, S; Marks, PW; Seropian, S, 2009)	2.09
" On the basis of preclinical studies indicating that hypomethylating agents can reverse platinum resistance in ovarian cancer cells, the authors conducted a phase 1 trial of low-dose decitabine combined with carboplatin in patients with recurrent, platinum-resistant ovarian cancer."	( A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer. Balch, C; Breen, T; Fang, F; Kulesavage, C; Li, L; Matei, DE; Nephew, KP; Schilder, J; Shen, C; Snyder, AJ; Zhang, S, 2010)	0.82
"Repetitive low-dose decitabine is tolerated when combined with carboplatin in ovarian cancer patients, and demonstrates biological (ie, DNA-hypomethylating) activity, justifying further testing for clinical efficacy."	( A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer. Balch, C; Breen, T; Fang, F; Kulesavage, C; Li, L; Matei, DE; Nephew, KP; Schilder, J; Shen, C; Snyder, AJ; Zhang, S, 2010)	0.95
"To investigate the impact of 5-aza-2'-deoxycytidine(5-aza-CdR) combined with imatinib on the proliferation, motility, invasion, and apoptosis of gastrointestinal stromal tumors(GIST) cells in vitro."	( [Therapeutic effect of in vitro 5-aza-2'-deoxycytidine combined with imatinib on gastrointestinal stromal tumor]. Liang, G; Liang, JF; Wu, LN; Xiao, H; Zhao, YZ; Zheng, HX, 2012)	0.38
" Patients were treated with escalating doses of decitabine (5-15 mg/m(2)) IV for 10 days in combination with VPA (10-20 mg/kg/day) PO on days 5-21 of a 28-day cycle."	( Phase I study of 5-aza-2'-deoxycytidine in combination with valproic acid in non-small-cell lung cancer. Aimiuwu, J; Chan, KK; Chu, BF; Grever, MR; Karpenko, MJ; Liu, Z; Otterson, GA; Villalona-Calero, MA, 2013)	0.65
" We hypothesized that epigenetic modulators will reverse chemotherapy resistance, and in this article, we report studies that sought to determine the recommended phase 2 dose (RP2D), safety, and efficacy of decitabine (DAC) combined with TMZ."	( Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis. Beumer, JH; Buch, SC; Christner, S; Egorin, MJ; Kirkwood, JM; Lin, Y; Moschos, S; Tarhini, AA; Tawbi, HA, 2013)	0.89
"This study was aimed to evaluate the effectiveness and safety of low methylation drug decitabine combined with autologous cytokine induced killer cells (CIK) to treat the elderly patients with acute myeloid leukemia (AML)."	( [Curative effect of decitabine combined with cytokine-induced killer cells in two elderly patients with acute myeloid leukemia]. Cai, LL; Chang, C; Fan, H; Guo, B; Han, WD; Li, SX; Lin, J; Liu, Y; Lu, XC; Ran, HH; Wang, Y; Yang, B; Yang, Y; Zhai, B; Zhang, F; Zhang, L; Zhu, HL, 2013)	0.94
" We conducted a study to evaluate the safety and efficacy of decitabine (a hypomethylating agent) in combination with panitumumab (mAb against EGFR) in mCRC patients."	( A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer. Boucher, K; Burr, L; Davidson, C; Garrido-Laguna, I; Gilcrease, W; Jakubowski, L; Jones, D; McGregor, KA; Morrell, G; Olpin, JD; Sharma, S; Soldi, R; Wade, M; Weis, J, 2013)	0.95
" Future studies evaluating hypomethylating agents in combination with EGFR mAb in patients with mCRC are warranted."	( A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer. Boucher, K; Burr, L; Davidson, C; Garrido-Laguna, I; Gilcrease, W; Jakubowski, L; Jones, D; McGregor, KA; Morrell, G; Olpin, JD; Sharma, S; Soldi, R; Wade, M; Weis, J, 2013)	0.7
"Here we investigated the effect of hydrodynamic IL-35-expressing plasmid injection in combination with a methyltransferase inhibitor (decitabine) on immune function and transplantation tolerance in mice."	( Inhibiting cardiac allograft rejection with interleukin-35 therapy combined with decitabine treatment in mice. Guo, H; He, X; Jiang, X; Wang, W; Zhao, N; Zhu, L, 2013)	0.82
" Thus, IL-35 gene therapy combined with decitabine provides a novel approach to induce transplantation tolerance."	( Inhibiting cardiac allograft rejection with interleukin-35 therapy combined with decitabine treatment in mice. Guo, H; He, X; Jiang, X; Wang, W; Zhao, N; Zhu, L, 2013)	0.88
"Decitabine (5-aza-2'-deoxycytidine; DAC) in combination with tetrahydrouridine (THU) is a potential oral therapy for sickle cell disease and β-thalassemia."	( Subchronic oral toxicity study of decitabine in combination with tetrahydrouridine in CD-1 mice. Chan, K; Covey, JM; Engelke, K; Ling, Y; Saunthararajah, Y; Sharpnack, D; Terse, P, )	1.85
" The differences of clinical outcome and adverse events among the patients treated with decitabine combined with DAG regimen, CAG regimen or "3+7" regimen were analyzed."	( [Comparative analysis of decitabine combined with DAG regimen and other regimens in treatment of refractory/relapsed acute myeloid leukemia]. Chen, Y; Duan, Y; Gu, X; Hao, J; Li, L; Liu, J; Liu, Z; Shen, Z; Wang, L; Wang, Y; Zhao, W, 2014)	0.93
"Decitabine combined with DAG regimen is effective and well tolerated in refractory/relapsed AML patients who were unsuitable for intensive chemotherapy and hematopoietic stem cell transplantation, and the patients with low marrow blast counts are more suitable for the application of decitabine combined with DAG regimen."	( [Comparative analysis of decitabine combined with DAG regimen and other regimens in treatment of refractory/relapsed acute myeloid leukemia]. Chen, Y; Duan, Y; Gu, X; Hao, J; Li, L; Liu, J; Liu, Z; Shen, Z; Wang, L; Wang, Y; Zhao, W, 2014)	2.15
" The present article describes our experience with ultra-low-dose decitabine combined with infusion of autologous cytokine-induced killer (CIK) cells for 2 elderly patients with myelodysplastic syndrome-transformed AML."	( Ultra-low-dose decitabine combined with autologous cytokine-induced killer cells for elderly patients with acute myeloid leukemia transformed from myelodysplastic syndrome. Cai, L; Chi, X; Li, S; Lu, X; Tuo, S; Wang, H; Wang, X; Wu, X; Yang, B; Yang, Y; Yu, R; Zhang, F; Zhu, H, 2014)	0.99
"2 mg/kg three times weekly for 2 weeks (starting on day 1), in combination with oral panobinostat 10, 20, or 30 mg every 96 h (starting on day 8), and oral temozolomide 150 mg/m(2)/day on days 9 through 13."	( Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide). Deutsch, J; Frees, M; Laux, D; Leon-Ferre, R; Milhem, M; Smith, BJ; Xia, C, 2014)	0.63
"This triple agent of dual epigenetic therapy in combination with traditional chemotherapy was generally well tolerated by the cohort and appeared safe to be continued in a Phase II trial."	( Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide). Deutsch, J; Frees, M; Laux, D; Leon-Ferre, R; Milhem, M; Smith, BJ; Xia, C, 2014)	0.63
"This study was aimed to investigate the clinical characteristics of relapsed-refractory acute myeloid leukemia (AML) with AML1-ETO⁺, and its therapeutic efficacy and side effects when decitabine combined with modified CAG regimen was used."	( [Clinical efficacy of decitabine combined with modified CAG regimen for relapsed-refractory acute myeloid leukemia with AML1-ETO⁺]. Jing, Y; Liu, SY; Niu, JH; Yang, H; Yu, L; Zhang, Q; Zhu, CY; Zhu, HY, 2014)	0.91
"This study was purposed to compare the clinical efficacy and adverse reactions of low-dose decitabine combined with CAG regimen (aclarubicin, Ara-C, and G-CSF) and CAG regimen alone in intermediate to high-risk myelodysplastic syndromes (MDS), and evaluate the validity and efficacy of the former regimen as new treatment method of intermediate to high-risk myelodysplastic syndromes."	( [Comparison of clinical efficacy between decitabine combined with CAG regimen and CAG regimen alone in patients with intermediate to high-risk myelodysplastic syndromes]. Cui, GX; Wu, WZ; Zhang, YP, 2014)	0.89
" The aim of the study presented here was to analyze the effects of a pharmacological inhibition of EZH2 alone and in combination with other anticancer drugs on RTs cells in vitro."	( Analysis of the antiproliferative effects of 3-deazaneoplanocin A in combination with standard anticancer agents in rhabdoid tumor cell lines. Borchardt, C; Clemens, D; Dirksen, U; Frühwald, MC; Kool, M; Unland, R, 2015)	0.42
"Treating MDS/AML with decitabine alone, in combination with half or one course CAG regimen produced high efficacy."	( [The clinical efficacy of the patients of acute myeloid leukemia and myelodysplastic syndromes treated with decitabine alone, combined with half or one couse of CAG regimen]. Chen, S; Fu, Z; Gao, S; Han, Y; Jin, Z; Ma, X; Qiu, H; Sun, A; Tang, X; Wu, D, 2014)	0.93
"This study was to investigate the therapeutic effectiveness and side effect of decitabine combined with modified CAG regimen for relapse or refractory patients with acute myeloid leukemia."	( [Clinical resarch of decitabine combined with modified CAG regimen for treatment of relapsed or refractory acute myeloid leukemia]. Jing, Y; Liu, SY; Niu, JH; Yang, H; Yu, L; Zhang, Q; Zhu, CY; Zhu, HY, 2015)	0.96
"After treatment by using decitabine combined with modified CAG regimen, 7 patients achived complete remission, 1 patient achived partial remission, 2 patient did not achieve remission, the overall remission rate was 80% (8/10), the median time of white blood cell count recovery was 18."	( [Clinical resarch of decitabine combined with modified CAG regimen for treatment of relapsed or refractory acute myeloid leukemia]. Jing, Y; Liu, SY; Niu, JH; Yang, H; Yu, L; Zhang, Q; Zhu, CY; Zhu, HY, 2015)	1.04
"The treatment of decitabine combined with modified CAG regimen for relapsed and refractory AML shows high response rate, low side effects, so it worthy to further clinical study."	( [Clinical resarch of decitabine combined with modified CAG regimen for treatment of relapsed or refractory acute myeloid leukemia]. Jing, Y; Liu, SY; Niu, JH; Yang, H; Yu, L; Zhang, Q; Zhu, CY; Zhu, HY, 2015)	1.08
"All patients in this study were treated with decitabine of 15 mg/m2 for 5 days and G-CSF for priming, in combination with cytarabine of 10-mg/m2 q12h for 7 days and aclarubicin of 10 mg/day for 4 days (D-CAG)."	( Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia. Chen, Y; Ding, J; Duan, L; Gu, J; Hong, M; Li, J; Li, Y; Liu, P; Lu, H; Pan, L; Qian, S; Qiu, H; Shi, J; Wang, J; Wu, H; Xu, J; Xu, Y; Yu, K; Zhang, R; Zhang, S; Zhou, J; Zhou, S; Zhu, H; Zhu, Y, 2015)	0.99
" In this open-label, phase I/II clinical study, we analyzed the toxicity and efficacy of low dose decitabine combined with taxol and platinum chemotherapy in treatment of refractory and recurrent ovarian cancer."	( Low Dose Decitabine Combined with Taxol and Platinum Chemotherapy to Treat Refractory/Recurrent Ovarian Cancer: An Open-Label, Single-Arm, Phase I/II Study. Chen, M; Fu, X; Han, W; Meng, Y; Nie, J; Wang, X; Wang, Y; Zhang, Y, 2015)	1.05
"Low dose decitabine combined with taxol and platinum was well-tolerated and suitable for treating refractory/refractory ovarian cancer."	( Low Dose Decitabine Combined with Taxol and Platinum Chemotherapy to Treat Refractory/Recurrent Ovarian Cancer: An Open-Label, Single-Arm, Phase I/II Study. Chen, M; Fu, X; Han, W; Meng, Y; Nie, J; Wang, X; Wang, Y; Zhang, Y, 2015)	1.25
" Patients are randomized to one of the four treatment groups: DAC alone or in combination with VPA or ATRA or with both add-on drugs."	( DECIDER: prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients >60 years with acute mye Cieslik, C; Döhner, K; Grishina, O; Hackanson, B; Lübbert, M; Lubrich, B; May, AM; Müller, MJ; Schmoor, C, 2015)	0.65
"To investigate the therapeutic efficacy and side effects of treating patients with myelodysplastic syndrome-RAEB (MDS-RAEB) and with refractory acute myeloid leukemia (AML) by using decitabine combined with CAG regimen."	( [Clinical Efficacy of Decitabine Combined with CAG Regimen for Myelodysplastic Syndrome-RAEB and Refractory Acute Myeloid Leukemia]. Cao, YB; DA, WM; Li, SW; Li, XH; Liu, B; Liu, ZY; Wu, XX; Wu, YM; Xu, LX; Yan, B; Yang, XL, 2015)	0.92
" All the patients received decitabine combined with CAG regimen consisting of decitabine 20 mg/(m(2) · d), d 1-5; aclarubicin 10 mg/d, d 6-13; cytarabine 20 mg/d, d 6-19; G-CSF 300 µg/d, d 6-19."	( [Clinical Efficacy of Decitabine Combined with CAG Regimen for Myelodysplastic Syndrome-RAEB and Refractory Acute Myeloid Leukemia]. Cao, YB; DA, WM; Li, SW; Li, XH; Liu, B; Liu, ZY; Wu, XX; Wu, YM; Xu, LX; Yan, B; Yang, XL, 2015)	1.03
"Decitabine combined with CAG regimen is effective and safe for treatment of MDS-RAEB and refractory AML patients, which can prolong lives of patiens with refractory hematological diseases."	( [Clinical Efficacy of Decitabine Combined with CAG Regimen for Myelodysplastic Syndrome-RAEB and Refractory Acute Myeloid Leukemia]. Cao, YB; DA, WM; Li, SW; Li, XH; Liu, B; Liu, ZY; Wu, XX; Wu, YM; Xu, LX; Yan, B; Yang, XL, 2015)	2.17
"We conducted a study exploring the clinical safety and efficacy of decitabine in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), combined with a complex karyotype."	( Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively. Chen, SN; Fu, JH; Gao, S; Han, Y; Hu, XH; Jin, ZM; Li, Z; Qiu, HY; Sun, AN; Tang, XW; Wu, DP; Xu, Y, 2015)	2.1
"From April 2009 to September 2013, a total of 35 patients with AML/MDS combined with a complex karyotype diagnosed in the First Affiliated Hospital of Soochow University were included for retrospective analysis."	( Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively. Chen, SN; Fu, JH; Gao, S; Han, Y; Hu, XH; Jin, ZM; Li, Z; Qiu, HY; Sun, AN; Tang, XW; Wu, DP; Xu, Y, 2015)	1.86
"Decitabine alone or combination with AAG can improve outcome of AML/MDS with a complex karyotype, there being no significant difference decitabine in inducing remission rates in patients with different karyotype."	( Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively. Chen, SN; Fu, JH; Gao, S; Han, Y; Hu, XH; Jin, ZM; Li, Z; Qiu, HY; Sun, AN; Tang, XW; Wu, DP; Xu, Y, 2015)	3.3
"In this study we retrospectively analyzed 53 refractory or relapsed CN- AML patients receiving the therapy including decitabine combined with CAG and CAG- like regimen in our center from April 2011 to October 2014."	( [Outcomes of refractory or relapsed DNMT3A + cytogenetically normal acute myeloid leukemia patients followed the therapy including decitabine combined with CAG or CAG-like regimen]. Chen, S; Qiu, H; Shen, H; Sun, A; Sun, Y; Wu, D; Xu, Y; Yang, Z, 2015)	0.83
"Decitabine combined with CAG or CAG-like regimen was an effective and safe treatment for refractory or relapsed CN- AML patients."	( [Outcomes of refractory or relapsed DNMT3A + cytogenetically normal acute myeloid leukemia patients followed the therapy including decitabine combined with CAG or CAG-like regimen]. Chen, S; Qiu, H; Shen, H; Sun, A; Sun, Y; Wu, D; Xu, Y; Yang, Z, 2015)	2.06
" We conducted a prospective study of 23 elderly patients (median age, 68 years; range, 60 to 87 years) with newly diagnosed AML to evaluate the efficacy and toxicity of decitabine plus granulocyte colony-stimulating factor priming, low-dose aclarubicin, and cytarabine (DCAG) chemotherapy combined with HLA-mismatched stem cell microtransplantation (SC-MST) without graft-versus-host disease (GVHD) prophylaxis."	( Decitabine before Low-Dose Cytarabine-Based Chemotherapy Combined with Human Leukocyte Antigen-Mismatched Stem Cell Microtransplantation Improved Outcomes in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia. Chen, Y; Huang, J; Li, J; Li, Y; Lian, Y; Qian, S; Wu, Y; Xie, Y; Zhang, X; Zhao, H; Zhu, Y, 2017)	2.09
"To investigate the clinical efficacy of decitabine combined with low-dose IA for treating patients with myelodysplastic syndrome-EB."	( [Clinical Observation of Therapeutic Regimen Consisted of Decitabine Combined with Low-Dose IA Regimen for Myelodysplastic Syndrome-EB]. Hao, JX; Li, J; Wu, D; Zhang, M, 2017)	0.97
"To investigate the clinical efficacy of low-dose decitabine combined with CAG regimen in patients with myelodysplastic syndrome-refractory anemia with excess blasts (MDS-RAEB) through retrospective analysis."	( [Clinical Efficacy of Low-dose Decitabine Combined with CAG Regimen in Patients with Myelodysplastic Syndrome-refractory Anemia with Excess Blasts(MDS-RAEB)]. Guo, R; Han, HH; Jiang, ZX; Liu, YF; Sun, H; Wang, M, 2017)	1
"Thirty-six patients with MDS-RAEB who ever received low-dose decitabine combined with CAG regimen were enrolled into decitabine + CAG group and 40 patients with MDS-RAEB treated by decitabine alone in our center were enolled into the control group."	( [Clinical Efficacy of Low-dose Decitabine Combined with CAG Regimen in Patients with Myelodysplastic Syndrome-refractory Anemia with Excess Blasts(MDS-RAEB)]. Guo, R; Han, HH; Jiang, ZX; Liu, YF; Sun, H; Wang, M, 2017)	0.98
"Low-dose decitabine combined with CAG regimen has better clinical efficacy for patients with MDS-RAEB than that of decitabine alone."	( [Clinical Efficacy of Low-dose Decitabine Combined with CAG Regimen in Patients with Myelodysplastic Syndrome-refractory Anemia with Excess Blasts(MDS-RAEB)]. Guo, R; Han, HH; Jiang, ZX; Liu, YF; Sun, H; Wang, M, 2017)	1.16
"To investigate the curative effect and safety of decitabine combined with IAG regimen for treating senile MDS-transformed AML patients."	( [Curative Effect of Decitabine Combined with IAG Regimen for Senile Patients with Myelodysplastic Syndrome (MDS) Transformed Acute Myeloid Leukemia]. Guo, XZ; Huang, YQ; Pan, JX; Wu, SX; Zhang, XY, 2017)	1.03
"Decitabine combined with IAG regimen is an effective for treating senile MDS-transformed AML patients."	( [Curative Effect of Decitabine Combined with IAG Regimen for Senile Patients with Myelodysplastic Syndrome (MDS) Transformed Acute Myeloid Leukemia]. Guo, XZ; Huang, YQ; Pan, JX; Wu, SX; Zhang, XY, 2017)	2.22
"To investigate the therapeutic effectiveness and side effects of decitabine combined with or without cytarabine-based low dose regimen for acute myeloid leukemia in geratic patients."	( [Clinical Efficacy of Decitabine Combined with or without Cytarabine-based Low Dose Regimen for Senile patients with Acute Myeloid Leukemia]. DU, Y; Jing, Y; Li, PF; Liu, M; Peng, CJ; Sun, JZ; Wang, ZH; Yao, YB; Zhou, HW; Zhou, MH, 2018)	1.03
"Decitabine combined with or without cytarabine-based low dose regimen is promising for the treatment of geriatric acute myeloid leukemia, thus improving the overall response rate, and prolonging overall survival time."	( [Clinical Efficacy of Decitabine Combined with or without Cytarabine-based Low Dose Regimen for Senile patients with Acute Myeloid Leukemia]. DU, Y; Jing, Y; Li, PF; Liu, M; Peng, CJ; Sun, JZ; Wang, ZH; Yao, YB; Zhou, HW; Zhou, MH, 2018)	2.24
"We retrospectively studied 87 patients aged from 55 to 69 years old with acute myeloid leukemia (AML) who received decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin (DCAG) or standard dose chemotherapy as induction therapy."	( Decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin is as effective as standard dose chemotherapy in the induction treatment for patients aged from 55 to 69 years old with newly diagnosed acute myeloid leukemia. Hong, M; Huang, J; Li, J; Lian, Y; Qian, S; Wu, Y; Zhang, X; Zhao, H; Zhao, X; Zhu, Y, 2018)	2.13
"To develop new rehabilitation therapies for chronic stroke, this study examined the effectiveness of task-specific training (TST) and TST combined with DNA methyltransferase inhibitor in chronic stroke recovery."	( Effect of Inhibition of DNA Methylation Combined with Task-Specific Training on Chronic Stroke Recovery. Choi, DH; Choi, IA; Kim, HY; Lee, CS; Lee, J, 2018)	0.48
"To investigate the efficacy of domestic decitabine (D) combined with pre-excitation chemotherapy consisted of Ara-c, THP and G-CSF(CTG) in treatment of middle-aged and elderly patients with MDS-transformed AML and prognosis-related factors."	( [Efficacy of Decitabine Combined with Pre-Excitation Chemotherapy in the Treatment of Middle-Aged and Elderly MDS Transformed Acute Myeloid Leukemia]. He, JX; Jiang, YR; Lai, YC; Li, K; Li, ZK; Liu, SY, 2018)	1.12
"The short-and long-term efficacy of domestic decitasine combined with preexcitation chenotherapy in treatment of middec-aged and eldery patients with MDS transformed AML is superior to single pre-excitation chenothrapy, moreover the incidence of adverse reactions did not increase."	( [Efficacy of Decitabine Combined with Pre-Excitation Chemotherapy in the Treatment of Middle-Aged and Elderly MDS Transformed Acute Myeloid Leukemia]. He, JX; Jiang, YR; Lai, YC; Li, K; Li, ZK; Liu, SY, 2018)	0.85
"The aim of our study was to investigate the strategy of immune tolerance induced by the demethylating drug decitabine (DAC) combined with multiple allogeneic bone marrow mononuclear cell (BMMNC) infusions."	( Immune Tolerance Induced by Decitabine Combined With Multiple Allogeneic Bone Marrow Mononuclear Cell Infusion. Dai, J; Huang, X; Li, C; Wang, C; Yang, X; Zhu, B; Zhu, Y, 2018)	0.99
"DAC combined with multiple allogeneic BMMNC infusion could successfully induce specific immune tolerance in mice, which may provide some new strategies to improve immune tolerance after organ transplant."	( Immune Tolerance Induced by Decitabine Combined With Multiple Allogeneic Bone Marrow Mononuclear Cell Infusion. Dai, J; Huang, X; Li, C; Wang, C; Yang, X; Zhu, B; Zhu, Y, 2018)	0.77
" The case of a 58-year-old female patient with AML transformed from PMF, who was treated with decitabine combined with all-trans retinoic acid, is reported."	( Decitabine combined with all-trans retinoic acid as treatment in a case of primary myelofibrosis transforming into acute myeloid leukaemia. Cao, Y; Dong, W; Gu, W; Lin, R; Lin, Y; Liu, Y; Xie, X; Zhou, G, 2019)	2.18
" In this study, we report the effects of single reagent DAC therapy and DAC combined with BZM on β-catenin accumulation, myeloma cell survival, apoptosis, and treatment sensitivity."	( Synergistic Efficacy of the Demethylation Agent Decitabine in Combination With the Protease Inhibitor Bortezomib for Treating Multiple Myeloma Through the Wnt/β-Catenin Pathway. Chen, X; Dong, B; Feng, J; Gao, G; Gu, H; Jin, Y; Shu, M; Wu, X; Xu, L; Zhang, J, 2019)	0.77
"PubMed, EMbase, The Cochrane Library, WanFang Data and CNKI databases were searched to collect randomized controlled trials (RCTs) of decitabine combined with CAG regimen for intermediate or high risk MDS and AML from inception to March, 2018."	( [Efficacy and Safety of Decitabine Combined with CAG (Cytarabine, Aclarubicin, G-CSF) for Patients with Intermediate or High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia: a Meta-Analysis]. Cao, YP; Li, JG; Zhang, JL, 2019)	1.02
"The objective of this research was to characterize the venetoclax exposure-efficacy and exposure-safety relationships and determine its optimal dose in elderly patients with newly diagnosed acute myeloid leukemia (AML) receiving venetoclax in combination with low intensity therapies (hypomethylating agent [HMA; azacitidine or decitabine] or low-dose cytarabine [LDAC])."	( Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis. Agarwal, S; Friedel, A; Gopalakrishnan, S; Hayslip, J; Kirschbrown, W; Menon, R; Mensing, S; Potluri, J; Salem, AH, 2019)	0.69
" Multivariate analysis indicated that the combination with DAC was independent factor for CR rate after the first induction therapy (OR = 2."	( A favorable inductive remission rate for decitabine combined with chemotherapy as a first course in <60-year-old acute myeloid leukemia patients with myelodysplasia syndrome features. Huang, B; Li, J; Liu, F; Liu, J; Su, C; Tong, X; Wang, H; Xu, D; Zheng, D; Zhou, Z; Zou, W, 2019)	0.78
"To investigate the efficacy and safety of decitabine combined with half-course pre-excitation for the treatment of elderly patients with acute myeloid leukemia (AML)."	( [Efficacy and Safety of Decitabine Combined with Half-Course Pre-excitation for the Treatment of Elderly Patients with Acute Myeloid Leukemia]. Kong, R; Liu, Q; Qiu, HC; Wang, Y; Wu, DH; Wu, PF; Zhang, XL, 2019)	1.09
"To retrospectively analyze the safety and efficacy of low dose subcutaneous decitabine combined with arsenic trioxide in patients with intermediate or high-risk myelodysplastic syndrome (MDS)."	( [The safety and efficacy of low dose subcutaneous decitabine combined with arsenic trioxide in patients with inermediate or higer-risk myelodysplastic syndrome]. Ai, H; Chen, L; Mi, RH; Song, YP; Wang, Q; Wei, XD; Yin, QS, 2019)	1
"DNA-hypomethylating agents are studied in combination with other epigenetic drugs, such as histone deacetylase inhibitors or differentiation inducers (eg, retinoids), in myeloid neoplasias."	( Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 × 2, Phase II Trial. Becker, H; Brugger, W; Bug, G; Crysandt, M; De Wit, M; Döhner, H; Döhner, K; Duyster, J; Ganser, A; Germing, U; Giagounidis, A; Götze, KS; Grishina, O; Hackanson, B; Heil, G; Heuser, M; Jost, E; Krauter, J; Kuendgen, A; Lindemann, HW; Lübbert, M; May, AM; Müller-Tidow, C; Neubauer, A; Salih, HR; Schittenhelm, MM; Schlenk, RF; Schmoor, C; Scholl, S; Schwaenen, C; Thol, F; Wäsch, R, 2020)	0.81
"To study the efficacy of small dose HAG combined with decitabine regimen in the treatment of elderly patients with acute myeloid leukemia (AML)."	( [Efficacy of Small Dose HAG Regimen Combined with Decitabine in Treatment of Elderly Patients with Acute Myeloid Leukemia]. Luo, ZQ; Pan, PJ, 2020)	1.06
" The AML patients in CAG group was treated with CAG regimen, while the AML patients in combined treatment group was treated with small dose HAG regimen combined with decitabine."	( [Efficacy of Small Dose HAG Regimen Combined with Decitabine in Treatment of Elderly Patients with Acute Myeloid Leukemia]. Luo, ZQ; Pan, PJ, 2020)	1.01
"Small dose HAG regimen combined with decitabine for elderly patients with acute myeloid leukemia has a certain curative efficacy."	( [Efficacy of Small Dose HAG Regimen Combined with Decitabine in Treatment of Elderly Patients with Acute Myeloid Leukemia]. Luo, ZQ; Pan, PJ, 2020)	1.08
" However, there are no studies on the use of cytotoxic T‑lymphocyte antigen 4 (CTLA‑4) monoclonal antibody in combination with the melanoma‑associated antigen A family (MAGE‑As) co‑antigen peptide (p248V9) for treating breast cancer, which should be explored."	( CTLA‑4 blockade combined with 5‑aza‑2'‑deoxycytidine enhances the killing effect of MAGE‑A family common antigen peptide‑specific cytotoxic T cells on breast cancer. Hao, X; Li, W; Sang, M; Shan, B; Wu, Y, 2020)	0.56
"To investigate the effects of decitabine combined with bortezomib on the proliferation of mantle cell lymphoma cell lines (Jeko-1 and Grante519) in vitro and explore the underlying mechanisms."	( [Effects of Decitabine Combined with Bortezomib on the Proliferation of Mantle Cell Lymphoma Cell Lines and Its Underling Mechanisms]. Chen, D; Guo, XN; Li, Y; Qiao, SK; Xing, LN; Zhang, JN, 2020)	1.23
" Compared with single-drug treatment group, DAC combined with BTZ significantly increased the inhibitory rate and apoptotic rate of Jeko-1 and Grante519 cells; PCDH8, Caspase 3 and BAX expression levels significantly increased, and the expression levels of NF-κB, BCL-2 and CCND1 significantly decreased in Jeko-1 and Grante519 cells."	( [Effects of Decitabine Combined with Bortezomib on the Proliferation of Mantle Cell Lymphoma Cell Lines and Its Underling Mechanisms]. Chen, D; Guo, XN; Li, Y; Qiao, SK; Xing, LN; Zhang, JN, 2020)	0.94
" This phase 1 trial investigated the maximum tolerated dose (MTD), safety, pharmacokinetics, and anti-leukemic activity of volasertib in combination with decitabine in AML patients aged ≥ 65 years."	( Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia. Borthakur, G; Cortes, J; Fagan, N; Kantarjian, H; Podoltsev, N; Rajeswari, S; Stahl, M; Taube, T; Uy, GL; Zeidan, AM, 2021)	1.06
"We recommend the "venetoclax + HMAs combined with dose-adjusted CAH/HAG" regimen as an effective treatment for adult R/RAML."	( Venetoclax + hypomethylating agents combined with dose-adjusted HAG for relapsed/refractory acute myeloid leukemia: Two case reports. Bai, J; Lian, X; Pei, Z; Song, Q; Wang, H; Wang, J; Zhang, B, 2020)	0.56
"To evaluate the efficacy of decitabine combined with low-dose CEG regimen (DCEG) and decitabine combined with low-dose CAG regimen (DCAG) in the treatment of elderly patients with MDS and MDS-transformed acute myeloid leukemia (AML)."	( [Comparison of the Curative Efficacy of Elderly Patients with High-Risk MDS and MDS-Transformed AML between Decitabine Combined with Low-Dose CEG Regimen and Decitabine Combined with Low-Dose CAG Regimen]. He, HS; Hua, JS; Li, F; Ma, IX; Wang, XH; Wang, XQ; Wu, M; Xie, YH; Yang, RY; Ye, XJ, 2020)	1.06
" The treament results of decitabine combined with CEG and decitabine combined with CAG were compared."	( [Comparison of the Curative Efficacy of Elderly Patients with High-Risk MDS and MDS-Transformed AML between Decitabine Combined with Low-Dose CEG Regimen and Decitabine Combined with Low-Dose CAG Regimen]. He, HS; Hua, JS; Li, F; Ma, IX; Wang, XH; Wang, XQ; Wu, M; Xie, YH; Yang, RY; Ye, XJ, 2020)	1.07
"Decitabine combined with CEG regimen could improve the survival of patients with high-risk MDS and MDS-transformed AML."	( [Comparison of the Curative Efficacy of Elderly Patients with High-Risk MDS and MDS-Transformed AML between Decitabine Combined with Low-Dose CEG Regimen and Decitabine Combined with Low-Dose CAG Regimen]. He, HS; Hua, JS; Li, F; Ma, IX; Wang, XH; Wang, XQ; Wu, M; Xie, YH; Yang, RY; Ye, XJ, 2020)	2.21
" The aim of this study was to compare the differential effects of standard chemotherapy regimens (FEC: 5-fluorouracil plus epirubicine plus cyclophosphamide) in combination with epigenetic modulators (decitabine, valproic acid): (a) on gene methylation levels of selected tumour biomarkers (LINE-1, uPA, PAI-1, DAPK); (b) their expression status (uPA and PAI-1); (c) differentiation status (5meC and H3K27me3)."	( Epigenetic modulators combination with chemotherapy in breast cancer cells. Akgun, O; Ari, F; Magdolen, V; Napieralski, R; Ulukaya, E, 2021)	0.81
" Herein, we reported the first case with DEK/CAN-positive AML who achieved complete remission of molecular biology via decitabine combined with a medium-dose cytarabine regimen."	( Decitabine combined with medium-dose cytarabine in the treatment of DEK/CAN-positive acute myeloid leukemia: a case report. Zhang, X, 2021)	2.27
" We evaluated two new lower-intensity regimens with clofarabine (n = 119) or cladribine (n = 129) combined with low-dose cytarabine (LDAC) alternating with decitabine."	( Long-term results of low-intensity chemotherapy with clofarabine or cladribine combined with low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. Borthakur, G; Burger, J; Daver, N; DiNardo, CD; Estrov, Z; Ferrajoli, A; Garcia-Manero, G; Huang, X; Jabbour, E; Jain, N; Kadia, TM; Kanagal-Shamanna, R; Kantarjian, H; Konopleva, M; Pemmaraju, N; Pierce, S; Popat, U; Rausch, C; Ravandi, F; Verstovsek, S; Wang, X, 2021)	1.02
" However, the synergistic inhibitory effect of Smo inhibitor jervine and its combination with decitabine in MUTZ-1 cell lines remains lacking."	( Synergistic inhibitory effect of Smo inhibitor jervine and its combination with decitabine can target Hedgehog signaling pathway to inhibit myelodysplastic syndrome cell line. Hao, JP; Jiang, M; Qin, YT; Tuerxun, N; Wang, H; Wang, J; Yao, L; Zhao, F, 2021)	1.07
"The Smo inhibitor jervine and its combination with decitabine have a synergistic effect on the proliferation, cell cycle, and apoptosis of MUTZ-1 cells, and its mechanism may be achieved by interfering with the Shh signaling pathway."	( Synergistic inhibitory effect of Smo inhibitor jervine and its combination with decitabine can target Hedgehog signaling pathway to inhibit myelodysplastic syndrome cell line. Hao, JP; Jiang, M; Qin, YT; Tuerxun, N; Wang, H; Wang, J; Yao, L; Zhao, F, 2021)	1.1
" Here, we investigated whether proscillaridin A exhibits epigenetic and anticancer activity against eRMS RD cells, overexpressing MYC oncogene, and its combination with decitabine."	( Repurposing proscillaridin A in combination with decitabine against embryonal rhabdomyosarcoma RD cells. Caron, M; Djibo, R; Huot, M; Najmanovich, R; Raynal, NJM; Richer, C; Sinnett, D; St-Onge, P, 2021)	1.07
" In addition, proscillaridin A produced synergistic growth inhibition and loss of clonogenicity when combined with the approved DNA demethylating drug decitabine."	( Repurposing proscillaridin A in combination with decitabine against embryonal rhabdomyosarcoma RD cells. Caron, M; Djibo, R; Huot, M; Najmanovich, R; Raynal, NJM; Richer, C; Sinnett, D; St-Onge, P, 2021)	1.07
"Proscillaridin A produces anticancer and epigenetic effects in the low nanomolar range and its combination with decitabine warrants further investigation for the treatment of eRMS."	( Repurposing proscillaridin A in combination with decitabine against embryonal rhabdomyosarcoma RD cells. Caron, M; Djibo, R; Huot, M; Najmanovich, R; Raynal, NJM; Richer, C; Sinnett, D; St-Onge, P, 2021)	1.09
"To analyze the evaluation of artificial intelligence algorithm combined with gastric computed tomography (CT) image in clinical chemotherapy for advanced gastric cancer, 112 patients with advanced gastric cancer were selected as the research object."	( Segmentation of Gastric Computerized Tomography Images under Intelligent Algorithms in Evaluation of Efficacy of Decitabine Combined with Paclitaxel in Treatment of Gastric Cancer. Ge, Z; Liu, Q; Wang, M, 2021)	0.83
"To investigate the effects of decitabine (DEC) combined with all-trans retinoic acid (ATRA) on the number of immune cells, efficacy and adverse reactions in the treatment of myeloid neoplasms patients."	( [The Effects of Decitabine Combined with All-Trans Retinoic Acid on the Number of Immune Cells in Myeloid Neoplasms]. Cao, Y; Dong, WM; Gu, WY; Guo, YT; Lin, RR; Lin, Y; Liu, Y; Shang, LM; Wang, F; Wei, W, 2022)	1.36
"Eighty-four patients with myeloid tumors, including AML, MDS-EB-1 or MDS-EB-2 treated by the regimen containing decitabine in our hospital from January 2009 to October 2019 were enrolled and retrospectively analyzed, among the patients, 21 patients treated with DEC alone, 24 patients treated with DEC combined with ATRA (DEC/ATRA) and 39 patients treated with DEC combined with G-CSF priming regimen (DEC/priming)."	( [The Effects of Decitabine Combined with All-Trans Retinoic Acid on the Number of Immune Cells in Myeloid Neoplasms]. Cao, Y; Dong, WM; Gu, WY; Guo, YT; Lin, RR; Lin, Y; Liu, Y; Shang, LM; Wang, F; Wei, W, 2022)	1.28
" We demonstrated the synergism of [Bis + ABT199/venetoclax] in combination with panobinostat (Pano), decitabine (DAC), or olaparib (Ola), known inhibitors of BCL2, histone deacetylase, DNA methyltransferase, and poly(ADP-ribose) polymerase, respectively, in AML cells."	( Enhanced cytotoxicity of bisantrene when combined with venetoclax, panobinostat, decitabine and olaparib in acute myeloid leukemia cells. Andersson, BS; Murray, D; Nieto, Y; Popat, U; Valdez, BC; Yuan, B, 2022)	1.16
"We analyzed the treatment effects of chidamide and decitabine in combination with a HAG (homoharringtonine, cytarabine, G-CSF) priming regimen (CDHAG) in acute myeloid leukemia (AML) patients with TP53 mutation."	( Chidamide and Decitabine in Combination with a HAG Priming Regimen for Acute Myeloid Leukemia with TP53 Mutation. Bai, J; Pei, Z; Song, Q; Wang, H; Wang, J; Wu, H; Zhang, B, 2022)	1.33
"Venetoclax (Ven) in combination with azacitidine or decitabine (hypomethylating agent; HMA) is the standard-of-care treatment for older (≥75 years) or intensive chemotherapy ineligible adults with newly diagnosed acute myeloid leukemia (AML)."	( Tumor lysis syndrome and infectious complications during treatment with venetoclax combined with azacitidine or decitabine in patients with acute myeloid leukemia. Arora, S; Bachiashvili, K; Bathini, S; Bhatia, R; Di Stasi, A; Diamond, B; Godby, K; Gupta, U; Jamy, O; Oliver, JD; Rangaraju, S; Salzman, D; Vachhani, P; Worth, S; Zainaldin, C, 2022)	1.18
"The purpose of this study was to identify the incidence, sites and main pathogens, and risk factors for infectious complications occurring in patients with adult acute myeloid leukemia (AML) during the first course of venetoclax combined with decitabine or azacitidine."	( A real-world study of infectious complications of venetoclax combined with decitabine or azacitidine in adult acute myeloid leukemia. Chen, RR; Jin, J; Li, L; Mai, WY; Meng, HT; Qian, JJ; Sun, JN; Tong, HY; Wang, LL; Xie, WZ; Ye, XJ; Yu, WJ; Zhang, Y; Zhu, HH; Zhu, LX, 2022)	1.13
"A retrospective cohort analysis was performed of 81 patients with AML older than 14 years who received the first cycle of venetoclax combined with a hypomethylating agent (HMA) between March 2018 and March 2021 at our institution."	( A real-world study of infectious complications of venetoclax combined with decitabine or azacitidine in adult acute myeloid leukemia. Chen, RR; Jin, J; Li, L; Mai, WY; Meng, HT; Qian, JJ; Sun, JN; Tong, HY; Wang, LL; Xie, WZ; Ye, XJ; Yu, WJ; Zhang, Y; Zhu, HH; Zhu, LX, 2022)	0.95
"Compared with conventional chemotherapy, the incidence of infectious complications of venetoclax combined with decitabine or azacitidine significantly decreased."	( A real-world study of infectious complications of venetoclax combined with decitabine or azacitidine in adult acute myeloid leukemia. Chen, RR; Jin, J; Li, L; Mai, WY; Meng, HT; Qian, JJ; Sun, JN; Tong, HY; Wang, LL; Xie, WZ; Ye, XJ; Yu, WJ; Zhang, Y; Zhu, HH; Zhu, LX, 2022)	1.16
" Low-dose chemotherapy in combination with decitabine or azacitidine showed a similar response rate and prognosis."	( Hypomethylating agents combined with low-dose chemotherapy for elderly patients with acute myeloid leukaemia unfit for intensive chemotherapy: a real-world clinical experience. Cao, J; Chen, Y; Hu, J; Luo, L; Yang, T; Yang, X; Ye, Y; Zheng, J; Zheng, X; Zheng, Z, 2023)	1.17
"This analysis aimed to assess the effect of decitabine combined with allogeneic hematopoietic stem cell transplantation (allo-HSCT) in treating recurrent and refractory acute myeloid leukemia."	( Efficacy of decitabine combined with allogeneic hematopoietic stem cell transplantation in the treatment of recurrent and refractory acute myeloid leukemia (AML): A systematic review and meta-analysis. Chen, J; Zhang, D, 2022)	1.36
"Decitabine combined with allo-HSCT can obtain lower recurrence risk and longer disease-free survival time, and improve the prognosis of patients."	( Efficacy of decitabine combined with allogeneic hematopoietic stem cell transplantation in the treatment of recurrent and refractory acute myeloid leukemia (AML): A systematic review and meta-analysis. Chen, J; Zhang, D, 2022)	2.54
" This trial investigated the efficacy of decitabine in combination with rituximab, cisplatin, cytarabine, dexamethasone (RDHAP) in R/R-DLBCL."	( Decitabine combined with RDHAP regimen in relapsed/refractory diffuse large B cell lymphoma. Chen, Q; Ding, M; Dong, M; Feng, X; Fu, X; Kong, X; Li, L; Li, X; Sun, Z; Wang, X; Wu, X; Yan, J; Zhang, L; Zhang, M; Zhang, X; Zhu, L, 2023)	2.62
"To investigate the biological effects and its relative mechanism of decitabine combined with anlotinib on multiple myeloma cells."	( [Effects of Decitabine Combined with Anlotinib on Proliferation and Apoptosis of Multiple Myeloma Cells]. Cao, Y; Chen, HJ; Gu, WY; Liu, Y; Shang, LM; Yang, HN; Yue, YH, 2023)	1.52
"Decitabine combined with anlotinib can effectively inhibit the proliferation and induce apoptosis of MM cells, which provides a certain experimental basis for the treatment of human MM."	( [Effects of Decitabine Combined with Anlotinib on Proliferation and Apoptosis of Multiple Myeloma Cells]. Cao, Y; Chen, HJ; Gu, WY; Liu, Y; Shang, LM; Yang, HN; Yue, YH, 2023)	2.73
"To evaluate the clinical efficacy and safety of decitabine combined with modified CAG regimen (D-CAG regimen) in patients aged ≥70 years with newly diagnosed acute myeloid leukemia (AML)."	( [Efficacy and Safety of Decitabine Combined with Modified CAG Regimen in Patients Aged ≥ 70 Years with Newly Diagnosed Acute Myeloid Leukemia]. Cao, L; Hong, M; Jiang, ZQ; Li, JY; Liu, WJ; Qian, SX; Sun, Q; Zhu, Y, 2023)	1.47
"To explore the efficacy of tyrosine kinase inhibitor (TKI) combined with decitabine, homoharringtonine, and interferon regimen as maintenance therapy for blast phase chronic myeloid leukemia (CML-BP)."	( [Efficacy of Tyrosine Kinase Inhibitor Combined with Decitabine, Homoharringtonine, Interferon in the Maintenance Therapy of Blast Phase Chronic Myeloid Leukemia]. Li, ZY; Song, YP; Zhang, YL; Zhao, HF, 2023)	1.39
" Kaplan-Meier survival analysis showed that patients in TKI combined with decitabine, homoharringtonine, interferon group had longer event-free survival (7."	( [Efficacy of Tyrosine Kinase Inhibitor Combined with Decitabine, Homoharringtonine, Interferon in the Maintenance Therapy of Blast Phase Chronic Myeloid Leukemia]. Li, ZY; Song, YP; Zhang, YL; Zhao, HF, 2023)	1.39
"The TKI combined with decitabine, homoharringtonine and interferon regimen can significantly prolong the survival of CML-BP patients who obtained the major hematological response compared with TKI combined with conventional chemotherapy regimen."	( [Efficacy of Tyrosine Kinase Inhibitor Combined with Decitabine, Homoharringtonine, Interferon in the Maintenance Therapy of Blast Phase Chronic Myeloid Leukemia]. Li, ZY; Song, YP; Zhang, YL; Zhao, HF, 2023)	1.47

Excerpt	Reference	Relevance
" However, it exhibits a low oral bioavailability (only 9% in mice), because of low permeability across the intestine membrane and rapid metabolism to inactive metabolite."	( A carrier-mediated prodrug approach to improve the oral absorption of antileukemic drug decitabine. Fan, R; Gao, Y; He, Z; Jin, L; Lian, H; Liu, J; Sun, J; Sun, Y; Xu, Y; Zhang, T; Zhang, Y, 2013)	0.61
"As an initial step towards the clinical translation of these drugs for the treatment of HIV-1 infection, we synthesized decitabine and gemcitabine prodrugs in order to increase drug permeability, which has generally been shown to correlate with increased bioavailability in vivo."	( Characterization of permeability, stability and anti-HIV-1 activity of decitabine and gemcitabine divalerate prodrugs. Bonnac, L; Clouser, CL; Mansky, LM; Patterson, SE, 2014)	0.84
" Tetrahydrouridine, a competitive inhibitor of cytidine deaminase, was used in the combination to improve oral bioavailability of DAC."	( Subchronic oral toxicity study of decitabine in combination with tetrahydrouridine in CD-1 mice. Chan, K; Covey, JM; Engelke, K; Ling, Y; Saunthararajah, Y; Sharpnack, D; Terse, P, )	0.41
" Appropriate delivery systems able to enrich Decitabine at the site of action and improve its bioavailability would reduce the incidence of toxicity on healthy tissues."	( Novel epigenetic target therapy for prostate cancer: a preclinical study. Cinti, C; Gherardini, L; Grimaldi, S; Naldi, I; Pani, L; Pelosi, G; Taranta, M; Viglione, F, 2014)	0.66
"Decitabine, a DNA methyltransferase 1 inhibitor or DNA hypomethylating compound, is not readily orally bioavailable because of rapid clearance by cytidine deaminase (CDA) in the gut and liver."	( An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study. Amrein, PC; Azab, M; DeZern, AE; Faderl, S; Garcia-Manero, G; Harb, W; Kantarjian, H; Lowder, J; Michaelis, LC; Odenike, O; Oganesian, A; Savona, MR; Steensma, DP, 2019)	2.24
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
" Venetoclax (ABT-199) is a novel, orally bioavailable small-molecule inhibitor of B-cell lymphoma 2 (BCL-2), a key regulator of the intrinsic apoptotic pathway."	( Venetoclax and decitabine for treatment of relapsed T-cell acute lymphoblastic leukemia: A case report and review of literature. Adams, CB; Farhadfar, N; Li, Y; May, WS, 2021)	0.97
" The development of oral HMAs has been an area of active interest; however, oral bioavailability has been quite poor due to rapid metabolism by cytidine deaminase (CDA)."	( Cedazuridine/decitabine: from preclinical to clinical development in myeloid malignancies. Cahill, K; Odenike, O; Patel, AA; Saygin, C, 2021)	0.99
" Recently, two orally bioavailable DNA methyltransferase inhibitors, CC-486 and ASTX727, were approved."	( Silylation of Deoxynucleotide Analog Yields an Orally Available Drug with Antileukemia Effects. Fukuda-Kurahashi, Y; Harada, H; Hattori, N; Hayashi, Y; Kamachi, K; Kawaguchi, A; Kimura, S; Kurahashi, Y; Okada, S; Tohyama, K; Ureshino, H; Ushijima, T; Watanabe, T; Yamamoto, Y; Yamashita, S; Yoshida-Sakai, N, 2021)	0.62
"Tetrahydrouridine and decitabine were rapidly absorbed into the systemic circulation after a single combination oral dose, with relative bioavailability of decitabine ≥74% in fasted males compared with separate oral administration of THU followed by decitabine 1 h later."	( Pharmacokinetics and pharmacodynamics of an oral formulation of decitabine and tetrahydrouridine. Clausen, WHO; Friedrich, U; Jacobberger, JW; Lau, H; Saunthararajah, Y; Woost, PG, 2023)	1.46

Excerpt	Relevance	Reference
"In mammals, X-chromosome dosage compensation is achieved by inactivating one X chromosome in female cells."	( Effect of ageing on reactivation of the human X-linked HPRT locus. Axelman, J; Beggs, AH; Migeon, BR, 1988)	0.27
" For aza-dC a dose-response relationship was demonstrated for doses up to 50 mg kg-1 (3 times q 12 h); a higher dose resulted in only a slight increase in median survival time (MST)."	( Comparison of the antileukaemic activity of 5 aza-2-deoxycytidine and arabinofuranosyl-cytosine in rats with myelocytic leukaemia. Colly, LP; Lurvink, E; Richel, DJ; Willemze, R, 1988)	0.27
" The present study was designed to determine the effect of repeated decitabine dosing on HbF levels and hematologic toxicity over a 9-month treatment period."	( Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia. Bressler, L; DeSimone, J; Dorn, L; Koshy, M; Lavelle, D; Molokie, R; Talischy, N, 2002)	0.8
" Responders were treated at all three decitabine dose levels, and no dose-response correlation was observed."	( Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias. Andersson, B; Champlin, R; Couriel, D; de Lima, M; Donato, M; Gajewski, J; Giralt, S; Kantarjian, H; Khouri, I; Ravandi, F; Shahjahan, M; van Besien, K, 2003)	0.84
" There was no evidence of a dose-response effect."	( Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Andreeff, M; Cortes, J; Faderl, S; Garcia-Manero, G; Giles, FJ; Issa, JP; Kantarjian, HM; Keating, M; O'Brien, S; Rios, MB; Shan, J; Talpaz, M, 2003)	0.71
" Chronic dosing and sustained increases in hemoglobin F and total hemoglobin levels may be possible."	( Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. Bressler, L; Chen, YH; DeSimone, J; Dorn, L; Gavazova, S; Hillery, CA; Hoffman, R; Lavelle, D; Molokie, R; Saunthararajah, Y, 2003)	0.32
" This information sparked further clinical trials using a lower dosing schedule since the original studies using higher doses were associated with significant myelosuppression and induction toxicity."	( Decitabine dosing schedules. Issa, JP; Kantarjian, HM, 2005)	1.77
" Decitabine appears to be a promising new therapy for the treatment of MDS; however, defining the optimal dosing schedule and exploring the possible use in combination with other agents such as the histone deacetylase inhibitors need further evaluation."	( Decitabine in myelodysplastic syndromes. Saba, HI; Wijermans, PW, 2005)	2.68
" Dose-response correlations and the duration of response to aza-deoxycytidine (ADC) and trichostatin A (TSA) were characterized."	( Epigenetic-mediated upregulation of progesterone receptor B gene in endometrial cancer cell lines. Dowdy, SC; Eberhardt, NL; Gonzalez Bosquet, J; Jiang, SW; Podratz, KC; Xiong, Y; Zhao, Y, 2005)	0.33
" One example of epigenetic gene regulation is dosage compensation of the X chromosome in mammalian females."	( X-inactivation status varies in human embryonic stem cell lines. Baetge, EE; Batten, JL; Carpenter, MK; Hall, L; Hoffman, LM; Lawrence, J; Pardasani, D; Young, H, )	0.13
"Since appropriate dosing schedules of decitabine are being investigated, comparison of the clinical effectiveness of 5-AzaC and decitabine would be premature at this time."	( 5-azacytidine and decitabine monotherapies of myelodysplastic disorders. Kuykendall, JR, 2005)	0.93
"MTT method and flow cytometry were used to detect the growth and apoptosis of Daudi cells after treated with different dosage of 5-Aza-CdIR."	( [SHP-1 gene's methylation status of Daudi lymphoma cell and the demethylation effect of 5-aza-2'-deoxycytidine]. Fang, JC; Feng, ZY; He, D; He, XL; Li, L; Qiu, G; Su, ZL; Zhu, MF, 2006)	0.33
"The PK of this dosing regimen was evaluated in sixteen patients with MDS or AML."	( Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Cashen, AF; DiPersio, J; Fisher, N; Shah, AK; Todt, L, 2008)	0.67
"0 ng/ml, and the mean area under the plasma concentration-time curve (AUC0-infinity), 152-163 ng h/ml, were unchanged during dosing of decitabine for 3 days."	( Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Cashen, AF; DiPersio, J; Fisher, N; Shah, AK; Todt, L, 2008)	0.87
"Decitabine dosed at 15 mg/m2 iv every 8 h for 3 days resulted in a predictable and manageable toxicity profile in patients with MDS/AML."	( Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Cashen, AF; DiPersio, J; Fisher, N; Shah, AK; Todt, L, 2008)	2.11
" Ongoing studies are evaluating alternative dosing schedules for these drugs and the activity and safety of this class of agent in combination with histone deacetylase inhibitors."	( Use of hypomethylating agents in myelodysplastic syndromes. Atallah, E; Garcia-Manero, G, 2007)	0.34
" Since these low-dose regimens are well-tolerated with minimal toxicity, they are suitable for chronic dosing to maintain promoter hypomethylation and expression of target genes."	( Oral decitabine reactivates expression of the methylated gamma-globin gene in Papio anubis. Chin, J; Desimone, J; Hankewych, M; Lavelle, D; Phiasivongsa, P; Redkar, S; Roxas, B; Saunthararajah, Y; Singh, M; Tang, C; Vaitkus, K; Will, R, 2007)	0.85
" Our data show that, in addition to gene dosage changes arising from LOI and hypermethylation-induced gene silencing, gene activation resulting from hypomethylation is also prevalent in WTs."	( Hypomethylation and aberrant expression of the glioma pathogenesis-related 1 gene in Wilms tumors. Baker, JA; Brown, KW; Chilukamarri, L; Dallosso, AR; Greenhough, A; Hancock, AL; Huang, TH; Malik, K; Malik, S; Royer-Pokora, B; Zabkiewicz, J, 2007)	0.34
" Recent clinical trials investigate new dosing schedules, routes of administration, and combination regimens."	( Current status of epigenetic treatment in myelodysplastic syndromes. Kuendgen, A; Lübbert, M, 2008)	0.35
" Optimizing dosing schedules of decitabine to maximize hypomethylation (low dose, high dose intensity, and multiple cycles) have further improved results, suggesting that decitabine is an active therapy that alters the natural course of MDS."	( Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies. Garcia-Manero, G; Issa, JP; Jabbour, E; Kantarjian, H, 2008)	1
" Further research is needed to determine the appropriate patient selection and dosing schedules."	( Review: recent clinical trials in epigenetic therapy. Issa, JP; Oki, Y, 2006)	0.33
" This study assessed the efficacy and safety of an alternative dosing regimen administered on an outpatient basis in academic and community-based practices."	( Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. Albitar, M; Arora, S; Baer, MR; Buckstein, R; Cullen, MT; Garcia-Manero, G; Godley, LA; Kantarjian, H; Larsen, JS; Slack, JL; Steensma, DP, 2009)	0.67
" Recent clinical trials have been investigating new dosing schedules, routes of administration, and combination of decitabine with other agents, including histone deacetylase (HDAC) inhibitors."	( Decitabine. Blagitko-Dorfs, N; Daskalakis, M; Hackanson, B, 2010)	2.01
" The present results show the applicability of our novel statistical methodology for quantitatively assessing drug synergy across a wide range of doses of agents with complex dose-response profiles, a methodology with great potential for advancing the development of chemopreventive combinations."	( Validation of a novel statistical model for assessing the synergy of combined-agent cancer chemoprevention. Fujimoto, J; Hong, WK; Kong, M; Lee, JJ; Lotan, R, 2010)	0.36
" The hydralazine dose was given according with the acetylator phenotype, and valproate was dosed at 30 mg/kg/day."	( Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial. Arias-Bofill, D; Candelaria, M; Cervera, E; de la Cruz-Hernández, E; Dueñas-Gonzalez, A; González-Fierro, A; Herrera, A; Labardini, J; Pérez-Cárdenas, E; Taja-Chayeb, L; Trejo-Becerril, C; Vidal, S, 2011)	0.37
" Hence, the study on the systems reported herein could provide a good basis for designing aza nucleoside prodrug systems that are less hydrophilic than their parental drugs and can be used, in different dosage forms, to release the parent drug in a controlled manner."	( Prodrugs of aza nucleosides based on proton transfer reaction. Karaman, R, 2010)	0.36
" However, the sequential schedule of decitabine 10 mg/m(2)/day on days 1 to 5 and vorinostat 200 mg twice a day on days 6 to 12 was more deliverable than both MTDs with fewer delays on repeated dosing and it represents the recommended phase II (RP2D) dose of this combination."	( Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas. Chen, EX; Egorin, MJ; Espinoza-Delgado, I; Hirte, HW; Holleran, JL; Hotte, SJ; Laughlin, A; McGill, S; Moretto, P; Oza, AM; Siu, LL; Stathis, A; Stayner, LA; Wang, L; Webster, S; Zhang, WJ, 2011)	0.98
" The US Food and Drug Administration has approved a 5-day outpatient decitabine dosing regimen, which might reduce administration costs compared with the standard 3-day inpatient regimen."	( Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes from a US payer perspective. Fleurence, R; Kim, E; Knopf, K; Linnehan, JE; Pan, F; Peng, S, 2010)	0.91
"The aim of this study was to assess the cost-effectiveness of 5-day dosing of decitabine versus BSC in US patients with intermediate- and high-risk MDS from a US payer perspective."	( Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes from a US payer perspective. Fleurence, R; Kim, E; Knopf, K; Linnehan, JE; Pan, F; Peng, S, 2010)	0.91
"In this study, decitabine administered on a 5-day dosing schedule was likely a cost-effective treatment option in patients with intermediate- and high-risk MDS from a US payer perspective."	( Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes from a US payer perspective. Fleurence, R; Kim, E; Knopf, K; Linnehan, JE; Pan, F; Peng, S, 2010)	1.03
" Most importantly, the elevated gene dosage of DNMT3B is associated with increased resistance to the growth-inhibitory effect mediated by DNA demethylating agents."	( DNMT3B gene amplification predicts resistance to DNA demethylating drugs. Esteller, M; Melo, SA; Simó-Riudalbas, L, 2011)	0.37
" The present study assessed an effective treatment dosage based on the cell viability, cytotoxicity, apoptosis and methylation assays for the investigated cell lines."	( Integrated epigenetics of human breast cancer: synoptic investigation of targeted genes, microRNAs and proteins upon demethylation treatment. Barekati, Z; Bitzer, J; Grussenmeyer, T; Hartmann, N; Jenoe, P; Kohler, C; Lefkovits, I; Letzkus, M; Moes, S; Radpour, R; Schumacher, MM; Staedtler, F; Zhong, XY, 2011)	0.37
" Over the years, the dosing of decitabine has been refined, such that for acute myeloid leukemia, a 5-day schedule of 20 mg/m(2) is now commonly utilized."	( Decitabine for acute myeloid leukemia. Marks, PW, 2012)	2.11
" Treatment with valproic acid (VPA), a histone deacetylase inhibitor, at 3 dosing regimens (300mg/kg at D2-9PP; 100mg/kg at D2-4PP, 200mg/kg at D5-7PP, 300mg/kg at D8-9PP; 100mg/kg at D2-5PP, 200mg/kg at D6-9PP) prior to daily separation reversed such a decrease in fear-potentiated startle."	( Neonatal isolation decreases cued fear conditioning and frontal cortical histone 3 lysine 9 methylation in adult female rats. Chen, LH; Cheng, LY; Cherng, CG; Kao, GS; Su, CC; Tzeng, WY; Wang, CY; Yu, L, 2012)	0.38
" This novel dosing schedule has yet to be evaluated in a Phase 3 trial."	( The role of decitabine for the treatment of acute myeloid leukemia. Ganetsky, A, 2012)	0.76
"5-AZn-2' deoxycytidylic acid had significant inhibition effect on proliferation of A549 cells in vitro, and the inhibition was notably dependent on time and dosage during 48-72 h; SOD level was significantly lower than those of control group (P<0."	( Effect of 5- AZn-2 '-deoxycytidine on proliferation of human lung adenocarcinoma cell line A549 in vitro. Cui, W; Huang, HQ; Li, N; Zhang, GS, 2013)	0.39
" A total of 79 patients received reduced dosage decitabine treatment (15 mg/M2/day intravenously for five consecutive days every four weeks)."	( Decitabine of reduced dosage in Chinese patients with myelodysplastic syndrome: a retrospective analysis. Chang, C; Chen, Y; Hou, M; Li, X; Song, L; Song, Q; Su, J; Wu, D; Wu, L; Xu, F; Zhang, X; Zhang, Z; Zhou, L, 2014)	2.1
" Recent and ongoing clinical trials investigate new dosing schedules, routes of administration, and combination of decitabine with other agents, including histone deacetylase inhibitors."	( Decitabine. Daskalakis, M; Hackanson, B, 2014)	2.06
" We summarize the results of recent preclinical studies and clinical trials for decitabine and discuss the connections among its hypomethylating effect, immune-activated mechanisms and clinical activity in solid tumors, keeping in mind the goal of optimizing dosing schedules."	( Decitabine: a promising epi-immunotherapeutic agent in solid tumors. Fu, X; Han, W; Li, X; Mei, Q; Nie, J, 2015)	2.09
"1% and 30-month overall survival rate after decitabine dosing 61."	( [Therapeutic efficacies of decitabine application prior to hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia]. Fu, C; Han, Y; Jin, Z; Liu, H; Ma, L; Miao, M; Qiu, H; Tang, X; Wang, J; Wang, P; Wu, D; Yan, S; Zheng, H; Zhou, J, 2015)	0.98
" The 5-AZA-CdR was selected as a representative demethylation agent to validate the principle of the TDQ method on three levels: significant dose-response relationships between the concentration of 5-AZA-CdR and the methylation level of promoters, mRNA expression level of the EGFP gene, and the fluorescence intensity of EGFP proteins."	( A novel quantification method for the total demethylation potential of aquatic sample extracts from Bohai Bay using the EGFP reporter gene. Guo, C; Han, M; Jiang, Y; Liang, B; Lv, Z; Nie, J; Qian, Y; Wang, X; Wei, Y; Wu, J; Yang, Y; Zhang, J, 2015)	0.42
"Our results provide an alternative approach for predicting what combinations, dosing and scheduling of drug delivery should be used to better individualize therapy of AML."	( Synergisitic and Antagonistic AML Cell Type-specific Responses to 5-Aza-2-deoxycitidine and 1-h-D-Arabinofuranoside. Arceci, RJ; Elmoneim, AA; Heuston, E; Triche, T; Wai, DH, 2016)	0.43
"X-chromosome inactivation is a mechanism of dosage compensation in which one of the two X chromosomes in female mammals is transcriptionally silenced."	( A high-throughput small molecule screen identifies synergism between DNA methylation and Aurora kinase pathways for X reactivation. Bartolomei, MS; Bedalov, A; Carrette, LL; Dial, TO; Hasaka, T; Jadhav, A; Kesner, B; Lee, JT; Lessing, D; Maloney, DJ; Payer, B; Simeonov, A; Szanto, A; Theriault, J; Wei, C, 2016)	0.43
" To aid clinicians in their daily clinical practice, we also comment on some practical aspects such as dosing and schedule, the choice of HMA and the use of complementary cellular therapies."	( Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation. Germing, U; Haas, R; Kobbe, G; Rautenberg, C; Schroeder, T, 2018)	0.48
" Several dose-response experiments were carried out during two periods, including not only the very first days of development (0-6 days post-fertilization, dpf), as done in previous studies, but also, and as a novelty, the period of gonadal development (10-30 dpf)."	( Treatment with a DNA methyltransferase inhibitor feminizes zebrafish and induces long-term expression changes in the gonads. Imués, MA; Piferrer, F; Ribas, L; Vanezis, K, 2017)	0.46
" After accounting for body size, decitabine pharmacokinetics were not affected by age, sex, race, dosing regimen, renal function (creatinine clearance), bilirubin, or disease type (AML or MDS) and all PK parameters (including clearance, steady-state volume of distribution, maximum concentration, time to reach maximal concentration, and terminal half-life) were comparable between adult and pediatric patients."	( Population Pharmacokinetic Analysis of Decitabine in Pediatric Patients With Acute Myeloid Leukemia. Appiani, C; Massarella, J; Nakahara, S; Nemat, S; Parasrampuria, DA; Poggesi, I; Zhang, L; Zhou, W, 2019)	1.06
" The current dosing regimen consists of one administration per day, for 5 days, each 4 weeks."	( Di- Bejaud, J; Bou Haidar, N; Briot, T; Guillet, C; Lagarce, F; Lautram, N; Legeay, S; Roger, E; Thépot, S, 2019)	0.51
"Epigenetic reprogramming using DNA demethylating drugs is a promising approach for cancer therapy, but its efficacy is highly dependent on the dosing regimen."	( Low-dose DNA demethylating therapy induces reprogramming of diverse cancer-related pathways at the single-cell level. Hattori, N; Takeshima, H; Ushijima, T; Wakabayashi, M; Yamashita, S; Yoda, Y, 2020)	0.56
"Design and development of efficient processes for continuous manufacturing of solid dosage oral formulations is of crucial importance for pharmaceutical industry in order to implement the Quality-by-Design paradigm."	( Experimental and thermodynamic modeling decitabine anti cancer drug solubility in supercritical carbon dioxide. Borousan, F; Hezave, AZ; Jamshidian, S; Marjani, A; Pishnamazi, M; Shirazian, S; Zabihi, S, 2021)	0.89
" However, as the efficacy and safety of rational dosing regimens are lacking, we evaluated the effectiveness and safety of reduced-dose azacitidine (AZA) vs."	( Evaluation of Reduced-Dose Decitabine and Azacitidine for Treating Myelodysplastic Syndromes: A Retrospective Study. Du, X; Hu, N; Pan, L; Qin, T; Qu, S; Wang, B; Wang, X; Xiao, Z; Xu, Z, 2021)	0.92
" Both HMAs led to objective hematologic or non-hematologic AEs (27%-43%), while dosage modification/delay were more frequent in patients treated with azacitidine (81% vs."	( Hypomethylating agents in the treatment of chronic myelomonocytic leukemia: a meta-analysis and systematic review. Deng, C; Du, X; Geng, S; Huang, X; Li, M; Weng, J; Wu, P; Xu, R, 2021)	0.62
" Although extended dosing may provide the optimal scheduling, the reliance of injectable formulation of the drug limits it to intermittent treatment."	( Optimizing DNA hypomethylating therapy in acute myeloid leukemia and myelodysplastic syndromes. Lane, SW; Straube, J; Vu, T, 2021)	0.62
"In this study, we perform dose-response curves of decitabine, a DNA methyltransferase inhibitor, on patient-cultured tumors and meningioma cell lines."	( Targeting DNA Methyl Transferases with Decitabine in Cultured Meningiomas. Damek, DM; Foreman, WB; Fringuello, AR; Graner, MW; Jensen, RL; Lillehei, KO; Ormond, DR; Scherer, SR; Tatman, PD; Wroblewski, TH; Youssef, AS, 2022)	1.24
"Combination therapy has become the hallmark of lung cancer treatment, as it reduces the dosage intensity of individual drugs while increasing their efficacy."	( The combination of decitabine and aspirin inhibits tumor growth and metastasis in non-small cell lung cancer. Li, N; Song, B; Xu, M; Yang, X, 2022)	1.05
" In this review, we discuss the path to regulatory approval of azacitidine and decitabine, highlighting the substantial efforts that have been made to optimize the dosing schedule and administration of these drugs, including the development of new, oral formulations of both agents."	( Hypomethylating agents for the treatment of myelodysplastic syndromes and acute myeloid leukemia: Past discoveries and future directions. Kantarjian, H; Short, NJ, 2022)	0.95
" Venetoclax treatment variables included dosing information, schedule modifications, and drug-drug interactions."	( Venetoclax and Hypomethylating Agents as First-line Treatment in Newly Diagnosed Patients with AML in a Predominately Community Setting in the US. Abbas, JA; Bui, CN; Donnellan, W; Flahavan, EM; Flores, B; Gershon, A; Jin, H; Ku, G; Ma, E; Montez, M; Onishi, M; Vachhani, P; Xu, T, 2022)	0.72

Class	Description
2'-deoxyribonucleoside
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathway	Proteins	Compounds
Disease	1278	231
Diseases of programmed cell death	36	11
Defective pyroptosis	4	7

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, Beta-lactamase	Escherichia coli K-12	Potency	112.2020	0.0447	17.8581	100.0000	AID485294
RAR-related orphan receptor gamma	Mus musculus (house mouse)	Potency	17.6874	0.0060	38.0041	19,952.5996	AID1159521; AID1159523
ATAD5 protein, partial	Homo sapiens (human)	Potency	0.5802	0.0041	10.8903	31.5287	AID504466
TDP1 protein	Homo sapiens (human)	Potency	0.1400	0.0008	11.3822	44.6684	AID686978; AID686979
progesterone receptor	Homo sapiens (human)	Potency	16.7855	0.0004	17.9460	75.1148	AID1346795
EWS/FLI fusion protein	Homo sapiens (human)	Potency	10.2218	0.0013	10.1577	42.8575	AID1259252; AID1259253; AID1259255; AID1259256
glucocorticoid receptor [Homo sapiens]	Homo sapiens (human)	Potency	26.8325	0.0002	14.3764	60.0339	AID720692
retinoid X nuclear receptor alpha	Homo sapiens (human)	Potency	6.7400	0.0008	17.5051	59.3239	AID1159527
estrogen-related nuclear receptor alpha	Homo sapiens (human)	Potency	2.1761	0.0015	30.6073	15,848.9004	AID1224841; AID1224848; AID1224849; AID1259403
farnesoid X nuclear receptor	Homo sapiens (human)	Potency	10.5901	0.3758	27.4851	61.6524	AID743217
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	10.4142	0.0002	29.3054	16,493.5996	AID743069; AID743075; AID743078
67.9K protein	Vaccinia virus	Potency	6.7833	0.0001	8.4406	100.0000	AID720579; AID720580
chromobox protein homolog 1	Homo sapiens (human)	Potency	79.4328	0.0060	26.1688	89.1251	AID540317
nuclear factor erythroid 2-related factor 2 isoform 2	Homo sapiens (human)	Potency	10.3225	0.0041	9.9848	25.9290	AID504444
potassium voltage-gated channel subfamily H member 2 isoform d	Homo sapiens (human)	Potency	35.4813	0.0178	9.6374	44.6684	AID588834
thyroid hormone receptor beta isoform 2	Rattus norvegicus (Norway rat)	Potency	5.6986	0.0003	23.4451	159.6830	AID743065; AID743066; AID743067
geminin	Homo sapiens (human)	Potency	0.2311	0.0046	11.3741	33.4983	AID624297
Cellular tumor antigen p53	Homo sapiens (human)	Potency	0.2371	0.0023	19.5956	74.0614	AID651631
Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus	Potency	19.9526	0.0096	10.5250	35.4813	AID1479145
ATPase family AAA domain-containing protein 5	Homo sapiens (human)	Potency	1.1883	0.0119	17.9420	71.5630	AID651632
Ataxin-2	Homo sapiens (human)	Potency	1.1883	0.0119	12.2221	68.7989	AID651632
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
exodeoxyribonuclease V subunit RecB	Escherichia coli str. K-12 substr. MG1655	IC50 (µMol)	118.4540	0.1000	0.1000	0.1000	AID652151
exodeoxyribonuclease V subunit RecC	Escherichia coli str. K-12 substr. MG1655	IC50 (µMol)	118.4540	0.1000	0.1000	0.1000	AID652151
ATP-binding cassette sub-family C member 3	Homo sapiens (human)	IC50 (µMol)	133.0000	0.6315	4.4531	9.3000	AID1473740
Multidrug resistance-associated protein 4	Homo sapiens (human)	IC50 (µMol)	133.0000	0.2000	5.6774	10.0000	AID1473741
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	133.0000	0.1100	7.1903	10.0000	AID1473738
DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)	IC50 (µMol)	0.0300	0.0186	1.6488	6.0000	AID1505769
Canalicular multispecific organic anion transporter 1	Homo sapiens (human)	IC50 (µMol)	133.0000	2.4100	6.3433	10.0000	AID1473739
Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)	IC50 (µMol)	10.0000	0.0025	1.1480	9.2000	AID1505768
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
xenobiotic metabolic process	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
bile acid and bile salt transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
leukotriene transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
monoatomic anion transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transport across blood-brain barrier	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
prostaglandin secretion	Multidrug resistance-associated protein 4	Homo sapiens (human)
cilium assembly	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet degranulation	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic metabolic process	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
bile acid and bile salt transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
cAMP transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
leukotriene transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
monoatomic anion transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
export across plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
transport across blood-brain barrier	Multidrug resistance-associated protein 4	Homo sapiens (human)
guanine nucleotide transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle G2/M phase transition	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
ER overload response	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
in utero embryonic development	Cellular tumor antigen p53	Homo sapiens (human)
somitogenesis	Cellular tumor antigen p53	Homo sapiens (human)
release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic progenitor cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
T cell proliferation involved in immune response	Cellular tumor antigen p53	Homo sapiens (human)
B cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
T cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
response to ischemia	Cellular tumor antigen p53	Homo sapiens (human)
nucleotide-excision repair	Cellular tumor antigen p53	Homo sapiens (human)
double-strand break repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
protein import into nucleus	Cellular tumor antigen p53	Homo sapiens (human)
autophagy	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
Ras protein signal transduction	Cellular tumor antigen p53	Homo sapiens (human)
gastrulation	Cellular tumor antigen p53	Homo sapiens (human)
neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
protein localization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA replication	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
determination of adult lifespan	Cellular tumor antigen p53	Homo sapiens (human)
mRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
rRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
response to salt stress	Cellular tumor antigen p53	Homo sapiens (human)
response to inorganic substance	Cellular tumor antigen p53	Homo sapiens (human)
response to X-ray	Cellular tumor antigen p53	Homo sapiens (human)
response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of gene expression	Cellular tumor antigen p53	Homo sapiens (human)
cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
viral process	Cellular tumor antigen p53	Homo sapiens (human)
glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
cerebellum development	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell growth	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
mitotic G1 DNA damage checkpoint signaling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of telomere maintenance via telomerase	Cellular tumor antigen p53	Homo sapiens (human)
T cell differentiation in thymus	Cellular tumor antigen p53	Homo sapiens (human)
tumor necrosis factor-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
regulation of tissue remodeling	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV	Cellular tumor antigen p53	Homo sapiens (human)
multicellular organism growth	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of mitochondrial membrane permeability	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
entrainment of circadian clock by photoperiod	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial DNA repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
transcription initiation-coupled chromatin remodeling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of proteolysis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
response to antibiotic	Cellular tumor antigen p53	Homo sapiens (human)
fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
circadian behavior	Cellular tumor antigen p53	Homo sapiens (human)
bone marrow development	Cellular tumor antigen p53	Homo sapiens (human)
embryonic organ development	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Cellular tumor antigen p53	Homo sapiens (human)
protein stabilization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of helicase activity	Cellular tumor antigen p53	Homo sapiens (human)
protein tetramerization	Cellular tumor antigen p53	Homo sapiens (human)
chromosome organization	Cellular tumor antigen p53	Homo sapiens (human)
neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic stem cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
type II interferon-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
cardiac septum morphogenesis	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of programmed necrotic cell death	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress	Cellular tumor antigen p53	Homo sapiens (human)
thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
necroptotic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to xenobiotic stimulus	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to ionizing radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV-C	Cellular tumor antigen p53	Homo sapiens (human)
stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to actinomycin D	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
replicative senescence	Cellular tumor antigen p53	Homo sapiens (human)
oxidative stress-induced premature senescence	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
oligodendrocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of execution phase of apoptosis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of G1 to G0 transition	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of miRNA processing	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of pentose-phosphate shunt	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
regulation of fibroblast apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
DNA methylation-dependent heterochromatin formation	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
DNA-templated transcription	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
positive regulation of gene expression	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
negative regulation of gene expression	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
methylation	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
epigenetic programming of gene expression	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
negative regulation of gene expression via chromosomal CpG island methylation	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
cellular response to amino acid stimulus	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
chromosomal DNA methylation maintenance following DNA replication	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
cellular response to bisphenol A	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferation	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
negative regulation of vascular associated smooth muscle cell apoptotic process	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
negative regulation of vascular associated smooth muscle cell differentiation involved in phenotypic switching	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
xenobiotic metabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
negative regulation of gene expression	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bile acid and bile salt transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
heme catabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic export from cell	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transepithelial transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
leukotriene transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
monoatomic anion transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
cellular response to starvation	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
regulation of DNA replication	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
DNA methylation-dependent heterochromatin formation	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
synaptonemal complex assembly	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
spermatid development	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
long-term memory	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
fertilization	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
peptidyl-lysine dimethylation	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
regulation of protein modification process	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
organ growth	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
phenotypic switching	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
negative regulation of gene expression via chromosomal CpG island methylation	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
response to ethanol	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
behavioral response to cocaine	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
oocyte development	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
neuron fate specification	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
response to fungicide	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
cellular response to cocaine	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
cellular response to xenobiotic stimulus	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
negative regulation of autophagosome assembly	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
cell population proliferation	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
positive regulation of B cell proliferation	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
nuclear DNA replication	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
signal transduction in response to DNA damage	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
isotype switching	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
positive regulation of DNA replication	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
positive regulation of isotype switching to IgG isotypes	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
DNA clamp unloading	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
regulation of mitotic cell cycle phase transition	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
positive regulation of cell cycle G2/M phase transition	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
negative regulation of receptor internalization	Ataxin-2	Homo sapiens (human)
regulation of translation	Ataxin-2	Homo sapiens (human)
RNA metabolic process	Ataxin-2	Homo sapiens (human)
P-body assembly	Ataxin-2	Homo sapiens (human)
stress granule assembly	Ataxin-2	Homo sapiens (human)
RNA transport	Ataxin-2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
ATP binding	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type bile acid transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATP hydrolysis activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
icosanoid transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
guanine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
purine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type bile acid transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
efflux transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP hydrolysis activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
transcription cis-regulatory region binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
core promoter sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
TFIID-class transcription factor complex binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
protease binding	Cellular tumor antigen p53	Homo sapiens (human)
p53 binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity	Cellular tumor antigen p53	Homo sapiens (human)
mRNA 3'-UTR binding	Cellular tumor antigen p53	Homo sapiens (human)
copper ion binding	Cellular tumor antigen p53	Homo sapiens (human)
protein binding	Cellular tumor antigen p53	Homo sapiens (human)
zinc ion binding	Cellular tumor antigen p53	Homo sapiens (human)
enzyme binding	Cellular tumor antigen p53	Homo sapiens (human)
receptor tyrosine kinase binding	Cellular tumor antigen p53	Homo sapiens (human)
ubiquitin protein ligase binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase regulator activity	Cellular tumor antigen p53	Homo sapiens (human)
ATP-dependent DNA/DNA annealing activity	Cellular tumor antigen p53	Homo sapiens (human)
identical protein binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase binding	Cellular tumor antigen p53	Homo sapiens (human)
protein heterodimerization activity	Cellular tumor antigen p53	Homo sapiens (human)
protein-folding chaperone binding	Cellular tumor antigen p53	Homo sapiens (human)
protein phosphatase 2A binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Cellular tumor antigen p53	Homo sapiens (human)
14-3-3 protein binding	Cellular tumor antigen p53	Homo sapiens (human)
MDM2/MDM4 family protein binding	Cellular tumor antigen p53	Homo sapiens (human)
disordered domain specific binding	Cellular tumor antigen p53	Homo sapiens (human)
general transcription initiation factor binding	Cellular tumor antigen p53	Homo sapiens (human)
molecular function activator activity	Cellular tumor antigen p53	Homo sapiens (human)
promoter-specific chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA binding	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
RNA binding	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
DNA (cytosine-5-)-methyltransferase activity	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
protein binding	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
zinc ion binding	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
methyl-CpG binding	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
DNA-methyltransferase activity	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
promoter-specific chromatin binding	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
protein binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP hydrolysis activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA binding	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
transcription corepressor binding	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
p53 binding	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
protein binding	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
zinc ion binding	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
protein-lysine N-methyltransferase activity	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
enzyme binding	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
histone H3K9 methyltransferase activity	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
histone H3K27 methyltransferase activity	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
C2H2 zinc finger domain binding	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
histone H3K56 methyltransferase activity	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
histone H3K9me2 methyltransferase activity	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
promoter-specific chromatin binding	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
protein binding	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
ATP binding	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
ATP hydrolysis activity	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
DNA clamp unloader activity	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
DNA binding	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
RNA binding	Ataxin-2	Homo sapiens (human)
epidermal growth factor receptor binding	Ataxin-2	Homo sapiens (human)
protein binding	Ataxin-2	Homo sapiens (human)
mRNA binding	Ataxin-2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basal plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basolateral plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
nucleolus	Multidrug resistance-associated protein 4	Homo sapiens (human)
Golgi apparatus	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet dense granule membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
external side of apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
nuclear body	Cellular tumor antigen p53	Homo sapiens (human)
nucleus	Cellular tumor antigen p53	Homo sapiens (human)
nucleoplasm	Cellular tumor antigen p53	Homo sapiens (human)
replication fork	Cellular tumor antigen p53	Homo sapiens (human)
nucleolus	Cellular tumor antigen p53	Homo sapiens (human)
cytoplasm	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrion	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial matrix	Cellular tumor antigen p53	Homo sapiens (human)
endoplasmic reticulum	Cellular tumor antigen p53	Homo sapiens (human)
centrosome	Cellular tumor antigen p53	Homo sapiens (human)
cytosol	Cellular tumor antigen p53	Homo sapiens (human)
nuclear matrix	Cellular tumor antigen p53	Homo sapiens (human)
PML body	Cellular tumor antigen p53	Homo sapiens (human)
transcription repressor complex	Cellular tumor antigen p53	Homo sapiens (human)
site of double-strand break	Cellular tumor antigen p53	Homo sapiens (human)
germ cell nucleus	Cellular tumor antigen p53	Homo sapiens (human)
chromatin	Cellular tumor antigen p53	Homo sapiens (human)
transcription regulator complex	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex	Cellular tumor antigen p53	Homo sapiens (human)
female germ cell nucleus	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
nucleus	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
nucleoplasm	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
replication fork	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
pericentric heterochromatin	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
nucleus	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
virion membrane	Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus
plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cell surface	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
intercellular canaliculus	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
nucleus	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
nucleoplasm	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
nuclear speck	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
chromatin	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
nucleus	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
Elg1 RFC-like complex	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
nucleus	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
cytoplasm	Ataxin-2	Homo sapiens (human)
Golgi apparatus	Ataxin-2	Homo sapiens (human)
trans-Golgi network	Ataxin-2	Homo sapiens (human)
cytosol	Ataxin-2	Homo sapiens (human)
cytoplasmic stress granule	Ataxin-2	Homo sapiens (human)
membrane	Ataxin-2	Homo sapiens (human)
perinuclear region of cytoplasm	Ataxin-2	Homo sapiens (human)
ribonucleoprotein complex	Ataxin-2	Homo sapiens (human)
cytoplasmic stress granule	Ataxin-2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID620534	Reactivation of MeCp2 mutant expression in human GM11272 cells after 6 days by PCR method	2011	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 21, Issue:18	Clonal Rett Syndrome cell lines to test compounds for activation of wild-type MeCP2 expression.
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1505768	Inhibition of human G9a using biotinylated-H3K9 peptide as substrate after 1 hr in presence of SAM by TR-FRET assay	2018	Journal of medicinal chemistry, Aug-09, Volume: 61, Issue:15	Discovery of Reversible DNA Methyltransferase and Lysine Methyltransferase G9a Inhibitors with Antitumoral in Vivo Efficacy.
AID1298358	Antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as reduction in U5-gag level at 0.25 to 8 uM after 2 to 72 hrs by qPCR method	2016	Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11	Synergistic reduction of HIV-1 infectivity by 5-azacytidine and inhibitors of ribonucleotide reductase.
AID1473740	Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID425653	Renal clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID1447872	Inhibition of DNMT in human HCT116 cells assessed as demethylation of CDKN2A promoter at 100 nM after 7 days by COBRA analysis relative to control	2017	Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11	Rational Design of Bisubstrate-Type Analogues as Inhibitors of DNA Methyltransferases in Cancer Cells.
AID700045	Antiviral activity against HIV1 infected in human U373-MAGI cells expressing CXCR4 assessed as frequency of viral mutagenesis at 70 nM preincubated for 2 hrs prior to infection followed by compound wash out measured after 48 hrs by flow cytometry relative	2012	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 22, Issue:21	Anti-HIV-1 activity of resveratrol derivatives and synergistic inhibition of HIV-1 by the combination of resveratrol and decitabine.
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1298425	Antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as Pol mutation at 3.8 uM incubated for 2 hrs prior to infection measured at 72 hrs post infection by illumina sequencing method (Rvb = 18.5%)	2016	Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11	Synergistic reduction of HIV-1 infectivity by 5-azacytidine and inhibitors of ribonucleotide reductase.
AID540212	Mean residence time in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1473741	Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID540209	Volume of distribution at steady state in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1199274	Half life in patient with myelodysplastic syndrome dosed via infusion	2015	Journal of medicinal chemistry, Mar-26, Volume: 58, Issue:6	Targeting DNA methylation with small molecules: what's next?
AID425652	Total body clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID1473738	Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1298427	Antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as Env mutation at 3.8 uM incubated for 2 hrs prior to infection measured at 72 hrs post infection by illumina sequencing method (Rvb = 21.4%)	2016	Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11	Synergistic reduction of HIV-1 infectivity by 5-azacytidine and inhibitors of ribonucleotide reductase.
AID699924	Antiviral activity against HIV1 infected in human U373-MAGI cells expressing CXCR4 assessed as infected host cells at 70 nM preincubated for 2 hrs prior to infection followed by compound wash out measured after 48 hrs by single round replication assay	2012	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 22, Issue:21	Anti-HIV-1 activity of resveratrol derivatives and synergistic inhibition of HIV-1 by the combination of resveratrol and decitabine.
AID1505769	Inhibition of human DNMT1 using polydeoxyinosine polydeoxycytosine DNA as substrate after 15 mins in presence of SAM by TR-FRET assay	2018	Journal of medicinal chemistry, Aug-09, Volume: 61, Issue:15	Discovery of Reversible DNA Methyltransferase and Lysine Methyltransferase G9a Inhibitors with Antitumoral in Vivo Efficacy.
AID540211	Fraction unbound in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID588213	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID540210	Clearance in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1447880	Inhibition of DNMT in human KG1 cells assessed as CpG site demethylation at CMV promoter at 1 uM after 24 hrs by NOMe-Seq method relative to control	2017	Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11	Rational Design of Bisubstrate-Type Analogues as Inhibitors of DNA Methyltransferases in Cancer Cells.
AID1298426	Antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as Vif mutation at 3.8 uM incubated for 2 hrs prior to infection measured at 72 hrs post infection by illumina sequencing method (Rvb = 19.2%)	2016	Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11	Synergistic reduction of HIV-1 infectivity by 5-azacytidine and inhibitors of ribonucleotide reductase.
AID98149	Compound was tested for its inhibitory activity against L1210 lymphoid leukemia	1987	Journal of medicinal chemistry, Feb, Volume: 30, Issue:2	Synthesis and antitumor activity of fluorine-substituted 4-amino-2(1H)-pyridinones and their nucleosides. 3-Deazacytosines.
AID588211	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1298294	Reduction in dCTP level in human U373-MAGI cells at EC75 after 4 hrs by LC-MS/MS analysis relative to control	2016	Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11	Synergistic reduction of HIV-1 infectivity by 5-azacytidine and inhibitors of ribonucleotide reductase.
AID1298428	Antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as Nef mutation at 3.8 uM incubated for 2 hrs prior to infection measured at 72 hrs post infection by illumina sequencing method (Rvb = 22.6%)	2016	Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11	Synergistic reduction of HIV-1 infectivity by 5-azacytidine and inhibitors of ribonucleotide reductase.
AID1447881	Inhibition of DNMT in human KG1 cells assessed as increase in DNA accessibility by opening the chromatin at 1 uM after 24 hrs by NOMe-Seq method relative to control	2017	Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11	Rational Design of Bisubstrate-Type Analogues as Inhibitors of DNA Methyltransferases in Cancer Cells.
AID1298424	Antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as Gag mutation at 3.8 uM incubated for 2 hrs prior to infection measured at 72 hrs post infection by illumina sequencing method (Rvb = 18.4%)	2016	Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11	Synergistic reduction of HIV-1 infectivity by 5-azacytidine and inhibitors of ribonucleotide reductase.
AID540213	Half life in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1473739	Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID588212	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1298416	Antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as reduction in gag level at 0.25 to 8 uM after 2 to 72 hrs by qPCR method	2016	Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11	Synergistic reduction of HIV-1 infectivity by 5-azacytidine and inhibitors of ribonucleotide reductase.
AID1447871	Inhibition of DNMT in human HCT116 cells assessed as demethylation of CDKN2A promoter at 100 nM after 3 days by COBRA analysis relative to control	2017	Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11	Rational Design of Bisubstrate-Type Analogues as Inhibitors of DNA Methyltransferases in Cancer Cells.
AID620532	Reactivation of MeCp2 mutant expression in human GM11272 cells at 1 to 100 nM by PCR method	2011	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 21, Issue:18	Clonal Rett Syndrome cell lines to test compounds for activation of wild-type MeCP2 expression.
AID1347110	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347119	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347117	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347124	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	103 (2.76)	18.7374
1990's	160 (4.29)	18.2507
2000's	1120 (30.00)	29.6817
2010's	1868 (50.04)	24.3611
2020's	482 (12.91)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	205 (5.39%)	5.53%
Reviews	278 (7.31%)	6.00%
Case Studies	104 (2.73%)	4.05%
Observational	7 (0.18%)	0.25%
Other	3,210 (84.38%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (399)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Randomized, Double Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Romiplostim (AMG 531) Treatment of Subjects With Low or Intermediate Risk Myelodysplastic Syndrome (MDS) Receiving Hypomethylating Agents [NCT00321711]	Phase 2	69 participants (Actual)	Interventional	2006-10-01	Completed
A Single Arm, Phase 2 Study Evaluating Safety and Efficacy of Maintenance Therapy With Hypomethylating Agent and Venetoclax After Allogeneic Stem Cell Transplantation in Patients With f High-risk Myeloid Malignancies. [NCT05841771]	Phase 2	78 participants (Anticipated)	Interventional	2023-01-01	Recruiting
A Phase II Study of Decitabine in Patients With Chronic Myelomonocytic Leukemia [NCT01098084]	Phase 2	41 participants (Actual)	Interventional	2008-11-30	Completed
Induction Therapy With Decitabine and Plerixafor Priming for Patients ≥ 60 Years With Acute Myeloid Leukemia [NCT01352650]	Phase 1	71 participants (Actual)	Interventional	2011-06-17	Completed
Phase I Study Targeting DNA Methyltransferases in Metastatic Triple-Negative Breast Cancer [NCT05673200]	Phase 1	24 participants (Anticipated)	Interventional	2023-09-25	Recruiting
Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Chronic Myelomonocytic Leukemia [NCT05038592]	Phase 1/Phase 2	64 participants (Anticipated)	Interventional	2022-03-04	Recruiting
A Phase 2 Study of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma [NCT04340843]	Phase 2	32 participants (Anticipated)	Interventional	2020-09-08	Suspended(stopped due to Other - Completed stage 1 accrual)
Phase I-Ib/II Open-label Multi-center Study of the Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Adult Patients With Advanced Malignancies [NCT02608268]	Phase 1/Phase 2	252 participants (Actual)	Interventional	2015-11-23	Terminated(stopped due to Business reasons)
Phase I Study of TK216 in Patients With Relapsed and Refractory Leukemias [NCT03752138]	Phase 1	0 participants (Actual)	Interventional	2019-03-31	Withdrawn(stopped due to The supporting pharamceutical company elected not to pursue this study at this time.)
Use of Decitabine in Myelodysplastic Syndrome (MDS) Following Azacitidine (AZA) Failure [NCT01133886]	Phase 2	50 participants (Anticipated)	Interventional	2010-09-30	Recruiting
An Open Label, Single Arm, Single-Center Exploratory Study to Evaluate the Efficacy and Safety of Selinexor and HAAG +/- HMA in Relapsed/Refractory Acute Leukemia (AML) Patients [NCT05805072]		20 participants (Anticipated)	Interventional	2023-05-01	Not yet recruiting
A Pilot Study of Decitabine Maintenance in Elderly Acute Myeloid Leukemia Patients Who Can Tolerate Aggressive Therapy [NCT01149408]	Phase 1	3 participants (Actual)	Interventional	2011-02-28	Completed
Targeted Demethylation to Enhance Response or Overcome Resistance to EGFR Blocking Agents in KRAS Wild-type Metastatic Colorectal Cancer Patients Using Sequential Decitabine and Panitumumab [NCT00879385]	Phase 1	21 participants (Actual)	Interventional	2009-12-31	Completed
An Open-Label, Multicenter, Extension Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers [NCT04093570]	Phase 2	332 participants (Anticipated)	Interventional	2019-09-30	Enrolling by invitation
Single Arm, Open Label, Phase I Study for Dose and Schedule Finding of Decitabine in Patients With Higher-risk MDS and MDS/AML Receiving Allogeneic Stem Cell Transplantation [NCT01277484]	Phase 1	19 participants (Actual)	Interventional	2011-01-31	Active, not recruiting
A Phase 1b Study to Evaluate the Effect of Food on Pharmacokinetics of ASTX727 (Cedazuridine and Decitabine) in Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia [NCT03813186]	Phase 1	18 participants (Actual)	Interventional	2018-11-08	Completed
Decitabine Plus mBU/CY Preconditioning for Relapse/Refractory Acute Leukemia Patients Undergoing HSCT [NCT03799224]	Phase 2/Phase 3	55 participants (Anticipated)	Interventional	2018-12-01	Recruiting
Prophylactic Donor Lymphocyte Infusion After Allo-PBSCT for Patients With Very High-risk Hematologic Malignancies [NCT03771222]	Phase 2	40 participants (Anticipated)	Interventional	2019-01-31	Not yet recruiting
A Phase I/II Combination Study of Sapacitabine in Acute Myeloid Leukemia or Myelodysplastic Syndromes [NCT01211457]	Phase 1/Phase 2	65 participants (Anticipated)	Interventional	2010-06-17	Recruiting
A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma [NCT03579082]	Phase 4	60 participants (Anticipated)	Interventional	2018-06-01	Recruiting
A Phase II Multicenter Open-label Study to Assess the Efficacy of Decitabine in the Treatment of Chronic Myelomonocytic Leukemia [NCT01251627]	Phase 2	43 participants (Actual)	Interventional	2010-04-30	Completed
Prospective Phase II Study of Decitabine Induction Therapy to Reduce Pre-transplant Disease Burden Prior to Allogeneic Hematopoietic Cell Transplant in Patients With Newly Diagnosed Myelodysplastic Syndromes. [NCT01333449]	Phase 2	6 participants (Actual)	Interventional	2010-07-31	Terminated(stopped due to Poor subject accrual)
An Expanded Access Program for Decitabine in Patients With Myelodysplastic Syndrome (MDS) [NCT01026376]		0 participants	Expanded Access	2008-06-30	No longer available
A Clinical Trial of Decitabine Combined With CODOX-M/IVAC in Relapsed or Refractory T-lymphoblastic Lymphoma [NCT03558412]	Phase 4	40 participants (Anticipated)	Interventional	2018-06-01	Recruiting
A Randomized, Double-blind Phase 3 Study of Vadastuximab Talirine (SGN-CD33A) Versus Placebo in Combination With Azacitidine or Decitabine in the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) [NCT02785900]	Phase 3	240 participants (Actual)	Interventional	2016-05-31	Terminated(stopped due to Due to safety; specifically a higher rate of deaths, including fatal infections, in the SGN33A arm versus the control arm)
A Phase II Study of Tosedostat in Combination With Either Cytarabine or Decitabine in Newly Diagnosed AML or High-Risk MDS [NCT01567059]	Phase 2	34 participants (Actual)	Interventional	2012-05-31	Completed
A Phase Ib/II Study of the Safety and Activity of Digoxin With Decitabine in Adult AML and MDS [NCT03113071]	Phase 1/Phase 2	1 participants (Actual)	Interventional	2017-06-02	Terminated(stopped due to Slow accrual)
Research for Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Myelodysplastic Syndrome (MDS) [NCT03184935]	Phase 1/Phase 2	40 participants (Anticipated)	Interventional	2023-12-31	Suspended(stopped due to Others)
A Phase I Study of Intravenous Decitabine in Combination With Arsenic Trioxide and Ascorbic Acid in Patients With Myelodysplastic Syndromes and Acute Myeloid Leukemia [NCT00671697]	Phase 1	13 participants (Actual)	Interventional	2008-05-31	Completed
A Multi-center Study of Low-dose Decitabine for the Treatment of Immune Thrombocytopenia [NCT01568333]	Phase 2	45 participants (Actual)	Interventional	2015-08-31	Completed
A Phase 1 Study of Triplet Therapy With Navitoclax, Venetoclax, and Decitabine for High-risk Myeloid Malignancies [NCT05455294]	Phase 1	36 participants (Anticipated)	Interventional	2022-07-18	Recruiting
Clinical Efficacy Observation of Demethylated Drug Decitabine in the Treatment of Locally Advanced Nasopharyngeal Carcinoma [NCT03701451]	Phase 1/Phase 2	30 participants (Anticipated)	Interventional	2018-02-28	Recruiting
HEC73543 Versus Salvage Chemotherapy in Relapsed or Refractory FLT3-ITD Acute Myeloid Leukemia: a Multicenter, Open-label, Randomized Phase 3 Trial [NCT05586074]	Phase 3	324 participants (Anticipated)	Interventional	2023-03-03	Recruiting
A Phase I Study of Pevonedistat (TAK-924) and Decitabine Combination Therapy in High Risk Acute Myeloid Leukemia [NCT03009240]	Phase 1	30 participants (Anticipated)	Interventional	2017-08-21	Active, not recruiting
Phase 1b/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib [NCT04774393]	Phase 1/Phase 2	84 participants (Anticipated)	Interventional	2021-05-24	Recruiting
A Randomized, Open-Label Study of the Efficacy and Safety of Galinpepimut-S (GPS) Maintenance Monotherapy Compared to Investigator's Choice of Best Available Therapy in Subjects With Acute Myeloid Leukemia Who Have Achieved Complete Remission After Second [NCT04229979]	Phase 3	140 participants (Anticipated)	Interventional	2021-02-08	Recruiting
A Study Comparing the Efficacy and Safety of Genotype-guided R-CHOP-X Versus R-CHOP in Patients With Diffuse Large B-Cell Lymphoma [NCT05351346]	Phase 3	1,100 participants (Anticipated)	Interventional	2022-06-01	Recruiting
Phase II Study of Venetoclax With Alternative Hypomethylating Agent for Patients With Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure: A University of California Hematologic Malignancies Consortium Protocol [NCT04905810]	Phase 2	20 participants (Anticipated)	Interventional	2022-02-09	Recruiting
A Pilot Study of Physical Conditioning and Decitabine for Newly Diagnosed AML Patients Age ≥ 60 Who Are Not Candidates for Standard Induction Chemotherapy [NCT02234037]	Phase 1	3 participants (Actual)	Interventional	2013-11-30	Terminated(stopped due to Slow accrual)
Retrospective, Observational, Monocentric Study to Assess Efficacy and Safety of the Combination of an Hypomethylating Agent in Combination With Venetoclax for Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Intensive Chemotherapy [NCT04454580]		15 participants (Anticipated)	Observational	2020-08-01	Recruiting
A Parallel Phase I/II Study of Low Dose Decitabine (5-Aza-Deoxycytidine) With Peginterferon Alfa-2b in Advanced Melanoma [NCT00791271]	Phase 1	17 participants (Actual)	Interventional	2008-09-02	Terminated
Decitabine+ Fludarabine+Busulfan Conditioning Regimen for Elderly Acute Myeloid Leukemia in Complete Remission Undergoing Allogeneic Hematopoietic Stem Cell Transplantation [NCT03530085]	Phase 2/Phase 3	60 participants (Anticipated)	Interventional	2018-06-15	Recruiting
A Phase II Study of the Combination of Decitabine, Venetoclax, and Ponatinib in Patients With Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase Chronic Myelogenous Leukemia [NCT04188405]	Phase 2	30 participants (Anticipated)	Interventional	2020-05-17	Recruiting
Pre-emptive Therapy With Low-dose Decitabine for Patients With Decreased Donor Chimerism After Allogeneic Stem Cell Transplantation [NCT03663751]	Phase 2	14 participants (Actual)	Interventional	2018-07-01	Completed
Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen for Elderly Patients With Acute Myeloid Leukemia: A Phase II Single-Arm Multicenter Study [NCT05258799]		130 participants (Anticipated)	Interventional	2022-01-21	Recruiting
Low-Dose Decitabine Plus Anti-PD-1 Treatment for Relapsed/Refractory Diffuse Large B Cell Lymphoma With Extranodal (Esp. Central Nervous System) Involvement: A PhaseⅡClinical Trial [NCT05816746]	Phase 2	20 participants (Anticipated)	Interventional	2023-05-15	Recruiting
A Phase IB Rescue Study With Oral Decitabine (AStX727) and Durvalumab (MEDI4736) Combination Therapy in Recurrent and/or Metastatic Head and Neck Cancer Patients Who Have Progressed on Anti-PD-1, Anti-PD-L1, or Anti-CTLA-4 Monotherapy [NCT03019003]	Phase 1/Phase 2	13 participants (Actual)	Interventional	2017-03-20	Active, not recruiting
A Phase II Study of Venetoclax in Combination With 10-day Oral Decitabine in Relapsed/Refractory Acute Myeloid Leukemia [NCT04975919]	Phase 2	19 participants (Actual)	Interventional	2021-09-29	Active, not recruiting
"Comparing the Efficacy and Safety of Venetoclax Combined With Decitabine Versus Conventional 7+3 Induction Chemotherapy of Acute Myeloid Leukemia in Young Adults" [NCT05177731]	Phase 3	188 participants (Anticipated)	Interventional	2022-03-01	Recruiting
A Phase I/IIa Study of TGFß Blockade in TCR-Engineered T-Cell Cancer Immunotherapy in Patients With Advanced Malignancies [NCT02650986]	Phase 1/Phase 2	15 participants (Actual)	Interventional	2017-07-14	Active, not recruiting
A Pilot Study of Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatric and Young Adult Patients With Relapsed and Refractory Solid Tumors or Lymphoma [NCT03445858]	Early Phase 1	21 participants (Anticipated)	Interventional	2018-02-12	Active, not recruiting
Addition of Decitabine to Carboplatin-Paclitaxel in First-Line Treatment of Advanced Ovarian Cancer: A Phase 2-3, Open-label, Randomised Controlled Trial [NCT02159820]	Phase 2/Phase 3	500 participants (Anticipated)	Interventional	2014-06-30	Recruiting
A Phase 2, Open-Label Study of Intravenous Pevonedistat in Combination With Oral Decitabine and Cedazuridine in Adult Patients With Higher-Risk Myelodysplastic Syndromes [NCT04985656]	Phase 2	0 participants (Actual)	Interventional	2021-10-01	Withdrawn(stopped due to Sponsor Decision to Terminate Trial)
Phase II Study on Venetoclax (VEN) Plus Decitabine (DEC) (VEN-DEC) for Elderly (≥60 <75years) Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) Elegible for Allogeneic Stem Cell Transplantation (Allo-SCT) [NCT04476199]	Phase 2	100 participants (Actual)	Interventional	2019-12-09	Completed
Modified Post-Transplant Cyclophosphamide Combined With DCAG as a Bridge Followed by Busulfan, Fludarabine and Melphalan Based Conditioning Regimen for Children With Juvenile Myelomonocytic Leukemia [NCT03687463]		6 participants (Actual)	Observational [Patient Registry]	2015-04-10	Enrolling by invitation
Outcomes of Patients After Allogenic Hematopoietic Cell Transplantation With Decitabine-containing Conditioning Regimen and Acetylcysteine Treatment [NCT04945096]	Phase 3	100 participants (Anticipated)	Interventional	2021-07-01	Not yet recruiting
Phase 1 Study of Venetoclax in Combination With Decitabine 10-Day Regimen in Subjects With Acute Myeloid Leukemia [NCT03844815]	Phase 1	26 participants (Anticipated)	Interventional	2019-11-18	Recruiting
PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma [NCT05137886]	Phase 2	47 participants (Anticipated)	Interventional	2022-01-31	Recruiting
Sequential Low-dose Decitabine Therapy With Novel CAR-T Carrying PD-1/CD28 Chimeric Switch Receptor in Relapsed or Refractory B-cell Lymphoma [NCT04850560]	Phase 1	30 participants (Anticipated)	Interventional	2021-05-18	Recruiting
Decitabine-primed Tandem Targeting CD19 and CD20 Chimeric Antigen Receptor T Cells Treatment in Relapsed and/or Refractory Non-Hodgkin's Lymphoma Patients [NCT04697940]	Phase 1/Phase 2	33 participants (Anticipated)	Interventional	2020-12-15	Recruiting
A PhaseⅠ/Ⅱ Trial of Chidamide，Decitabine and Immune Checkpoint Inhibitors in Relapsed/Refractory Non-Hodgkin Lymphoma and Advanced Solid Tumors [NCT05320640]	Phase 1/Phase 2	100 participants (Anticipated)	Interventional	2022-03-30	Recruiting
Phase I Study of Decitabine (Dacogen) and Selinexor (KPT-330) in Acute Myeloid Leukemia [NCT02093403]	Phase 1	25 participants (Actual)	Interventional	2014-03-31	Completed
Randomized Phase 3 Trial of Decitabine Versus Patient's Choice With Physician's Advice of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia [NCT00260832]	Phase 3	485 participants (Actual)	Interventional	2005-11-30	Completed
Phase I Study of Decitabine, Vorinostat, and Cytarabine in Acute Myeloid Leukemia [NCT01130506]	Phase 1	17 participants (Actual)	Interventional	2010-05-17	Completed
Phase I Open-Label Study of Decitabine in Combination With Midostaurin (PKC412) for Elderly (Age ≥ 60) Newly Diagnosed or Relapsed/Refractory Adult Patients With Acute Myeloid Leukemia [NCT01130662]	Phase 1	16 participants (Actual)	Interventional	2010-03-31	Completed
Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia [NCT02996474]	Phase 1/Phase 2	10 participants (Actual)	Interventional	2016-12-16	Completed
An Open-label, Crossover, Pharmacokinetic and Efficacy Bridging Study of Oral ASTX727 Versus IV Decitabine in Chinese Subjects With Myelodysplastic Syndromes [NCT06091267]	Phase 1/Phase 2	72 participants (Anticipated)	Interventional	2023-10-16	Recruiting
Single-arm, Open Label, Phase II Study of MBG453 (Sabatolimab) Added to FDA Approved Hypomethylating Agents of Investigator's Choice (IV/SC/Oral) for Patients With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R Criteria [NCT04878432]	Phase 2	90 participants (Anticipated)	Interventional	2022-03-17	Recruiting
A Pilot Study of Pacritinib in Combination With Low Dose Decitabine in Patients With Intermediate-High Risk Myelofibrosis or MPN/MDS Syndromes [NCT02564536]	Phase 1	0 participants (Actual)	Interventional	2017-06-30	Withdrawn(stopped due to Lack of funding following full FDA clinical hold)
Phase 1B/2A Study of Weekly Decitabine and Venetoclax Treatment as Maintenance Therapy in High-Risk Myeloid Malignancy Patients Post Allograft Stem Cell Transplant [NCT06129734]	Phase 1/Phase 2	20 participants (Anticipated)	Interventional	2024-04-01	Not yet recruiting
A Phase 1 Study of Adding Venetoclax to a Reduced Intensity Conditioning Regimen and to Maintenance in Combination With a Hypomethylating Agent After Allogeneic Hematopoietic Cell Transplantation for Patients With High Risk AML, MDS, and MDS/MPN Overlap S [NCT03613532]	Phase 1	78 participants (Anticipated)	Interventional	2018-10-24	Recruiting
Multicenter Phase 1/2 Study of Combination Therapy w/ DNA Methyltransferase Inhibitor Decitabine & Poly ADP Ribose Polymerase Inhibitor Talazoparib for Untreated AML in Adults Unfit for Cytotoxic Chemotherapy or R/R AML [NCT02878785]	Phase 1/Phase 2	25 participants (Actual)	Interventional	2016-08-31	Completed
Phase I Study of Decitabine and Haplo-identical Natural Killer Cells in Acute Myeloid Leukemia (AML) [NCT02316964]	Phase 1	8 participants (Actual)	Interventional	2015-04-21	Completed
A Phase I Clinical Trial on Decitabine (5-aza-2'-Deoxycytidine) Administered by Hepatic Arterial Infusion in Patients With Unresectable Liver-predominant Metastases From Colorectal Cancer [NCT02316028]	Phase 1/Phase 2	11 participants (Actual)	Interventional	2014-03-31	Completed
A Phase 1b Clinical Trial: Improving Outcomes With Androgen Pathway Inhibitors by Targeting DNA Methyltransferase Activity [NCT05037500]	Phase 1	18 participants (Anticipated)	Interventional	2022-01-26	Recruiting
Phase I Study of The Combination of Bortezomib and Sorafenib Followed by Decitabine in Patients With Acute Myeloid Leukemia [NCT01861314]	Phase 1	15 participants (Actual)	Interventional	2013-07-03	Active, not recruiting
An Open Label, Multicenter, Phase II Trial Testing Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia [NCT03063203]	Phase 2	17 participants (Actual)	Interventional	2017-07-14	Terminated(stopped due to Futility)
A Phase 2, Prospective, Multi-center Intervention Trial in Patients With Acute Myeloid Leukemia Secondary to Myeloproliferative Neoplasms Unfit for Intensive Chemotherapy Investigating a Treatment Combination Including Decitabine and Venetoclax [NCT04763928]	Phase 2	101 participants (Anticipated)	Interventional	2021-12-03	Recruiting
A Phase 3, Open Label, Single Arm, Multi-Center Study to Evaluate the Efficacy and Safety of Decitabine Combined With HAAG Regimen in Newly Diagnosed ETP-ALL/LBL, T/M-MPAL and ALL/LBL With Myeloid or Stem Cell Markers Patients [NCT04446130]	Phase 3	100 participants (Anticipated)	Interventional	2019-01-01	Recruiting
Clinical Efficacy and Safety of DLAAG Protocol in the Treatment of Refractory/Relapse of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast Excess: a Multicenter, Single-arm, Prospective Clinical Study [NCT03356080]	Phase 2	50 participants (Anticipated)	Interventional	2017-07-07	Recruiting
A PHASE 1 DOSE ESCALATION STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVENOUS PF-06747143, ADMINISTERED AS SINGLE AGENT OR IN COMBINATION WITH STANDARD CHEMOTHERAPY IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA [NCT02954653]	Phase 1	8 participants (Actual)	Interventional	2016-11-28	Terminated(stopped due to The study was terminated due to a change in sponsor prioritization.)
Combined Chemotherapy and PD-1 Antibody(SHR-1210) With or Without Low-dose Decitabine Priming for Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL):Two Stage, Phase I/II Trail [NCT03346642]	Phase 1/Phase 2	30 participants (Anticipated)	Interventional	2017-05-01	Recruiting
Decitabine Plus mBU/CY for High Risk Acute Leukemia With Minimal Residual Disease Pre-HSCT [NCT03793517]	Phase 2/Phase 3	55 participants (Anticipated)	Interventional	2018-09-01	Recruiting
An Open-label Two Strata Study of Bisantrene in Combination With Cytarabine Arabinoside or Bisantrene in Combination With Oral Decitabine/Cedazuridine for the Treatment of Acute Myeloid Leukemia Patients With Extramedullary Disease [NCT05456269]	Phase 1	0 participants (Actual)	Interventional	2022-07-29	Withdrawn(stopped due to commercial reason)
A Randomized, Open-label, Parallel-Group Study Comparing the Efficacy and Safety of DACOGEN (Decitabine) for Injection and VIDAZA (Azacitidine) for Injection In Subjects With Intermediate or High Risk Myelodysplastic Syndromes (MDS) [NCT01011283]	Phase 4	26 participants (Actual)	Interventional	2009-11-30	Terminated(stopped due to The study was stopped due to insufficient enrollment.)
Phase I/II Study of Azacitidine and CAPOX (Capecitabine + Oxaliplatin) in Metastatic Colorectal Cancer Patients Enriched for Hypermethylation of CpG Promoter Islands [NCT01193517]	Phase 1/Phase 2	26 participants (Actual)	Interventional	2010-08-31	Completed
An Expanded Access Protocol to Administer Decitabine to Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome [NCT00760084]	Phase 2	10 participants (Actual)	Interventional	2005-07-31	Completed
[NCT02662647]	Phase 2	30 participants (Actual)	Interventional	2015-04-30	Completed
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML) [NCT04113616]	Phase 1/Phase 2	86 participants (Anticipated)	Interventional	2019-09-25	Active, not recruiting
An Open-Label, Randomized, Four-Period, Three-Block, Pharmacokinetic Study of Three Formulations of Decitabine/Tetrahydrouridine (THU) Combination Modified Release Capsules in Healthy Adults Under Fasting and Fed Conditions [NCT04086238]	Phase 1	46 participants (Actual)	Interventional	2019-10-08	Completed
Clinical Study of Targeted T-cell Therapy in Solid Tumors [NCT04076137]	Early Phase 1	10 participants (Anticipated)	Interventional	2019-05-01	Recruiting
A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial) [NCT03013998]	Phase 1/Phase 2	2,000 participants (Anticipated)	Interventional	2016-11-30	Recruiting
Phase I Evaluation of Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in Patients Undergoing Pulmonary Metastasectomy [NCT02839694]	Phase 1	0 participants (Actual)	Interventional	2016-07-07	Withdrawn
Randomized Open-label Phase 2 Study of Low Dose Dacogen® for Injection (Decitabine) in Patients With Low or Intermediate 1 Risk Myelodysplastic Syndromes [NCT00619099]	Phase 2	67 participants (Actual)	Interventional	2008-05-31	Completed
Addition of Chidamide to the Combination Treatment of Decitabine Plus Camrelizumab in Combination Treatment Resistant/Relapsed Patients With Classical Hodgkin Lymphoma: an Open-label, Single Arm, Phase II Trial [NCT04233294]	Phase 2	100 participants (Anticipated)	Interventional	2020-02-02	Recruiting
Venetoclax in Combination With ASTX727, an All-ORal Therapy for Chronic Myelomonocytic Leukemia and Other MDS/MPN With Excess Blasts (VICTORY-MDS/MPN): a Randomized, Phase 2 Trial [NCT05600894]	Phase 2	132 participants (Anticipated)	Interventional	2023-06-27	Recruiting
A Phase II Study of Omacetaxine (OM) and Decitabine (DAC) in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) [NCT02141477]	Phase 1	2 participants (Actual)	Interventional	2015-05-06	Terminated(stopped due to Slow Accrual-2 patients were registered Phase I and none in Phase II)
Leukemia SPORE Phase II Randomized Study of Decitabine Versus Decitabine and Carboplatin Versus Decitabine and Arsenic in Relapsed, Refractory, and Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) [NCT02190695]	Phase 2	92 participants (Actual)	Interventional	2013-04-01	Completed
A Phase 1 Study of DEC205mAb-NY ESO 1 Fusion Protein (CDX-1401) Given With Adjuvant Poly-ICLC in Conjunction With 5-Aza-2'Deoxycytidine (Decitabine) and Nivolumab in Patients With MDS or Low Blast Count AML [NCT03358719]	Phase 1	8 participants (Actual)	Interventional	2018-03-27	Completed
A Phase I/IIa Study of Decitabine in Combination With Genistein in Pediatric Patients With Relapsed or Refractory Solid Tumors and Leukemia [NCT02499861]	Phase 1/Phase 2	6 participants (Actual)	Interventional	2015-07-31	Completed
Epigenetic Reprogramming in Relapse AML: A Phase 1 Study of Decitabine and Vorinostat Followed by Fludarabine, Cytarabine and G-CSF (FLAG) in Children and Young Adults With Relapsed/Refractory AML [NCT03263936]	Phase 1	37 participants (Actual)	Interventional	2017-07-11	Completed
A Phase 1 Study of Nivolumab in Combination With ASTX727 in B-Cell Lymphoma (NHL or HL) With an Expansion Cohort in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) [NCT05272384]	Phase 1	27 participants (Anticipated)	Interventional	2022-11-03	Recruiting
"A Randomized Phase II/III Trial of Novel Therapeutics Versus Azacitidine in Newly Diagnosed Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older LEAP: Less-Intense AML Platform Trial" [NCT03092674]	Phase 2/Phase 3	78 participants (Actual)	Interventional	2018-02-02	Active, not recruiting
Evaluation of the Incidence and Prognostic Impact of Molecular and Genetic Abnormalities in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myeloproliferative Neoplasms [NCT02084563]	Phase 2	455 participants (Actual)	Interventional	2012-10-31	Completed
An Open-labelled, Parallel, Multiple Ascending Dose, Phase Ib Clinical Study of Decitabine and Paclitaxel Combination Therapy in Treating Patients With Metastatic and Locally Advanced Breast Cancer [NCT03282825]	Phase 1	18 participants (Anticipated)	Interventional	2017-03-28	Active, not recruiting
Multi-center Randomized Study to Compare Efficacy and Safety of Decitabine Plus CHOP (D-CHOP) Versus CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma [NCT03553537]	Phase 3	100 participants (Anticipated)	Interventional	2018-06-30	Not yet recruiting
10-day Decitabine, Fludarabine and 2 Gray TBI as Conditioning Strategy for Poor and Very Poor Risk AML in CR1 [NCT02252107]	Phase 2	46 participants (Actual)	Interventional	2014-10-31	Completed
Phase I/Ib Study of Azacitidine or Decitabine With Hedgehog Pathway Inhibition in Myeloid Malignancies [NCT02129101]	Phase 1	63 participants (Actual)	Interventional	2014-05-31	Completed
Low Dose Decitabine + Modified BUCY Conditioning Regimen for High Risk Acute Myeloid Leukemia Undergoing Allo-HSCT [NCT03256071]	Phase 2/Phase 3	90 participants (Anticipated)	Interventional	2017-09-30	Recruiting
"10-day Decitabine Versus Conventional Chemotherapy (3+7) Followed by Allografting in AML Patients ≥ 60 Years: a Randomized Phase III Study of the EORTC Leukemia Group, CELG, GIMEMA and German MDS Study Group" [NCT02172872]	Phase 3	606 participants (Actual)	Interventional	2014-11-28	Active, not recruiting
Multicenter Phase I/II Trial of Ruxolitinib in Combination With Decitabine in Patients With Accelerated Phase Myeloproliferative Neoplasm (MPN) or Post-MPN AML [NCT02076191]	Phase 1/Phase 2	49 participants (Actual)	Interventional	2014-02-28	Completed
Safety and Efficacy Evaluation of Decitabine With R-GDP on Refractory or Relapsed NHL Patients [NCT03535753]	Phase 1	50 participants (Anticipated)	Interventional	2017-09-01	Recruiting
An Open Label, Randomized, Single Dose, Two Way Crossover, Bioavailability Study of a Combination Formulation of Decitabine/Tetrahydrouridine (2.5 mg/100 mg) Modified Release Capsules in Healthy, Fasting, Male Adults [NCT05816356]	Phase 1	10 participants (Anticipated)	Interventional	2023-03-24	Recruiting
Proof-Of-Concept Study of Metabolically Optimized, Non-Cytotoxic 5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies [NCT04187703]	Early Phase 1	20 participants (Anticipated)	Interventional	2020-11-16	Recruiting
Phase II Study of Low Dose Decitabine (5-Aza-Deoxycytidine) With Interferon Alfa-2b in Advanced Renal Cell Carcinoma [NCT00561912]	Phase 2	2 participants (Actual)	Interventional	2007-10-31	Terminated(stopped due to Low accrual.)
Phase II Prospective Randomized Control Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Inducti [NCT05766514]	Phase 2	98 participants (Anticipated)	Interventional	2024-03-31	Not yet recruiting
"Phase II Randomized Study of Low-Dose Decitabine (5-AZA-2'-Deoxycytidine) With or Without Valproic Acid in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia -SPORE" [NCT00414310]	Phase 2	153 participants (Actual)	Interventional	2006-12-31	Completed
The ABNL-MARRO 001 Study: A Phase 1/2 Study of Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes. [NCT04061421]	Phase 1/Phase 2	105 participants (Anticipated)	Interventional	2021-12-10	Recruiting
Maintenance Therapy With Decitabine After Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome [NCT00986804]	Phase 1	24 participants (Actual)	Interventional	2009-12-31	Completed
Phase I/II Study of Decitabine and All-Trans Retinoic Acid (Tretinoin) for Patients With Myelodysplastic Syndromes [NCT00382200]	Phase 1/Phase 2	54 participants (Actual)	Interventional	2006-07-31	Completed
Novel Immuno-epigenetic Based Platform for Patients With Peripheral T-cell Lymphoma (PTCL) and Cutaneous T-cell Lymphoma (CTCL): an International Phase Ib Study of Pembrolizumab Combined With Decitabine and/or Pralatrexate [NCT03240211]	Phase 1	37 participants (Anticipated)	Interventional	2022-02-02	Recruiting
A Proof-of-concept, Biomarker-driven, Phase-II Clinical Trial to Explore the Activity of Decitabine Repurposing Against Advanced, Refractory, KRAS-dependent Pancreatic Ductal Adenocarcinoma (PDAC):The ORIENTATE Trial [NCT05360264]	Phase 2	18 participants (Anticipated)	Interventional	2022-01-15	Recruiting
A Phase IIa, Open-label, Clinical Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of BP1001 (a Liposomal Grb2 Antisense Oligonucleotide) in Combination With Venetoclax Plus Decitabine in Patients With AML Who Are Ineligible [NCT02781883]	Phase 2	108 participants (Anticipated)	Interventional	2016-05-31	Recruiting
A Phase Ib Open Label Study of Navitoclax in Combination With Venetoclax + Decitabine in Relapsed/Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax [NCT05222984]	Phase 1	36 participants (Anticipated)	Interventional	2022-07-29	Recruiting
A Phase I/II Study of ASTX727, Venetoclax, and Gilteritinib for Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome With an Activating FLT3 Mutation [NCT05010122]	Phase 1/Phase 2	42 participants (Anticipated)	Interventional	2021-07-08	Recruiting
Phase 1b Study of Pembrolizumab, Decitabine +/- Venetoclax Combination Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome [NCT03969446]	Phase 1	54 participants (Anticipated)	Interventional	2020-05-04	Recruiting
Prospective Observation of the indUction Regimen for Acute Non-Promyelocytic Myeloid Leukemia in Elderly; Decitabine for Chemotherapy Unfit Korean Acute Myeloid Leukemia (AML) Patients in Real Practice [NCT02698124]		136 participants (Anticipated)	Observational	2016-03-31	Not yet recruiting
Clinical Study of Low Dose of Decitabine Combined With Gemcitabine in First-line Treatment of Locally Advanced, Unresectable or Metastatic Pancreatic Cancer [NCT02685228]		20 participants (Anticipated)	Interventional	2016-03-31	Not yet recruiting
A Phase Ib Study Evaluating the Safety and Efficacy of IBI188 in Combination With Demethylating Agents in Subjects With Acute Myeloid Leukemia [NCT04485052]	Phase 1/Phase 2	222 participants (Anticipated)	Interventional	2020-09-25	Suspended(stopped due to Pause for changes in development strategies)
Treatment of Decitabine-primed Tandem Targeting CD19 and CD20 Chimeric Antigen Receptor T Cells Plus Epigenetic Agents in Aggressive Relapsed and/or Refractory Non-Hodgkin's Lymphoma Patients With Huge Tumor Burden [NCT04553393]	Phase 1/Phase 2	80 participants (Anticipated)	Interventional	2020-09-09	Recruiting
A Pilot Phase II Study of Decitabine, Arsenic Trioxide and Ascorbic Acid for Patients With Myelodysplastic Syndrome [NCT00621023]	Phase 2	7 participants (Actual)	Interventional	2007-11-30	Completed
Comparing the Efficacy and Safety of Venetoclax Combined With Decitabine/Azacitidine and Aclarubicin Versus Venetoclax Combined With Decitabine/Azacitidine in Treatment-Naive Elderly Patients With Acute Myeloid Leukemia [NCT05264883]	Phase 3	170 participants (Anticipated)	Interventional	2021-03-01	Recruiting
Phase I/II Evaluation of Oral Decitabine/Tetrahydrouridine as Epigenetic Priming for Pembrolizumab Immune Checkpoint Blockade in Inoperable Locally Advanced or Metastatic Non-Small Cell Lung Cancers, Esophageal Carcinomas, or Pleural Mesotheliomas [NCT03233724]	Phase 1/Phase 2	9 participants (Actual)	Interventional	2018-04-11	Terminated(stopped due to Study terminated due to drug supply issues.)
Inhibition of DNA Methylation by 1-hr Infusion of 5-aza-2'-Deoxycytidine (Decitabine) x 10 Days (M-F) With Escalating Doses of Sub-Q Pegylated (PEG) Interferon-alfa 2B (PEG-Intron): A Phase I Study With Molecular Correlates [NCT00886457]	Phase 1	3 participants (Actual)	Interventional	2009-04-30	Terminated(stopped due to low accrual)
Clinical Evaluation of ASTX727 in Combination With Venetoclax All-Oral Therapy vs Standard of Care Cytarabine and Anthracycline Induction Chemotherapy for Younger FLT3WT Patients With ELN High- Risk Acute Myeloid Leukemia [NCT04817241]	Phase 1/Phase 2	55 participants (Anticipated)	Interventional	2022-02-10	Active, not recruiting
A Randomized Study of Epigenetic Priming Using Decitabine With Front Line Induction Chemotherapy Compared With Immediate Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects. [NCT00943553]	Phase 2	0 participants (Actual)	Interventional	2010-06-30	Withdrawn(stopped due to Terminated by Sponsor)
Phase II Study of Maintenance Therapy With Decitabine (NSC #127716) Following Standard Induction and Cytogenetic Risk-Adapted Intensification in Previously Untreated Patients With AML < 60 Years [NCT00416598]	Phase 2	546 participants (Actual)	Interventional	2006-11-15	Completed
A Phase I Study of Lenalidomide in Combination With Decitabine for Patients With High Grade Myelodysplastic Syndromes [NCT00828802]	Phase 1	15 participants (Actual)	Interventional	2009-03-31	Completed
Inhibition of DNA Methylation by 1-Hr Infusion of 5-aza-2'-Deoxycitidine (Decitabine) x 10 Days (M-F) With Escalating Doses of Sub-Q Pegylated (PEG) Interferon-alpha 2B (PEG-Intron): A Phase I Study With Molecular Correlates [NCT00701298]	Phase 1	30 participants (Actual)	Interventional	2009-04-30	Terminated
Clinical Study of Efficacy and Safety of Novel Targeted Drugs Combined With R-ICE Regimen in the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma [NCT05348213]	Phase 2	76 participants (Anticipated)	Interventional	2022-05-16	Recruiting
A Phase IIA Study of Subcutaneous 5-aza-2'- Deoxycytidine (Decitabine) in Patients With Thalassemia Intermedia [NCT00661726]	Phase 2	6 participants (Actual)	Interventional	2008-01-31	Completed
A Cancer Research UK Randomised, Multicentre, Phase II Trial of the DNAhypomethylating Agent, 5-Aza-2'-Deoxycytidine (Decitabine) Given Intravenously in Combination With Carboplatin, Versus Carboplatin Alone Given 4 Weekly in Patients With Progressive, Ad [NCT00748527]	Phase 2	134 participants (Anticipated)	Interventional	2007-07-31	Terminated(stopped due to "The study was withdrawn due to certain adverse events [hypersensitivity].")
International Proof of Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory HEMatological Malignancies in Children, Subprotocol A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractor [NCT05740449]	Phase 1/Phase 2	26 participants (Anticipated)	Interventional	2023-10-01	Not yet recruiting
Clinical Study of Descitabine Enhanced Infusion of Autologous DC-CIK Cells as a Post-remission Treatment for Malignant Tumors [NCT04292769]	Phase 3	200 participants (Anticipated)	Interventional	2020-01-21	Recruiting
Low Dose Decitabine for Poor Graft Function Post Allogenic Hematopoietic Stem Cell Transplantation [NCT05907499]	Phase 3	76 participants (Anticipated)	Interventional	2023-07-01	Not yet recruiting
Phase Ib/II: Epigenetic Modification of Chemosensitivity and Apoptosis in Metastatic Melanoma: Treatment of a Resistant Disease Using Decitabine, Temozolomide and Panobinostat [NCT00925132]	Phase 1/Phase 2	39 participants (Actual)	Interventional	2009-12-31	Terminated(stopped due to Change in the number of approved drugs for metastatic melanoma)
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS) [NCT03502668]	Phase 1/Phase 2	160 participants (Actual)	Interventional	2018-07-27	Active, not recruiting
A Phase II Study of the Impact of Clinicogenetic Risk-Stratified Management on Outcomes of Acute Myeloid Leukemia in Older Patients [NCT03226418]	Phase 2	75 participants (Actual)	Interventional	2017-07-07	Active, not recruiting
Phase 1b, Multi-arm, Open-label Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome [NCT03066648]	Phase 1	241 participants (Actual)	Interventional	2017-07-06	Completed
A Randomized Study of Decitabine Alternating With Clofarabine Versus Decitabine Until Failure in Patients With Higher Risk Myelodysplastic Syndromes (MDS) [NCT00903760]	Phase 2	42 participants (Actual)	Interventional	2010-01-31	Completed
A Phase I Clinical Trial of Dendritic Cell/AML Fusion Cell Vaccine Alone and in Conjunction With Decitabine Following Allogeneic Transplantation in AML Patients [NCT03679650]	Phase 1	45 participants (Anticipated)	Interventional	2018-10-11	Recruiting
A Phase I/II Study of LBH589 Plus Decitabine for Patients Age ≥ 60 Years With High Risk MDS or AML [NCT00691938]	Phase 1/Phase 2	52 participants (Actual)	Interventional	2008-06-30	Completed
A Phase II, Multicenter Study of Decitabine (5-aza-2'Deoxycytidine) in Chronic Myelogenous Leukemia Blast Phase Refractory to Imatinib Mesylate (STI 571) [NCT00042003]	Phase 2	40 participants	Interventional	2002-07-31	Completed
Pre-operative Decitabine in Colon Cancer: a Proof of Principle Study [NCT01882660]		10 participants (Actual)	Interventional	2013-07-31	Terminated(stopped due to Inclusion of patients was slow. Could not reach the target within the studyperiod.)
Phase II Study of Low-Dose Intravenous Decitabine in Patients Aged > 60 Years With Acute Myeloid Leukemia Who Are Not Eligible for Standard Induction Chemotherapy [NCT00866073]	Phase 2	238 participants (Actual)	Interventional	2003-04-30	Completed
A Phase 1 Study of NKX101, an Activating Chimeric Receptor Natural Killer Cell Therapy, in Subjects With Hematological Malignancies or Dysplasias [NCT04623944]	Phase 1	90 participants (Anticipated)	Interventional	2020-09-21	Recruiting
A Proof of Concept Study of Non-DNA Damaging DNMT1 Depletion Therapy for Myelodysplastic Syndrome [NCT01165996]	Phase 1/Phase 2	25 participants (Actual)	Interventional	2010-07-31	Completed
A Phase III Randomized Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia [NCT01303796]	Phase 3	482 participants (Actual)	Interventional	2011-10-01	Completed
Oral Decitabine-Based Maintenance Therapy in Patients With AML in Remission [NCT05010772]	Phase 1	125 participants (Anticipated)	Interventional	2021-10-25	Recruiting
Phase II Study Assessing Safety and Clinical Activity of the Combination of ASTX727 With Dasatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) [NCT05007873]	Phase 2	70 participants (Anticipated)	Interventional	2021-10-21	Recruiting
A Phase 3, Open Label, Single Arm, Multi-Center Study to Evaluate the Efficacy and Safety of Decitabine Combined With HAAG Regimen in Elderly Newly Diagnosed Acute Myeloid Leukemia Patients. [NCT04083911]	Phase 3	50 participants (Anticipated)	Interventional	2019-04-01	Recruiting
A Phase IB/II Study to Evaluate the Safety, Tolerability, and Efficacy of ASTX727 and FT-2102 in IDH1-Mutated Myelodysplastic Syndrome or Acute Myeloid Leukemia [NCT04013880]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2019-08-27	Withdrawn(stopped due to Loss of funding)
A Phase I Study Of Decitabine (DAC) (IND # 50733) In Children With Relapsed Or Refractory Acute Leukemia [NCT00042796]	Phase 1	21 participants (Actual)	Interventional	2002-12-31	Terminated(stopped due to Administratively complete.)
A Phase I/II Clinical Study of JNJ-30979754 (Decitabine) in Patients With Myelodysplastic Syndrome [NCT00796003]	Phase 1	39 participants (Actual)	Interventional	2008-07-31	Completed
Decitabine Treatment in HPV-Induced Anogenital and Head and Neck Cancer Patients After Radiotherapy or as Novel Late Salvage (DERANO) [NCT04252248]	Phase 1	3 participants (Actual)	Interventional	2019-10-11	Terminated(stopped due to Organizational reasons)
Clofarabine Plus Low-Dose Cytarabine Induction Followed by Consolidation of Clofarabine Plus Low-Dose Cytarabine Alternating With Decitabine in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) [NCT00778375]	Phase 2	122 participants (Actual)	Interventional	2008-10-31	Completed
p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Advanced Pancreatic Cancer That Has Progressed Through One or More Lines of Therapy [NCT02847000]	Early Phase 1	13 participants (Actual)	Interventional	2016-12-20	Completed
Prospective, Open, Multi-center, Double Arm Clinical Trial Evaluating the Efficacy of Ultra Low Dose of Decitabine in Myelodysplastic Syndromes (MDS) [NCT02779569]		80 participants (Anticipated)	Interventional	2016-03-31	Recruiting
A Phase II Multi-center Study of 5-AZA-2'-Deoxycytidine (Decitabine) Single Agent in Taiwanese Patients With Myelodysplastic Syndrome (MDS) [NCT00744757]	Phase 2	37 participants (Actual)	Interventional	2008-08-31	Completed
A Phase 1-2, Open-Label Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Activity of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Subjects With Relapsed/Refractory Peripheral [NCT05403450]	Phase 1/Phase 2	132 participants (Anticipated)	Interventional	2022-06-23	Recruiting
A Phase 2 Study of Venetoclax in Combination With ASTX727 in Patients With Relapsed/Refractory Acute Myeloid Leukemia, and Newly Diagnosed Elderly Patients With AML Who Are Not Candidates for Intensive Chemotherapy [NCT04746235]	Phase 2	40 participants (Anticipated)	Interventional	2021-02-22	Recruiting
A Phase I/II Study of Venetoclax in Combination With ASTX727 (Cedazuridine/Decitabine) in Treatment-Naïve High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) [NCT04655755]	Phase 1/Phase 2	52 participants (Anticipated)	Interventional	2021-01-19	Recruiting
Decitabine+Busulfan+Cyclophosphamide vs Busulfan+Cyclophosphamide Conditioning Regimen for Myeloid Tumors Undergoing Allogeneic Hematopoietic Stem Cell Transplantation [NCT04098653]	Phase 2/Phase 3	196 participants (Anticipated)	Interventional	2019-09-30	Recruiting
A Pilot/Phase 1b Study of Glasdegib-Based Treatment Combinations in Adult Patients With Relapsed AML Post Allogeneic Hematopoietic Cell Transplantation [NCT04655391]	Phase 1	0 participants (Actual)	Interventional	2022-06-25	Withdrawn(stopped due to Drug availability)
A Low Dose Decitabine Combined With Tirelizumab Prospective Phase II Clinical Study Comparing Tirelizumab in Patients With Advanced Esophageal Squamous Cell Carcinoma Who Did Not Progress With First-line Immunotherapy Combined With Chemotherapy [NCT05638984]	Phase 2	60 participants (Anticipated)	Interventional	2023-01-01	Not yet recruiting
Decitabine Plus Carboplatin in the Treatment of Metastatic Triple Negative Breast Cancer [NCT03295552]	Phase 2	12 participants (Actual)	Interventional	2017-11-15	Terminated(stopped due to Slow enrollment.)
Prospective Randomized Multicenter Phase II Trial of Low-dose Decitabine (DAC) Administered Alone or in Combination With the Histone Deacetylase Inhibitor Valproic Acid (VPA) and All-trans Retinoic Acid (ATRA) in Patients > 60 Years With Acute Myeloid Leu [NCT00867672]	Phase 2	204 participants (Actual)	Interventional	2011-08-31	Completed
A Phase 2 Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Advanced-Stage Myelodysplastic Syndromes [NCT00260065]	Phase 2	99 participants (Actual)	Interventional	2005-05-31	Completed
Phase I/II Trial of Decitabine + R-CHOP in Diffuse Large B-Cell Lymphoma [NCT02951728]	Phase 1/Phase 2	58 participants (Anticipated)	Interventional	2016-10-31	Active, not recruiting
Phase I Study of Epigenetic Priming Using Decitabine With Induction Chemotherapy in Patients With Acute Myelogenous Leukemia (AML) [NCT00538876]	Phase 1	30 participants (Anticipated)	Interventional	2007-07-31	Completed
A Phase 3, Randomized, Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Decitabine Combined With HAAG Regimen in Newly Diagnosed Acute Myeloid Leukemia Patients Younger Than 60 Years [NCT04087967]	Phase 3	162 participants (Anticipated)	Interventional	2019-04-01	Recruiting
A Phase II Study of Decitabine For the Front-line Treatment of Older Patients With Acute Myeloid Leukemia [NCT00358644]	Phase 2	55 participants (Actual)	Interventional	2005-03-31	Completed
A Phase I Trial of SAHA (NSC 701852) and Decitabine (IND 50733, NSC 127716) in Patients With Relapsed, Refractory or Poor Prognosis Leukemia [NCT00357708]	Phase 1	50 participants (Actual)	Interventional	2006-06-30	Completed
Phase 1/2 Study Epigenetic Modification of BRAF-mutated Metastatic Melanoma: Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib [NCT01876641]	Phase 1	18 participants (Actual)	Interventional	2013-10-31	Terminated(stopped due to Loss of funding)
A Phase 1b/2 Study of IMGN632 as Monotherapy or Combination With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia [NCT04086264]	Phase 1/Phase 2	292 participants (Anticipated)	Interventional	2019-11-06	Recruiting
A Phase 1b, Open-label, Parallel Group, Multiple-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Oral Decitabine and Cedazuridine (ASTX727) in Cancer Patients With Severe Renal Impairment and Cancer Patients With Normal Renal Func [NCT04953897]	Phase 1	18 participants (Anticipated)	Interventional	2021-12-15	Recruiting
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin &Amp; Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Dia [NCT02085408]	Phase 3	727 participants (Actual)	Interventional	2011-02-04	Active, not recruiting
Phase 1/2 Study of Concurrent Decitabine in Combination With G-CSF, Cladribine, Cytarabine, and Mitoxantrone (G-CLAM) in Adults With Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS) [NCT02921061]	Phase 1/Phase 2	28 participants (Actual)	Interventional	2016-11-17	Completed
A Randomized, Controlled, Multi-center Collaborative Phase Ⅳ Study to Evaluate the Safety and Efficacy of Decitabine in Myelodysplastic Syndrome [NCT02013102]	Phase 4	240 participants (Anticipated)	Interventional	2013-03-31	Recruiting
Phase II Evaluation of Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma [NCT05960773]	Phase 2	15 participants (Anticipated)	Interventional	2024-01-03	Not yet recruiting
Ruxolitinib and Decitabine Intensified Conditioning Regimen for Patients With High Risk Hematological Malignancies Underwenting Allogeneic Stem Cell Transplantation [NCT04582604]	Phase 1/Phase 2	60 participants (Anticipated)	Interventional	2020-09-01	Recruiting
Phase I/II Trial of Decitabine as a Sensitizer to Carboplatin in Platinum Resistant Recurrent Ovarian Cancer [NCT00477386]	Phase 1/Phase 2	28 participants (Actual)	Interventional	2007-07-31	Completed
A Phase I Clinical Trial of Vorinostat in Combination With Decitabine in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome [NCT00479232]	Phase 1	71 participants (Actual)	Interventional	2007-06-30	Completed
A Phase II, Single Arm Study of Tislelizumab Combined With DNA Demethylation Agent +/- CAG Regimen in the Treatment of Patients With High-risk AML or AML Patients Older Than 60 Years of Age Who Are Unfit for Intensive Chemotherapy [NCT04541277]	Phase 2	55 participants (Anticipated)	Interventional	2020-09-01	Recruiting
A Randomized, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of Decitabine as Epigenetic Priming With Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects [NCT01177540]	Phase 2	25 participants (Actual)	Interventional	2011-03-03	Terminated(stopped due to The study was terminated early due to enrollment difficulties and the futility of observing differences in remission rate between treatment arms.)
A Multi-center Prospective Single Arm Clinical Study of Prolonged Ultra Low-dose Decitabine Combined With Venetoclax (Bcl-2 Inhibitor) as First Line Treatment for Elderly Acute Myeloid Leukemia and High-risk Myelodysplastic Syndromes [NCT06046313]	Phase 2	120 participants (Anticipated)	Interventional	2023-09-27	Not yet recruiting
A Phase 1, Multicenter, Open-Label, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered FHD-286, as Monotherapy or Combination Therapy, in Subjects With Advanced Hemato [NCT04891757]	Phase 1	144 participants (Anticipated)	Interventional	2021-06-14	Recruiting
A Phase 2 Trial Investigating Decitabine in Combination With a JAK-Inhibitor as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant in Patients With Accelerated/Blast Phase Myeloproliferative Neoplasms [NCT04282187]	Phase 2	25 participants (Anticipated)	Interventional	2020-03-24	Recruiting
A Phase II Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia [NCT03164057]	Phase 2	206 participants (Actual)	Interventional	2017-06-15	Active, not recruiting
A Phase 1, Open-Label, Dose-Escalation With Expansion Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome [NCT04245397]	Phase 1	151 participants (Anticipated)	Interventional	2020-05-12	Recruiting
Phase II Multicenter Open-Label Single-Arm Study of Decitabine Combined With Oxaliplatin in Patients With Relapsed/Metastatic Renal Cell Carcinoma [NCT04049344]	Phase 2	25 participants (Anticipated)	Interventional	2019-08-15	Recruiting
A Trial for Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome [NCT02272478]	Phase 2/Phase 3	1,600 participants (Anticipated)	Interventional	2014-10-30	Recruiting
A Randomized Phase II Multicenter Study to Assess the Tolerability and Efficacy of the Addition of Midostaurin to 10-day Decitabine Treatment in Unfit Adult Acute Myeloid Leukemia and High Risk Myelodysplasia Patients [NCT04097470]	Phase 2	140 participants (Actual)	Interventional	2019-12-05	Active, not recruiting
A Phase I Study of Decitabine in Combination With Escalating Doses of Rapamycin in Patients With Relapsed or Refractory Acute Myeloid Leukemia [NCT00861874]	Phase 1	13 participants (Actual)	Interventional	2010-01-31	Completed
A Phase I Dose Escalation Study of Intravenous Decitabine in Combination With Oral Bexarotene in Patients With Acute Myeloid Leukemia (AML) [NCT01001143]	Phase 1	19 participants (Actual)	Interventional	2010-05-31	Completed
Phase II Study of (Early) Combination Salvage Therapy With Venetoclax and in Intensified Decitabine in Relapsed/Refractory AML [NCT06156579]	Phase 2	27 participants (Anticipated)	Interventional	2023-11-04	Recruiting
Decitabine and HQP1351-based Chemotherapy Regimen for the Treatment Advanced Chronic Myeloid Leukemia [NCT05376852]	Phase 2	40 participants (Anticipated)	Interventional	2021-12-01	Recruiting
D-CTAG in the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Elderly Patients [NCT04168138]		20 participants (Anticipated)	Interventional	2019-11-01	Recruiting
A Phase Ib, Multicenter, Open-label Dose Escalation and Expansion Platform Study of Select Combinations in Adult Patients With Myelofibrosis [NCT04283526]	Phase 1	0 participants (Actual)	Interventional	2020-11-30	Withdrawn(stopped due to This study was cancelled before enrolling any patients for business related reasons.)
p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies [NCT02846935]	Early Phase 1	7 participants (Actual)	Interventional	2017-04-25	Completed
Phase I Study of Decitabine Mediated Induction of Tumor Antigen and Tumor Suppressor Gene Expression in Lung Cancer Patients [NCT00019825]	Phase 1	0 participants	Interventional	1999-10-31	Completed
A Phase 1b/2 Study of PCM-075 (Onvansertib) in Combination With Either Low-Dose Cytarabine or Decitabine in Subjects With Acute Myeloid Leukemia (AML) [NCT03303339]	Phase 1/Phase 2	72 participants (Actual)	Interventional	2017-11-17	Completed
An Evaluation of the Effectiveness and Safety of Decitabine Combined With TQB2450 Injection (PD-L1 Monoclonal Antibody) or Decitabine + Anlotinib Combined With TQB2450 Injection in the Treatment of PD-1 Monoclonal Antibody-resistant Digestive System Tumor [NCT04611711]	Phase 1/Phase 2	60 participants (Anticipated)	Interventional	2020-11-01	Not yet recruiting
A Phase Ib Study of Oral Decitabine/Cedazuridine as Maintenance Therapy Following Allogeneic Hematopoietic Cell Transplantation for Patients With Myeloid Neoplasms [NCT04980404]	Phase 1	22 participants (Anticipated)	Interventional	2021-09-17	Recruiting
A Prospective Multicenter Observational Study for Dacogen Long-Term Treatment in Patients With Myelodysplastic Syndrome [NCT01400633]		156 participants (Actual)	Observational	2010-12-31	Completed
Phase 2/3 Study of Efficacy Study of CHG Regimen vs Decitabine to Treat Higher-risk MDS [NCT01417767]	Phase 2/Phase 3	50 participants (Anticipated)	Interventional	2011-09-30	Not yet recruiting
Phase I Study of Prolonged Low Dose Decitabine (5-Aza-Deoxycytidine, NSC #127716) in Patients With Biopsiable Advanced Cancers Refractory to Standard Therapy [NCT00089089]	Phase 1	42 participants (Actual)	Interventional	2004-09-30	Terminated
Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural Malignancies [NCT00037817]	Phase 1	34 participants (Actual)	Interventional	2002-05-17	Completed
Decitabine and Arsenic Trioxide(ATO) in the Treatment of Myelodysplasic Syndrome [NCT03377725]	Phase 3	0 participants (Actual)	Interventional	2018-03-20	Withdrawn(stopped due to No patient was involved.)
A Phase II, Multicenter Study of Decitabine (5-Aza-2'Deoxycytidine) in Chronic Myelogenous Leukemia Accelerated Phase Refractory to Imatinib Mesylate (STI 571) [NCT00041990]	Phase 2	40 participants	Interventional	2002-07-31	Completed
Phase I/II Trial of the Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma [NCT00715793]	Phase 1/Phase 2	39 participants (Actual)	Interventional	2008-06-30	Completed
Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation [NCT01806116]	Phase 4	30 participants (Anticipated)	Interventional	2009-09-30	Active, not recruiting
Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen in Acute Myeloid Leukemia: Study Protocol for a Randomized Controlled Trial [NCT05382390]	Phase 3	130 participants (Anticipated)	Interventional	2022-01-21	Recruiting
Phase I Study of Decitabine (Dacogen) and Bortezomib (Velcade) in Acute Myeloid Leukemia [NCT00703300]	Phase 1	19 participants (Actual)	Interventional	2008-06-30	Completed
A Multicentre Trial Evaluating the Efficacy and Safety of Oral Decitabine Tetrahydrouridine (NDec) in Patients With Sickle Cell Disease [NCT05405114]	Phase 2	84 participants (Anticipated)	Interventional	2022-07-07	Recruiting
Phase II Evaluation of Nivolumab, an Immune Checkpoint Inhibitor Alone or in Combination With Oral Decitabine/Tetrahydrouridine as Second Line Therapy for Non-small Cell Lung Cancer [NCT02664181]	Phase 2	13 participants (Actual)	Interventional	2017-06-06	Active, not recruiting
Phase I/II Study of Ruxolitinib Plus Decitabine in Patients With Post Myeloproliferative Neoplasm - Acute Myeloid Leukemia (AML) [NCT02257138]	Phase 1/Phase 2	30 participants (Actual)	Interventional	2015-02-12	Completed
Phase 1/2 Study of Decitabine Combined With Modified CAG Followed by HLA Haploidentical T Cell Infusion in Treating Elderly Patients With Intermediate-high Risk Myelodysplastic Syndrome(MDS) or Acute Myeloid Leukemia(AML） [NCT01690507]	Phase 1/Phase 2	29 participants (Actual)	Interventional	2012-11-30	Completed
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML [NCT05184842]	Phase 2	33 participants (Anticipated)	Interventional	2022-03-23	Recruiting
Efficacy of Decitabine in Clearance of MRD [NCT03021395]	Phase 1/Phase 2	300 participants (Anticipated)	Interventional	2017-02-08	Suspended(stopped due to The previous data needs to be analyzed.)
Decitabine for COVID-19 Pneumonia-ARDS Treatment: DART Trial [NCT04482621]	Phase 2	33 participants (Actual)	Interventional	2020-09-14	Active, not recruiting
Phase I/II Trial of Decitabine and Allogeneic Peripheral Blood Stem Cells Transplantation for Treatment of Relapse Post Allogeneic Bone Marrow Transplantation [NCT00002832]	Phase 1/Phase 2	14 participants (Actual)	Interventional	1995-08-31	Completed
A Phase II Study of Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) [NCT00968071]	Phase 2	71 participants (Actual)	Interventional	2008-02-29	Completed
Combined PD1 Inhibitor and Decitabine in Elderly Patients With Relapse and Refractory Acute Myeloid Leukemia : An Open-Label, Single-Arm, Phase 2 Study. [NCT04353479]	Phase 2	29 participants (Anticipated)	Interventional	2020-04-25	Not yet recruiting
A Randomized, Open-label, Phase 2 Trial of Chidamide+Decitabine+Camrelizumab Versus Decitabine+Camrelizumab in Anti-PD-1 Antibody Resistant Patients With Classical Hodgkin Lymphoma. [NCT04514081]	Phase 2	200 participants (Anticipated)	Interventional	2020-08-01	Recruiting
A Phase 2 Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab for Previously Untreated Subjects With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS) [NCT05835011]	Phase 2	100 participants (Actual)	Interventional	2023-07-14	Terminated(stopped due to Termination due to discontinuation of magrolimab development in MDS.)
A Pilot Open Label Phase I Trial to Evaluate the Safety and the Tolerability of a Combination of Two HIV-1 Inducers in HIV+ Sub-type B Patients Under cART With Undetectable Viral Load [NCT05230368]	Phase 1	15 participants (Anticipated)	Interventional	2022-12-14	Recruiting
A Phase I/II Trial of Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant [NCT04742634]	Phase 1/Phase 2	126 participants (Anticipated)	Interventional	2022-05-12	Recruiting
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (A [NCT03306264]	Phase 3	200 participants (Actual)	Interventional	2018-02-15	Completed
Randomized Phase II Study on Decitabine Plus Carboplatin Versus Physician's Choice Chemotherapy in Recurrent, Platinum-resistant Ovarian Cancer. [NCT03467178]	Phase 2	119 participants (Anticipated)	Interventional	2018-07-30	Recruiting
Phase I Clinical Study of TQB2618 Injection in Combination With Demethylation Drugs in Patients With Recurrent/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes [NCT05426798]	Phase 1	73 participants (Anticipated)	Interventional	2022-04-29	Recruiting
A Phase 1b, Open-label, Parallel Group, Multiple-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Oral Decitabine and Cedazuridine (ASTX727) in Cancer Patients With Moderate and Severe Hepatic Impairment [NCT04953910]	Phase 1	27 participants (Anticipated)	Interventional	2022-12-23	Recruiting
A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients With Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone [NCT01993641]	Phase 2	45 participants (Actual)	Interventional	2013-12-31	Completed
Randomized Study of Decitabine Versus Observation or Continued Standard Chemotherapy as Maintenance Therapy for Adults With Unfavorable Risk AML in First Complete Remission (CR) or Adults With Relapsed AML in Second or Greater CR [NCT00398983]	Phase 2/Phase 3	50 participants (Actual)	Interventional	2006-08-31	Completed
A Phase I Study of DEC205mAb-NY-ESO-1 Fusion Protein (CDX-1401) Given With Adjuvant PoIylCLC in Conjunction With 5-Aza-2'Deoxycytidine (Decitabine) in Patients With MDS or Low Blast Count AML [NCT01834248]	Phase 1	9 participants (Actual)	Interventional	2013-07-30	Completed
Phase II Randomized Study of Lower Doses of Decitabine (DAC; 20 mg/m2 IV Daily for 3 Days Every Month) Versus Azacitidine (AZA; 75 mg/m2 SC/IV Daily for 3 Days Every Month) in Myelodysplastic Syndrome (MDS) Patients With Low and Intermediate-1 Risk Diseas [NCT01720225]	Phase 2	113 participants (Actual)	Interventional	2012-11-06	Completed
A Phase I Study of Decitabine in Combination With Valproic Acid in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma [NCT00109824]	Phase 1	42 participants (Actual)	Interventional	2006-03-31	Completed
A Phase 1 Study of Vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in Combination With Decitabine in Patients With Advanced Solid Tumors, Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myel [NCT00275080]	Phase 1	80 participants (Actual)	Interventional	2006-02-28	Completed
A Phase I/Ib Study of BP1002 (a Liposomal Bcl-2 Antisense Oligodeoxynucleotide) in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML) [NCT05190471]	Phase 1	48 participants (Anticipated)	Interventional	2022-08-16	Recruiting
Phase II Study of Cladribine Plus Low Dose Cytarabine (LDAC) Induction Followed By Consolidation With Cladribine Plus LDAC Alternating With Decitabine in Patients With Untreated Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) [NCT01515527]	Phase 2	160 participants (Anticipated)	Interventional	2012-02-07	Recruiting
Combination of Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma : a Single Arm,Open-lable,Phase II Study [NCT04279379]	Phase 2	20 participants (Anticipated)	Interventional	2020-04-01	Recruiting
Phase Ib/II Study of Enzalutamide With Decitabine, a DNA Hypomethylating Agent, in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC) [NCT03709550]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2021-04-15	Withdrawn(stopped due to lack of funding)
A Phase I Study of 5-AZA-2'-Deoxycytidine and Depsipeptide in Patients With Relapsed/Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disease [NCT00114257]	Phase 1	36 participants (Actual)	Interventional	2005-05-31	Completed
[NCT01758367]	Phase 1/Phase 2	30 participants (Anticipated)	Interventional	2012-12-31	Recruiting
Phase I Study of Palbociclib Alone and in Combination in Patients With Relapsed and Refractory Leukemias [NCT03132454]	Phase 1	54 participants (Anticipated)	Interventional	2017-07-25	Recruiting
A Phase 2 Study of Fludarabine, Cytarabine, Filgrastim-sndz,Gemtuzumab Ozogamicin and Idarubicin in Newly Diagnosed Core Binding Factor Associated Acute Myelogenous Leukemia [NCT00801489]	Phase 2	270 participants (Anticipated)	Interventional	2007-04-04	Recruiting
Thalassemia Clinical Research Network (TCRN) [NCT00000623]		1,000 participants (Anticipated)	Observational	2000-07-31	Completed
Phase II Study of Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome [NCT00882102]	Phase 2	43 participants (Actual)	Interventional	2009-04-30	Completed
A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies [NCT05796570]	Phase 2	37 participants (Anticipated)	Interventional	2023-04-19	Recruiting
A Phase I Pharmacokinetic Trial of Decitabine (Dacogen) Administered as a 3-hour Infusion to Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome [NCT01378416]	Phase 1	16 participants (Actual)	Interventional	2005-04-30	Completed
A Phase I Trial Combining Decitabine and Vaccine Therapy for Patients With Relapsed Neuroblastoma and Sarcoma. [NCT01241162]	Phase 1	19 participants (Actual)	Interventional	2010-08-31	Completed
Clinical Study of Decitabine Combined With NK Cell Infusion in the Treatment of Malignant Tumors [NCT05143125]	Phase 1/Phase 2	60 participants (Anticipated)	Interventional	2021-02-05	Recruiting
An Open-label, Multicenter, phase2/3 Study of Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin Lymphoma [NCT04510610]	Phase 2/Phase 3	100 participants (Anticipated)	Interventional	2019-09-01	Recruiting
A Phase II, Multicenter Study of Decitabine (5-aza-2'Deoxycytidine) in Chronic Myelogenous Leukemia Chronic Phase Refractory to Imatinib Mesylate (STI 571) [NCT00042016]	Phase 2	40 participants	Interventional	2002-07-31	Completed
A Randomized, Open-label, Phase III Trial of Decitabine (5-aza-2'Deoxycytidine) Versus Supportive Care in Adults With Advanced-stage Myelodysplastic Syndrome [NCT00043381]	Phase 3	160 participants	Interventional	2001-04-30	Completed
Phase I Study of 5-Aza-2'-Deoxycytidine (Decitabine) as a Biologic Modifier of Retinoid Responsive Genes in Patients With High-Risk Myelodysplastic Syndromes and Acute Myelogenous Leukemia (De-novo, Relapsed or Secondary) [NCT00049582]	Phase 1	36 participants (Actual)	Interventional	2002-09-30	Terminated
Phase I/II Study of 5-aza-2'-Deoxycytidine and Valproic Acid in Patients With Relapsed/Refractory Leukemia or Myelodysplastic Syndromes [NCT00075010]	Phase 1/Phase 2	54 participants (Actual)	Interventional	2004-01-23	Completed
A Phase I Study of Decitabine (NSC# 127716, IND# 50733) in Combination With Doxorubicin and Cyclophosphamide in the Treatment of Relapsed or Refractory Solid Tumors [NCT00075634]	Phase 1	21 participants (Actual)	Interventional	2003-12-31	Completed
A Phase I Study of Decitabine in Combination With Valproic Acid in Patients With Selected Hematologic Malignancies [NCT00079378]	Phase 1	84 participants (Actual)	Interventional	2004-02-29	Completed
A Phase I Study Of The Toxicities, Biologic And Clinical Effects Of Daily 5 Aza 2'Deoxycytidine (DAC), NSC 127716 (IND 50733) For Four Weeks In Patients With Advanced Malignancies [NCT00030615]	Phase 1	24 participants (Actual)	Interventional	2001-12-31	Completed
A Randomized, Parallel-arm, Phase 2 Clinical Trial of the Combination of Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia Who Are Unfit for or Refuse Intensive Chemotherapy (GLAD-AML) [NCT04051996]	Phase 2	1 participants (Actual)	Interventional	2019-12-06	Terminated(stopped due to Unable to accrue patients following COVID-19 study pause.)
A Phase I Open Label Clinical Trial Evaluating the Safety and Efficacy of Adoptive Transfer of NY-ESO-1 TCR Engineered Autologous T Cells in Combination With Decitabine in Patients With Recurrent or Treatment Refractory Ovarian Cancer [NCT03017131]	Phase 1	9 participants (Actual)	Interventional	2017-12-08	Active, not recruiting
Intravenous Low-Dose Decitabine Versus Supportive Care in Elderly Patients With Primary Myelodysplastic Syndrome (MDS) (>10% Blasts or High-Risk Cytogenetics), Secondary MDS or Chronic Myelomonocytic Leukemia (CMML) Who Are Not Eligible for Intensive Ther [NCT00043134]	Phase 3	220 participants (Anticipated)	Interventional	2002-05-31	Active, not recruiting
Phase II Study of Imatinib Mesylate (Gleevec, STI-571) (NSC#716051) and Decitabine (5-AZA-2'-Deoxycitidine) (NSC#127716), in Chronic Myelogenous Leukemia in Accelerated and Blastic Phases [NCT00054431]	Phase 2	80 participants (Actual)	Interventional	2003-01-31	Completed
A Phase I Study of Decitabine in Combination With Valproic Acid in Patients With Non-Small Cell Lung Cancer [NCT00084981]	Phase 1	25 participants (Actual)	Interventional	2004-04-30	Completed
Combination of Decitabine and ATO to Treat AML/MDS Expressing a Classified Type of Mutant p53 [NCT03855371]	Phase 1	5 participants (Anticipated)	Interventional	2018-01-10	Recruiting
A Phase 1b Study: Treatment of Refractory Pancreatic Adenocarcinoma and Advanced Soft Tissue or Bone Sarcomas Using Decitabine Combined With Gemcitabine [NCT02959164]	Phase 1	36 participants (Actual)	Interventional	2016-12-05	Completed
Phase II Study of Decitabine in Acute Myeloid Leukemia [NCT00492401]	Phase 2	55 participants (Actual)	Interventional	2007-05-31	Completed
A Phase I/II Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome [NCT01893320]	Phase 1/Phase 2	66 participants (Actual)	Interventional	2013-07-18	Completed
Phase 1/2 Study of Decitabine Alone and/or in Combination With Chemotherapy and/or Cytokine Induced Killer Cell Transfusion in Patients With Relapsed or Refractory Solid Tumors and B Cell Lymphomas [NCT01799083]	Phase 1/Phase 2	100 participants (Anticipated)	Interventional	2012-12-31	Recruiting
Phase II Study of Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes [NCT02469415]	Phase 2	3 participants (Actual)	Interventional	2015-09-30	Terminated(stopped due to FDA Clinical Hold)
Phase II Study of Eltrombopag in Combination With Decitabine in Subjects With Advanced Myelodysplastic Syndrome [NCT02010645]	Phase 2	6 participants (Actual)	Interventional	2014-03-31	Terminated(stopped due to PI Request)
Phase I/II Study of Decitabine (DAC) Followed by Clofarabine, Idarubicin, and Cytarabine (CIA) in Acute Leukemia [NCT01794702]	Phase 1/Phase 2	65 participants (Actual)	Interventional	2013-02-20	Completed
A Randomized Phase II Trial of Decitabine-Based Induction Strategies for Patients >/= 60 Years Old With Acute Myeloid Leukemia (AML) [NCT01420926]	Phase 2	165 participants (Actual)	Interventional	2011-11-16	Completed
Decitabine and Umbilical Cord Blood for Poor Graft Function Post Allogenic Hematopoietic Stem Cell Transplantation [NCT05669079]	Phase 3	100 participants (Anticipated)	Interventional	2023-08-01	Not yet recruiting
A Phase I Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor (CDAi) With Oral Decitabine in Subjects With Solid Tumors [NCT03875287]	Phase 1	30 participants (Anticipated)	Interventional	2019-04-17	Recruiting
Phase I/II Trial of Subcutaneous Decitabine Maximizing Genomic Demethylation in Patients With Myelodysplastic Syndrome. [NCT00282399]	Phase 1	41 participants (Actual)	Interventional	2006-10-31	Terminated
Phase 1 Study of Oral Decitabine and Tetrahydrouridine (THU) in Patients With High Risk Sickle Cell Disease [NCT01685515]	Phase 1	25 participants (Actual)	Interventional	2012-08-31	Completed
A Phase Ib/II Multicenter Open-label Study of BGB324 as a Single Agent and in Combination With Cytarabine or Decitabine in Patients With Acute Myeloid Leukemia or as a Single Agent in Patients With Myelodysplastic Syndrome [NCT02488408]	Phase 1/Phase 2	121 participants (Actual)	Interventional	2014-09-30	Active, not recruiting
Anti-PD-1 Antibody Alone or in Combination With Low-dose Decitabine and/or Chemotherapy in Relapsed or Refractory Malignancies: an Open-label Phase I/II Trial [NCT02961101]	Phase 1/Phase 2	250 participants (Anticipated)	Interventional	2016-05-31	Recruiting
Department of Hematology, The Second Affiliated Hospital of Kunming Medical University. [NCT06073730]	Phase 3	154 participants (Anticipated)	Interventional	2023-11-01	Not yet recruiting
Phase 2 Study of Decitabine and Cedazuridine in Combination With Venetoclax for AML Relapse After Allogeneic Hematopoietic Cell Transplantation [NCT05799079]	Phase 2	51 participants (Anticipated)	Interventional	2023-12-31	Recruiting
A Phase II Study of Venetoclax in Combination With 10-Day Decitabine in Newly Diagnosed Elderly or Relapsed/Refractory Acute Myeloid Leukemia and Relapsed High-Risk Myelodysplastic Syndrome and Blastic Plasmacytoid Dendritic Cell Neoplasm [NCT03404193]	Phase 2	440 participants (Anticipated)	Interventional	2018-01-18	Recruiting
Phase II Randomized Study of Three Different Schedules of Low-Dose Decitabine (5-AZA-2'-Deoxycytidine) in Myelodysplastic Syndrome (MDS) [NCT00067808]	Phase 2	128 participants (Actual)	Interventional	2003-10-31	Completed
An Single-arm Open-label Phase II Study of Decitabine Plus Penpulimab as Second-line Therapy for Advanced Esophageal Squamous Cell Carcinoma Treated With PD-1 Blockade [NCT05265962]	Phase 2	85 participants (Anticipated)	Interventional	2022-12-01	Not yet recruiting
Randomized Phase II Study of Epigenetic Priming Using Decitabine With Induction Chemotherapy in Patients With Acute Myelogenous Leukemia (AML) [NCT01627041]	Phase 2	178 participants (Actual)	Interventional	2011-09-16	Active, not recruiting
A Phase I/IIa Dose-Escalation Study of the Decitabine-Genistein Drug Combination in Advanced Solid Tumors and Non-Small Cell Lung Cancer (NSCLC) Subjects [NCT01628471]	Phase 1/Phase 2	20 participants (Actual)	Interventional	2012-11-30	Completed
A Single-Arm, Open-Label Pharmacokinetic, Safety, and Efficacy Study of ASTX727 in Combination With Venetoclax in Adult Patients With Acute Myeloid Leukemia [NCT04657081]	Phase 1/Phase 2	188 participants (Anticipated)	Interventional	2021-02-09	Recruiting
The Clinical Research About the Therapeutic Effect and Safety of 10 Days Regimen With Single-agent of Decitabine for Elderly AML Patients [NCT01633099]	Phase 3	46 participants (Anticipated)	Interventional	2012-05-31	Active, not recruiting
Phase II Trial Examining Epigenetic Priming With Decitabine Followed by Idarubicin and Cytarabine for Patients With Relapsed or Refractory AML. [NCT01607645]	Phase 2	7 participants (Actual)	Interventional	2012-07-31	Terminated(stopped due to The study was terminated early because there were other competing protocols.)
A Phase 1b Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine in Treatment-Naive Subjects With Acute Myelogenous Leukemia Who Are Greater Than or Equal to 60 Years of Age and Who Are Not Eligible for Standard Induction Therapy [NCT02203773]	Phase 1	212 participants (Actual)	Interventional	2014-10-06	Terminated(stopped due to Strategic considerations)
An Open-label, Multicenter, Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab. [NCT05201066]	Phase 2	70 participants (Anticipated)	Interventional	2023-02-13	Recruiting
A Pilot/Safety Study of sEphB4-HSA in Combination With a Hypomethylating Agent (HMA) for Patients With Relapsed or Refractory Myelodysplastic Syndrome (MDS) and AML Previously Treated With a Hypomethylating Agent [NCT03146871]	Phase 2	7 participants (Actual)	Interventional	2017-04-20	Terminated(stopped due to Lack of funding)
A Phase I Study of Oral Decitabine and Cedazuridine (ASTX727) In Combination With Defactinib (VS-6063) as Therapy of Myelodysplastic Syndromes and Low-blast Acute Myeloid Leukaemia [NCT05636514]	Phase 1	12 participants (Anticipated)	Interventional	2022-12-14	Recruiting
Phase I Study of AR-42 and Decitabine in Acute Myeloid Leukemia [NCT01798901]	Phase 1	13 participants (Actual)	Interventional	2013-09-17	Completed
[NCT01809392]	Phase 2/Phase 3	15 participants (Anticipated)	Interventional	2013-01-31	Active, not recruiting
Phase I Trial of Fedratinib in Combination With Decitabine in Patients With Myeloproliferative Neoplasms in Accelerated and Blast Phase [NCT05524857]	Phase 1	13 participants (Anticipated)	Interventional	2022-01-28	Recruiting
The Use of Decitabine as Induction Therapy for Acute Myeloid Leukemia With Complex and/or Monosomal Karyotype [NCT03080766]	Phase 2	20 participants (Anticipated)	Interventional	2017-03-01	Recruiting
An Extended Phase 2 Study of Decitabine in Subjects With High Risk Sickle Cell Disease [NCT01375608]	Phase 2	10 participants (Actual)	Interventional	2011-06-30	Completed
A Randomized Phase II Study of Two Schedules of Decitabine for Frontline Therapy of Older or Unfit Patients With Acute Myeloid Leukemia (AML) [NCT01786343]	Phase 2	74 participants (Actual)	Interventional	2013-02-05	Completed
G-CSF+DAC+BUCY vs. G-CSF+DAC+BF Conditioning Regimen for Patients With Secondary Acute Myeloid Leukemia Evolving From MDS Undergoing Allogeneic Hematopoietic Stem Cell Transplantation [NCT05449899]	Phase 2/Phase 3	232 participants (Anticipated)	Interventional	2022-07-31	Recruiting
Genomic Predictors of Decitabine Response in AML/MDS [NCT01687400]	Phase 2	114 participants (Actual)	Interventional	2013-02-12	Completed
A PHASE 1B/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-04449913, AN ORAL HEDGEHOG INHIBITOR, IN COMBINATION WITH INTENSIVE CHEMOTHERAPY, LOW DOSE ARA-C OR DECITABINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC SYNDROME [NCT01546038]	Phase 2	255 participants (Actual)	Interventional	2012-06-27	Completed
An Open-Label, Randomized, Single-Dose, Four-Way Crossover, Bioavailability Study of Three Formulations of Decitabine/Tetrahydrouridine (THU) Combination Modified Release Capsules (5 mg/250 mg) in Healthy and Fasting Adults [NCT03828084]	Phase 1	16 participants (Actual)	Interventional	2019-04-03	Completed
A Phase I Study of Entrectinib in Combination With ASTX727 (35 mg Decitabine and 100 mg Cedazuridine) in Patients With Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia (AML) [NCT05396859]	Phase 1	12 participants (Anticipated)	Interventional	2022-10-28	Recruiting
Phase I-II Study of Low-Dose Azacitidine (Vidaza) in Patients With Chronic Myeloid Leukemia Who Have Minimal Residual Disease While Receiving Therapy With Tyrosine Kinase Inhibitors (VZ-CML-PI-0236) [NCT01460498]	Phase 1	3 participants (Actual)	Interventional	2012-08-08	Completed
PRO#0118: A Phase I Study of Decitabin in Combination With Fludarabin and Busulfan as a Reduced Intensity Conditioning Regimen for the Treatment of Myeloid Malignancies [NCT01455506]	Phase 1	20 participants (Actual)	Interventional	2009-05-31	Completed
A Phase I Study of the Biologic and Clinical Effects of 5-AZA-2'Deoxycytidine (DAC) in Patients With Advanced Malignancies [NCT00002980]	Phase 1	0 participants	Interventional	1997-05-31	Completed
A Phase 3b, Single-Arm, Multicenter Open-Label Study of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in AML Patients Ineligible for Intensive Chemotherapy [NCT03941964]	Phase 3	60 participants (Actual)	Interventional	2019-08-15	Completed
A Phase I/Pilot II Trial Combining Decitabine and Vaccine Therapy for Patients With Relapsed or Refractory Pediatric High Grade Gliomas, Medulloblastomas, and Central Nervous System Primitive Neuroectodermal Tumors (CNS PNETs) [NCT02332889]	Phase 1/Phase 2	1 participants (Actual)	Interventional	2015-04-30	Terminated(stopped due to Transition to a different immunotherapy strategy in the future at our institution)
A Randomized, Phase 2 Study of Biomarker Guided Treatment in DLBCL [NCT04025593]	Phase 2	128 participants (Anticipated)	Interventional	2019-07-17	Recruiting
A Phase I/II Trial of BMS-986253 in Myelodysplastic Syndromes [NCT05148234]	Phase 1/Phase 2	200 participants (Anticipated)	Interventional	2022-11-29	Active, not recruiting
Salsalate + Venetoclax/Decitabine for Patients With Acute Myelogenous Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease [NCT04146038]	Phase 2	5 participants (Actual)	Interventional	2020-10-26	Completed
Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab as a Strategy to Enhance the Efficacy of Immune Checkpoint Blockade in Unresectable or Metastatic Mucosal Melanoma [NCT05089370]	Phase 1/Phase 2	30 participants (Anticipated)	Interventional	2022-06-20	Recruiting
A Phase 1 Open-Label, Dose Escalation Study to Determine the Absolute Bioavailability of a Single Oral Dose Administration of Decitabine in Patients With Myelodysplastic Syndrome (MDS) [NCT00941109]	Phase 1	12 participants (Actual)	Interventional	2009-12-31	Completed
A Single-center Prospective Clinical Trial of the Efficacy and Safety of Ultra Small Dose Decitabine for the Lower Risk Myelodysplastic Syndrome Patients With Transfusion Dependent [NCT03045510]	Phase 2	50 participants (Anticipated)	Interventional	2016-12-01	Recruiting
Phase II Study of Decitabine in Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Radioiodine [NCT00085293]	Phase 2	12 participants (Actual)	Interventional	2004-05-31	Completed
Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming With Decitabine in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS): A Phase 1/2 Study [NCT01729845]	Phase 1/Phase 2	52 participants (Actual)	Interventional	2012-12-20	Completed
Phase II Study of Low-Dose Decitabine (5-AZA-2'-Deoxycytidine) in Myelodysplastic Syndrome (MDS) Post Azacytidine (AZA) Failure [NCT00113321]	Phase 2	16 participants (Actual)	Interventional	2005-03-31	Terminated(stopped due to Low Accrual)
Induction Therapy With Pacritinib Combined With Decitabine or Cytarabine in Older Patients With Acute Myeloid Leukemia (AML) [NCT02532010]	Phase 2	13 participants (Actual)	Interventional	2015-06-15	Terminated(stopped due to The study was put on clinical hold by the sponsor since Feb 9th 2016, and was later decided not to re-open due to financial constraints.)
A Phase 1b/2, Open-label Clinical Study to Determine Preliminary Safety and Efficacy of Alvocidib When Administered in Sequence After Decitabine or Azacitidine in Patients With MDS [NCT03593915]	Phase 1/Phase 2	20 participants (Actual)	Interventional	2018-08-29	Terminated(stopped due to The sponsor decided not to continue the study based on the overall company strategy in AML.)
An Open-label, Phase I/II Trial to Determine the Maximum Tolerated Dose and Investigate Safety, Pharmacokinetics and Efficacy of BI 836858 in Combination With Decitabine in Patients With Acute Myeloid Leukemia [NCT02632721]	Phase 1/Phase 2	49 participants (Actual)	Interventional	2016-06-16	Completed
A Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination With Chemotherapy in Patients With Acute Myeloid Leukemia (AML) [NCT02343939]	Phase 1/Phase 2	148 participants (Actual)	Interventional	2015-07-01	Terminated
A Therapeutic Trial of Decitabine and Vorinostat in Combination With Chemotherapy (Vincristine, Prednisone, Doxorubicin and PEG-Asparaginase) for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL) [NCT00882206]	Phase 2	15 participants (Actual)	Interventional	2009-04-30	Terminated(stopped due to Slow accrual)
Initial Cytoreductive Therapy for Myelodysplastic Syndrome Prior to Allogeneic Hematopoietic Cell Transplantation (the ICT-HCT Study) [NCT01812252]	Phase 2	46 participants (Actual)	Interventional	2013-04-02	Completed
Decitabine+Busulfan+Cyclophosphamide vs Busulfan+Cyclophosphamide Conditioning Regimen for TP53+ Myeloid Tumors Undergoing Allogeneic Hematopoietic Stem Cell Transplantation [NCT04123392]	Phase 2/Phase 3	196 participants (Anticipated)	Interventional	2019-10-31	Recruiting
Phase I Study of Low Dose 5-Aza-2'-Deoxycytidine Administered Daily for 5 Days Every Other Week for Patients With Relapsed or Refractory Acute Lymphocytic Leukemia [NCT00349596]	Phase 1	40 participants (Actual)	Interventional	2006-07-31	Completed
Granulocyte Colony-stimulating Factor+Decitabine+Busulfan+Cyclophosphamide vs Busulfan+Cyclophosphamide Conditioning Regimen for Patients With RAEB-1, RAEB-2 and AML Secondary to MDS Undergoing Allogeneic Hematopoietic Stem Cell Transplantation [NCT02744742]	Phase 2/Phase 3	202 participants (Actual)	Interventional	2016-04-18	Completed
A Randomized Phase 2/3 Study of DACOGEN® (Decitabine) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus DACOGEN (Decitabine) Alone in Patients With AML Who Are Not Candidates for Intensive Chemotherapy [NCT02472145]	Phase 2/Phase 3	326 participants (Actual)	Interventional	2015-08-04	Completed
Phase II Study With Decitabine (5-aza-2'-Deoxycytidine, DAC) in Myelodysplastic Syndromes [NCT00003361]	Phase 2	75 participants (Anticipated)	Interventional	1998-04-30	Completed
A Phase I/II Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients [NCT02109744]	Phase 1/Phase 2	27 participants (Actual)	Interventional	2014-03-31	Completed
Efficacy and Safety of Low-dose Decitabine in Refractory Aplastic Anemia (LODACA): a Phase 2, Single-arm, Open-label Study [NCT04854889]	Phase 2	3 participants (Actual)	Interventional	2021-04-22	Terminated(stopped due to Not achieve the desired effect)
A Phase II Study of Combination Midostaurin and Decitabine (MIDDAC) in Elderly Patients Newly Diagnosed With Acute Myeloid Leukemia and FLT3 Mutation [NCT02634827]	Phase 2	1 participants (Actual)	Interventional	2015-12-30	Terminated
A Prospective Study of Patients With Isolated Thrombocytopenia Following Hematopoietic Stem Cell Transplantation [NCT02487563]	Phase 3	97 participants (Actual)	Interventional	2015-10-31	Completed
Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed AML [NCT01829503]	Phase 2	44 participants (Actual)	Interventional	2013-02-28	Completed
Phase II Randomized Study of Lower Doses of Decitabine (DAC; 20 mg/m2 IV Daily for 3 Days Every Month) Versus Azacitidine (AZA; 75 mg/m2 SC/IV Daily for 3 Days Every Month) Versus Azacitidine (AZA; 75 mg/m2 SC/IV Daily for 5 Days Every Month) in MDS Patie [NCT02269280]	Phase 2	268 participants (Actual)	Interventional	2014-10-13	Active, not recruiting
A Pilot Proof-of-Concept Study of Talazoparib-Based Therapy for Cohesin-Mutated AML and MDS With Excess Blasts [NCT03974217]	Phase 1	12 participants (Anticipated)	Interventional	2019-08-01	Recruiting
Phase 3 Randomized Trial of DFP-10917 vs Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High & Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second, [NCT03926624]	Phase 3	450 participants (Anticipated)	Interventional	2019-11-22	Recruiting
G-CSF+DAC+BUCY vs. G-CSF+DAC+BF Conditioning Regimen for Patients With High-risk MDS Undergoing Allogeneic Hematopoietic Stem Cell Transplantation [NCT05453552]	Phase 2/Phase 3	242 participants (Anticipated)	Interventional	2022-07-01	Recruiting
Chidamide in Combination With Decitabine in Non-Hodgkin's Lymphoma Relapsed After Chimeric Antigen Receptor : An Open-label Phase I/II Trial [NCT04337606]	Phase 1/Phase 2	100 participants (Anticipated)	Interventional	2020-04-04	Recruiting
G-CSF+DAC+BUCY vs. G-CSF+DAC+BF Conditioning Regimen for Patients With RAEB-1, RAEB-2 and AML Secondary to MDS Undergoing Allogeneic Hematopoietic Stem Cell Transplantation [NCT04713956]	Phase 2/Phase 3	242 participants (Anticipated)	Interventional	2021-01-15	Recruiting
Phase I/II Trial of Tamoxifen Following Epigenetic Regeneration of Estrogen Receptor Using Decitabine and LBH 589 in Patients With Triple Negative Metastatic Breast Cancer [NCT01194908]	Phase 1/Phase 2	5 participants (Actual)	Interventional	2010-07-31	Terminated(stopped due to Slow accrual)
An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357) [NCT01498445]	Phase 1/Phase 2	32 participants (Actual)	Interventional	2012-06-12	Terminated(stopped due to The study was terminated early during the phase II portion of the study due to slow enrollment.)
Proof-of-concept Study of Nicotinamide and Oral Tetrahydrouridine (THU) and Decitabine to Treat High Risk Sickle Cell Disease [NCT04055818]	Phase 1	20 participants (Anticipated)	Interventional	2020-01-24	Recruiting
A Phase 1/2 Study of Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML [NCT04493099]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2020-10-31	Withdrawn(stopped due to The original sponsor was acquired by a new company and has elected to end funding for all Investigator Sponsored Trials (ISTs))
A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia [NCT02204085]	Phase 1/Phase 2	33 participants (Actual)	Interventional	2014-09-30	Active, not recruiting
A Phase1-2 Pharmacokinetic Guided Dose-Escalation and Dose-Confirmation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 With Oral Decitabine in Subjects With Myelodysplastic Syndromes (MDS) [NCT02103478]	Phase 1/Phase 2	130 participants (Actual)	Interventional	2014-10-28	Completed
Allogeneic Hematopoietic Stem Cell Transplantation as Initial Salvage Therapy for Patients With Primary Induction Failure Acute Myeloid Leukemia Refractory to High-Dose Cytarabine-Based Induction Chemotherapy [NCT02441803]	Phase 2	11 participants (Actual)	Interventional	2015-09-14	Active, not recruiting
Epigenetic Reprogramming in Relapse AML: A Phase 1 Study of Decitabine and Vorinostat Followed by Fludarabine, Cytarabine and G-CSF (FLAG) in Children and Young Adults With Relapsed/Refractory AML [NCT02412475]	Phase 1	3 participants (Actual)	Interventional	2015-02-21	Terminated(stopped due to We opened a competing study with the TACL consortium)
A Multi-Center Phase 2 Study of Combined Modality Treatment With Ruxolitinib, Decitabine, and Donor Lymphocyte Infusion for Post-Transplant Relapse of AML or MDS [NCT04055844]	Phase 2	14 participants (Actual)	Interventional	2020-02-17	Completed
The Clinical Study of Individualized Induction Therapy for Non-elderly Patients With Acute Myeloid Leukemia and Adverse Risk Features Guided by Rapid Screening With FISH and NGS [NCT04752527]	Phase 2	42 participants (Anticipated)	Interventional	2021-02-20	Recruiting
A Randomized Phase III Study of Decitabine (DAC) With or Without Hydroxyurea (HY) Versus HY in Patients With Advanced Proliferative Chronic Myelomonocytic Leukemia (CMML) [NCT02214407]	Phase 3	170 participants (Actual)	Interventional	2014-10-14	Completed
Infusion of 5-Azacytidine (5-AZA) Into the Fourth Ventricle or Resection Cavity in Children and Adults With Recurrent Posterior Fossa Ependymoma: A Phase I Study [NCT03572530]	Phase 1	9 participants (Anticipated)	Interventional	2019-02-08	Recruiting
Minimizing Leukemia Relapse: A Phase I, Dose Escalation Study of Decitabine in High Risk Pediatric Leukemia Post Allogeneic Transplant [NCT02264873]	Phase 1	3 participants (Actual)	Interventional	2014-10-31	Completed
Phase 1-2 Safety and Efficacy Study of DACOGEN in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia [NCT01853228]	Phase 1/Phase 2	17 participants (Actual)	Interventional	2013-10-22	Terminated(stopped due to EMA/PDCO acknowledged that available results from this study do not support further clinical studies in relapsed/refractory AML paediatric patients.)
Phase II Trial of Low Dose Decitabine (Dacogen) in Patients With Primary Myelofibrosis and Post ET/PV Myelofibrosis [NCT00630994]	Phase 2	4 participants (Actual)	Interventional	2008-03-31	Terminated(stopped due to Stopped due to slow accrual)
A Phase 2 Study of Decitabine in Combination With Midostaurin (PKC412) for Elderly Patients With Newly Diagnosed FLT3-ITD/TKD Positive Acute Myeloid Leukemia [NCT01846624]	Phase 2	13 participants (Actual)	Interventional	2013-06-30	Terminated(stopped due to Accrual factor)
Decitabine Plus Cytarabine for Induction of Remission in Newly Diagnosed Elderly Acute Myeloid Leukemia (AML) and Advanced Myelodysplastic Syndrome (MDS) [NCT02121418]		12 participants (Actual)	Interventional	2014-06-30	Completed
A Phase II, Multi-center, Open Label, Randomized Study of Ribavirin and Hedgehog Inhibitor With or Without Decitabine in Acute Myeloid Leukemia (AML) [NCT02073838]	Phase 2	23 participants (Actual)	Interventional	2015-05-31	Completed
A Study of Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy in Patients With Acute Myeloid Leukemia Who Had Relapsed/Refractory Disease or Positive Minimal Residual Disease [NCT05362942]	Phase 2	52 participants (Anticipated)	Interventional	2022-05-01	Not yet recruiting
Phase I Study of Tegavivint (BC-2059) in Patients With Relapsed and Refractory Leukemias [NCT04874480]	Phase 1	54 participants (Anticipated)	Interventional	2021-09-27	Recruiting
T-Cell Immune Checkpoint Inhibition Plus Hypomethylation for Locally Advanced HER2-Negative Breast Cancer - A Phase 2 Neoadjuvant Window Trial of Pembrolizumab and Decitabine Followed by Standard Neoadjuvant Chemotherapy [NCT02957968]	Phase 2	46 participants (Actual)	Interventional	2017-01-24	Active, not recruiting
A Phase I Clinical Trial of NY-ESO-1 Protein Immunization in Combination With 5-AZA-2'-Deoxycytidine (Decitabine) in Patients Receiving Liposomal Doxorubicin for Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma [NCT01673217]	Phase 1	18 participants (Actual)	Interventional	2009-04-30	Completed
A Phase I/II Study of High-Dose Deoxyazacytidine, Busulfan, and Cyclophosphamide With Allogeneic Stem Cell Transplantation for Hematologic Malignancies [NCT00002831]	Phase 1/Phase 2	24 participants (Actual)	Interventional	1995-08-01	Completed
An Open Label, Phase I, Dose Escalation Trial to Investigate the Maximum Tolerated Dose, Safety, Pharmacokinetics, and Efficacy of Volasertib in Combination With Decitabine in Patients >= 65 Years With Acute Myeloid Leukemia [NCT02003573]	Phase 1	13 participants (Actual)	Interventional	2014-01-29	Terminated
Decitabine and Vorinostat With CD3/CD19 Depleted Haploidentical Donor Natural Killer (NK) Cells for the Treatment of High Risk Myelodysplastic Syndromes (MDS) [NCT01593670]	Phase 2	9 participants (Actual)	Interventional	2013-03-31	Completed
An Open-label, Multi-center, Phase IIIb Study for Decitabine in Patients With Myelodysplastic Syndrome (MDS) [NCT01751867]	Phase 3	135 participants (Actual)	Interventional	2009-08-31	Completed
A Phase 1, Parallel, Open-Label Study of the Safety and Tolerability, Pharmacokinetics, and Antileukemic Activity of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) [NCT04155580]	Phase 1	68 participants (Actual)	Interventional	2020-06-12	Terminated(stopped due to Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention)
A Phase 3b, Randomized, Open-Label, Double Crossover Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Adult Patients With IPSS R Intermediate Myelodysplastic Syndrome, Low Blast Acute Myeloid Leukemia, IPSS Inte [NCT05883956]	Phase 3	42 participants (Anticipated)	Interventional	2023-11-30	Not yet recruiting
Anti-PD-1 Antibody SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma:an Open-label Phase II Trial [NCT03250962]	Phase 2	280 participants (Anticipated)	Interventional	2017-09-11	Recruiting
Efficacy and Safety of Decitabine in Combination With Low-dose Cytarabine as Inductive Treatment in Newly Diagnosed Elderly Patients With Acute Myeloid Leukemia [NCT02985372]	Phase 3	30 participants (Anticipated)	Interventional	2016-12-31	Enrolling by invitation
Decitabine+Busulfan+Cyclophosphamide vs Busulfan+Cyclophosphamide Conditioning Regimen for Mixed-lineage-leukemia (MLL)-Rearranged Acute Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation [NCT03596892]	Phase 2/Phase 3	122 participants (Anticipated)	Interventional	2018-07-31	Recruiting
Combination of the Hypomethylating Agent Decitabine and the Nuclear Export Receptor XPO-1 Inhibitor Selinexor to Reverse Platinum Resistance in Relapsed/Refractory Epithelial Ovarian Cancer [NCT05983276]	Phase 2	40 participants (Anticipated)	Interventional	2023-08-28	Not yet recruiting
Phase I Study of Pacritinib and Chemotherapy in Patients With Acute Myeloid Leukemia and FLT3 Mutations [NCT02323607]	Phase 1	13 participants (Actual)	Interventional	2016-01-12	Completed
A Multicenter Randomized Control Clinical Trail of Evaluating Effect of Demethylation Drug Combined With Chemotherapy in Patients With Intermediate-risk AML After Hematological Complete Remission [NCT03417427]	Phase 2	100 participants (Anticipated)	Interventional	2018-02-01	Recruiting
A Phase I Study of Avelumab in Combination With Decitabine as First Line Treatment of Patients With AML, Who Are Unfit for Intensive Chemotherapy [NCT03395873]	Phase 1	7 participants (Actual)	Interventional	2018-01-29	Terminated(stopped due to Recent FDA approval of a new drug for the same patient population)
Decitabine,Cytarabine(Ara-C) and Arsenic Trioxide(ATO) in the Treatment of Acute Myeloid Leukemia With p53 Mutations [NCT03381781]	Phase 2	100 participants (Anticipated)	Interventional	2018-03-31	Not yet recruiting
A Pilot Study of Nivolumab in Combination With Decitabine and Venetoclax in TP53-Mutated Acute Myeloid Leukemia [NCT04277442]	Phase 1	13 participants (Anticipated)	Interventional	2020-03-11	Active, not recruiting
A Phase 1B Study of KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Acute Myeloid Leukemia [NCT03041688]	Phase 1	58 participants (Anticipated)	Interventional	2018-02-08	Recruiting
A Phase 1 Study of Ipilimumab in Combination With Decitabine in Relapsed or Refractory Myelodysplastic Syndrome/Acute Myeloid Leukemia [NCT02890329]	Phase 1	48 participants (Anticipated)	Interventional	2017-09-05	Active, not recruiting
A Phase II Study of Decitabine in Myelofibrosis [NCT00095784]	Phase 2	21 participants (Actual)	Interventional	2004-09-29	Active, not recruiting
A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL [NCT01483690]	Phase 1/Phase 2	23 participants (Actual)	Interventional	2011-12-31	Terminated(stopped due to Toxicity)
A Prospective, Randomized, Controlled Trial of Decitabine Versus Conventional Chemotherapy for Maintenance Therapy of Patients With Acute Myeloid Leukemia With t(8;21) [NCT03026842]	Phase 4	180 participants (Anticipated)	Interventional	2017-01-31	Active, not recruiting
Phase I Trial of OPB-111077 in Combination With Decitabine and Venetoclax for the Treatment of AML Refractory to or Ineligible for Intensive Chemotherapy [NCT03063944]	Phase 1	37 participants (Actual)	Interventional	2017-03-17	Active, not recruiting
OAG and Decitabine for Newly Diagnosed Acute Myeloid Leukemia Patients Greater Than or Equal to 65 Years of Age [NCT02029417]	Phase 2	2 participants (Actual)	Interventional	2014-07-31	Terminated(stopped due to Major revisions needed in study)
A Phase I/II Study of Quizartinib in Combination With Decitabine and Venetoclax for the Treatment of Patients With Acute Myeloid Leukemia (AML) [NCT03661307]	Phase 1/Phase 2	72 participants (Actual)	Interventional	2018-10-31	Active, not recruiting
A Multicenter Prospective Randomized Study of Dexamethasone Combined With Decitabine Versus Dexamethasone in the Treatment of Newly Diagnosed Primary Immune Thrombocytopenia (ITP) [NCT03252457]	Phase 3	200 participants (Anticipated)	Interventional	2018-09-01	Not yet recruiting
A Phase Ib/II Study Evaluating Navitoclax After Failure of Hypomethylating Agent and Venetoclax for Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome [NCT05564650]	Phase 1/Phase 2	37 participants (Anticipated)	Interventional	2023-01-12	Recruiting
Decitabine Followed by Bone Marrow Transplant and High-Dose Cyclophosphamide for the Treatment of Relapsed and Refractory Acute Myeloid Neoplasms [NCT01707004]	Phase 2	20 participants (Actual)	Interventional	2013-05-16	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00067808 (1) [back to overview]	Participant Responses
NCT00085293 (2) [back to overview]	Frequency of Adverse Events According to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0
NCT00085293 (2) [back to overview]	Restoration of Radioiodine Uptake in Metastatic Lesions as Demonstrated by Diagnostic Whole-body Scanning After Decitabine Administration
NCT00095784 (20) [back to overview]	Incidence of Toxicities, Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v3.0
NCT00095784 (20) [back to overview]	CD34+ Cells
NCT00095784 (20) [back to overview]	CXCR4
NCT00095784 (20) [back to overview]	CD34+ Cells
NCT00095784 (20) [back to overview]	Response Rate (Complete Response, Partial Response, or Hematologic Improvement.
NCT00095784 (20) [back to overview]	CXCR4
NCT00095784 (20) [back to overview]	Hemoglobin F
NCT00095784 (20) [back to overview]	Hemoglobin F
NCT00095784 (20) [back to overview]	Hemoglobin F
NCT00095784 (20) [back to overview]	CD34+ Cells
NCT00095784 (20) [back to overview]	Hemoglobin F
NCT00095784 (20) [back to overview]	Hemoglobin F
NCT00095784 (20) [back to overview]	Hemoglobin F
NCT00095784 (20) [back to overview]	CD34+ Cells
NCT00095784 (20) [back to overview]	CXCR4
NCT00095784 (20) [back to overview]	CXCR4
NCT00095784 (20) [back to overview]	CXCR4
NCT00095784 (20) [back to overview]	CXCR4
NCT00095784 (20) [back to overview]	CD34+ Cells
NCT00095784 (20) [back to overview]	CD34+ Cells
NCT00113321 (1) [back to overview]	Overall Response
NCT00260065 (2) [back to overview]	Best Response and Overall Improvement
NCT00260065 (2) [back to overview]	Number of Participants Who Achieved Overall Response
NCT00260832 (2) [back to overview]	Overall Survival in Patients 65 Years or Older Who Have Newly Diagnosed de Novo or Secondary AML.
NCT00260832 (2) [back to overview]	Percentage of Participants With Complete Remission (CR) Plus Complete Remission With Incomplete Platelet Recovery (CRp)
NCT00321711 (4) [back to overview]	Hypomethylating Agent Dose Reduction and Delay Due to Thrombocytopenia
NCT00321711 (4) [back to overview]	Occurrence of a Clinically Significant Thrombocytopenic Event
NCT00321711 (4) [back to overview]	Platelet Transfusion
NCT00321711 (4) [back to overview]	Achieving an Overall Response (Complete or Partial Response, CR or PR) at the End of the Treatment Period
NCT00358644 (1) [back to overview]	Complete Response = Morphologic Complete Remission (mCR)
NCT00398983 (1) [back to overview]	Number of Participants With Relapse-Free Response at 1 Year
NCT00414310 (3) [back to overview]	Response Duration
NCT00414310 (3) [back to overview]	Participant Response Rates to Decitabine With or Without Valproic Acid in MDS and AML
NCT00414310 (3) [back to overview]	Overall Survival Rate
NCT00416598 (2) [back to overview]	Number of Participants Who Completed Maintenance Decitabine.
NCT00416598 (2) [back to overview]	Disease-free Survival (DFS) Rate at 1 Year
NCT00477386 (4) [back to overview]	Phase I: Maximum Tolerated Dose (MTD) for Use in Phase II
NCT00477386 (4) [back to overview]	Phase II: Percent of Patients With Objective Response, CA125 Response or Stable Disease > 3 Months
NCT00477386 (4) [back to overview]	Phase II: Progression Free Survival
NCT00477386 (4) [back to overview]	Phase II: Percent of Patients With Objective Response
NCT00479232 (3) [back to overview]	Objective Response Rate in Participants Treated With Vorinostat + Decitabine With Refractory or Relapse Acute Myelogenous Leukemia (AML)
NCT00479232 (3) [back to overview]	Objective Response Rate in Participants Treated With Vorinostat + Decitabine With Intermediate-high Risk Myelodysplastic Syndrome (MDS) or Untreated Acute Myelogenous Leukemia (AML)
NCT00479232 (3) [back to overview]	Number of Participants Experiencing Dose Limiting Toxicity (DLT) Events
NCT00492401 (2) [back to overview]	Rate of Complete Remission
NCT00492401 (2) [back to overview]	Measurement of DNMT Protein in Peripheral Blood or Bone Marrow Cells
NCT00619099 (1) [back to overview]	The Overall Improvement Rate
NCT00621023 (2) [back to overview]	Number of Patients With an Unacceptable Toxicity
NCT00621023 (2) [back to overview]	Number of Patients With an Overall Response of Complete Response (CR) or Partial Response (PR)
NCT00630994 (2) [back to overview]	Number of Participants With Severe Adverse Events
NCT00630994 (2) [back to overview]	Number of Participants Who Achieve a Confirmed Response (Complete Remission (CR), Partial Remission (PR), or Clinical Improvement (CI)), According to International Working Group (IWG) Consensus Criteria.
NCT00661726 (12) [back to overview]	Change in Absolute Fetal Hemoglobin (HbF) From Baseline to Peak (the Follow-up Time Point With the Highest Value)
NCT00661726 (12) [back to overview]	Change in Absolute Reticulocyte Count From Baseline to Nadir (the Follow-up Time Point With the Lowest Value)
NCT00661726 (12) [back to overview]	Change in Erythropoietin Levels From Baseline to Nadir (the Follow-up Time Point With the Lowest Value)
NCT00661726 (12) [back to overview]	Change in Indirect Bilirubin From Baseline to Nadir (the Follow-up Time Point With the Lowest Value)
NCT00661726 (12) [back to overview]	Change in Neutrophil Counts From Baseline to Nadir (the Follow-up Time Point With the Lowest Value)
NCT00661726 (12) [back to overview]	Change in Percentage of Annexin-positive Cells From Baseline to Nadir (the Follow-up Time Point With the Lowest Value)
NCT00661726 (12) [back to overview]	Change in Platelet Count From Baseline to Peak (the Follow-up Time Point With the Highest Value)
NCT00661726 (12) [back to overview]	Change in Serum Lactate Dehydrogenase (LDH) From Baseline to Nadir (the Follow-up Time Point With the Lowest Value)
NCT00661726 (12) [back to overview]	Change in Total Hemoglobin (Hb) From Baseline to Peak (the Follow-up Time Point With the Highest Value)
NCT00661726 (12) [back to overview]	Number of Evaluable Patients With an Increase From Baseline in Hemoglobin (Hb) of ≥1.5 g/dL
NCT00661726 (12) [back to overview]	Change in Red Blood Cell (RBC) Deformability From Baseline to Peak (the Follow-up Time Point With the Highest Value)
NCT00661726 (12) [back to overview]	Change in Percentage of Red Blood Cell (RBC) Hb Concentration From Baseline to Peak (the Follow-up Time Point With the Highest Value)
NCT00691938 (10) [back to overview]	Event-free Survival
NCT00691938 (10) [back to overview]	Overall Survival
NCT00691938 (10) [back to overview]	Phase I: Maximum Tolerated Dose (MTD) of LBH589 When Given in Combination With Decitabine
NCT00691938 (10) [back to overview]	Phase II: Overall Rate of Morphologic Complete Remission (CR) + Cytogenetic Complete Remission (CRc) + Morphologic Complete Remission With Incomplete Blood Count Recovery (CRi)
NCT00691938 (10) [back to overview]	Rate of Cytogenetic Complete Remission (CRc)
NCT00691938 (10) [back to overview]	Rate of Hematologic Improvement.
NCT00691938 (10) [back to overview]	Rates of Morphologic Complete Remission With Incomplete Count Recovery (CRi)
NCT00691938 (10) [back to overview]	Remission Duration
NCT00691938 (10) [back to overview]	Time to Response
NCT00691938 (10) [back to overview]	Safety and Tolerability of Regimen as Measured by the Rate of the Most Common Adverse Events Experienced
NCT00715793 (8) [back to overview]	6-month Progression-free Survival (PFS) Rate
NCT00715793 (8) [back to overview]	Disease Control Rate (DCR)
NCT00715793 (8) [back to overview]	Overall Response Rate (ORR)
NCT00715793 (8) [back to overview]	Overall Survival (OS)
NCT00715793 (8) [back to overview]	Percentage of Participants That Experienced a Dose Limiting Toxicity (DLT)
NCT00715793 (8) [back to overview]	Progression-free Survival (PFS)
NCT00715793 (8) [back to overview]	Recommended Phase 2 Dose (RP2D) of DAC + TMZ
NCT00715793 (8) [back to overview]	1-year Overall Survival (OS) Rate
NCT00744757 (10) [back to overview]	Percentage of Participants With Hematologic Treatment Response
NCT00744757 (10) [back to overview]	Quality of Life Assessment
NCT00744757 (10) [back to overview]	Percentage of Participants With Cytogenetic Response
NCT00744757 (10) [back to overview]	Number of Events Which Led to Hospitalization
NCT00744757 (10) [back to overview]	Duration for Hospitalization
NCT00744757 (10) [back to overview]	Time to Acute Myeloid Leukemia (AML) Progression or Death
NCT00744757 (10) [back to overview]	Percentage of Participants With Transfusion Independency
NCT00744757 (10) [back to overview]	Percentage of Participants With Transfusion Dependency
NCT00744757 (10) [back to overview]	Percentage of Participants With Response
NCT00744757 (10) [back to overview]	Overall Survival
NCT00760084 (1) [back to overview]	The Number of Subjects With Adverse Events
NCT00778375 (6) [back to overview]	Median Overall Survival (OS)
NCT00778375 (6) [back to overview]	Number of Participants With Complete Remission [Complete Response (CR), Complete Response With Platelet Recover (CRp) or Complete Response With Incomplete Marrow Recovery (CRi)]
NCT00778375 (6) [back to overview]	Overall Response Rate (CR, CRp/CRi and PR)
NCT00778375 (6) [back to overview]	Event Free Survival (EFS)
NCT00778375 (6) [back to overview]	Disease-free (DFS) or Relapse-free Survival (RFS) Time
NCT00778375 (6) [back to overview]	Complete Remission (CR) Rate for First 60 Participants
NCT00796003 (11) [back to overview]	Phase I and II: Number of Participants Who Experienced Adverse Events
NCT00796003 (11) [back to overview]	Phase I: Maximum Observed Plasma Concentration of Decitabine (Cmax)
NCT00796003 (11) [back to overview]	Phase II: Median Time to Remission
NCT00796003 (11) [back to overview]	Phase I: Area Under the Plasma Concentration-time Curve (AUC)
NCT00796003 (11) [back to overview]	Phase II: Median Time to Improvement
NCT00796003 (11) [back to overview]	Phase II: Median Duration of Remission
NCT00796003 (11) [back to overview]	Phase II: Median Duration of Overall Improvement
NCT00796003 (11) [back to overview]	Phase II: Overall Remission Rate (ORR): Number of Participants Who Achieved Complete Remission (CR)+Partial Remission (PR) - as Per International Working Group (IWG) Response Criteria (2000)
NCT00796003 (11) [back to overview]	Phase II: Overall Improvement Rate: Number of Participants Who Achieved Complete Response (CR)+Partial Response (PR)+Hematological Improvement (HI) - as Per International Working Group (IWG) Response Criteria (2000)
NCT00796003 (11) [back to overview]	Phase II: Number of Participants With Cytogenic Response - as Per International Working Group (IWG) Response Criteria 2000 (Major/Minor) and IWG 2006 (Complete/Partial)
NCT00796003 (11) [back to overview]	Phase I: Number of Participants Who Achieved Complete Remission (CR)+Partial Remission (PR)+Hematological Improvement (HI) - as Per International Working Group (IWG) Response Criteria (2000)
NCT00882102 (1) [back to overview]	Number of Participants With a Complete Response
NCT00882206 (4) [back to overview]	Response to Treatment
NCT00882206 (4) [back to overview]	Level of Methylation
NCT00882206 (4) [back to overview]	Level of Methylation
NCT00882206 (4) [back to overview]	Level of Methylation
NCT00903760 (2) [back to overview]	Event Free Survival (EFS) at 1 Year
NCT00903760 (2) [back to overview]	Participant Response
NCT00925132 (2) [back to overview]	Phase 2 -Number of Patients With a Decrease in Tumor Size Using RECIST and CHOI's Criteria
NCT00925132 (2) [back to overview]	Phase I - Number of Participants With Dose Limiting Toxicities (DLTs) at a Given Dose Level
NCT00968071 (1) [back to overview]	Number of Participants With Complete Response (CR)
NCT01011283 (2) [back to overview]	Overall Response Rate (ORR), Defined as Proportion of Patients Having Complete Response (CR) and Marrow Complete Response (mCR) After Completion of 3 Cycles of Study Drug.
NCT01011283 (2) [back to overview]	Overall Response Rate (ORR), Defined as Proportion of Patients Having Complete Response (CR) and Marrow Complete Response (mCR) After Completion of 6 Cycles of Study Drug.
NCT01165996 (7) [back to overview]	Number of Patients That Experience > Grade 2 Non-hematologic Toxicity by National Cancer Institute (NCI)/Cancer Therapy Evaluation Program (CTEP) v4 Criteria
NCT01165996 (7) [back to overview]	Proportion of Patients With Bone Marrow Evidence of Terminal Differentiation Response to Therapy.
NCT01165996 (7) [back to overview]	Proportion of Patients With Particular Genetic Abnormalities Detected by Whole Exome Sequencing Correlation With Clinical Response
NCT01165996 (7) [back to overview]	Cytogenetic Response as Per IWG Criteria
NCT01165996 (7) [back to overview]	Number of Patients With Response as Defined by IWG (International Working Group) Criteria for Myelodysplasia
NCT01165996 (7) [back to overview]	Proportion of Patients With Bone Marrow Evidence of Cytotoxicity.
NCT01165996 (7) [back to overview]	Proportion of Patients With Pharmacodynamic Evidence of Drug Effect.
NCT01177540 (7) [back to overview]	Time to CR
NCT01177540 (7) [back to overview]	Percentage of Participants With Morphologic Complete Remission (CR)
NCT01177540 (7) [back to overview]	Time to Neutrophil Recovery
NCT01177540 (7) [back to overview]	Percentage of Participants With Minimal Residual Disease (MRD) at Baseline and Day 50
NCT01177540 (7) [back to overview]	Leukemia-free Survival (LFS)
NCT01177540 (7) [back to overview]	Overall Survival (OS)
NCT01177540 (7) [back to overview]	Time to Platelet Recovery
NCT01193517 (2) [back to overview]	Response Rate of Azacitidine, and Capecitabine and Oxaliplatin (CAPOX)
NCT01193517 (2) [back to overview]	Maximum Tolerated Dose (MTD) of Azacitidine, and Capecitabine and Oxaliplatin (CAPOX)
NCT01303796 (9) [back to overview]	1-year Survival
NCT01303796 (9) [back to overview]	Duration of Stable Disease (dSD)
NCT01303796 (9) [back to overview]	Duration of Partial Remission (dPR)
NCT01303796 (9) [back to overview]	Duration of Complete Remission With Incomplete Platelet Count Recovery (dCRp)
NCT01303796 (9) [back to overview]	Duration of Hematological Improvement (dHI)
NCT01303796 (9) [back to overview]	Duration of Complete Remission (dCR)
NCT01303796 (9) [back to overview]	Hospitalized Days
NCT01303796 (9) [back to overview]	Overall Survival
NCT01303796 (9) [back to overview]	Blood Products Transfused
NCT01378416 (5) [back to overview]	Tmax (Time at Which Cmax First Observed)
NCT01378416 (5) [back to overview]	Safety: The Most Frequently Reported Adverse Events (Regardless of Causality)
NCT01378416 (5) [back to overview]	Cmax (Maximum Plasma Concentration)
NCT01378416 (5) [back to overview]	AUC (0-∞) - Area Under the Plasma Concentration-time Curve Extrapolated to Infinity
NCT01378416 (5) [back to overview]	Average Total Body Clearance (Calculated From Rate and Concentration)
NCT01420926 (5) [back to overview]	Disease-free Survival (DFS)
NCT01420926 (5) [back to overview]	Complete Remission Rate (CR and CRi)
NCT01420926 (5) [back to overview]	Overall Survival (OS) Time
NCT01420926 (5) [back to overview]	Progression-free Survival
NCT01420926 (5) [back to overview]	Adverse Events
NCT01483690 (2) [back to overview]	Disease Response Rate After Treatment.
NCT01483690 (2) [back to overview]	Number of Participants Who Experienced a Dose Limiting Toxicity (DLT).
NCT01498445 (4) [back to overview]	Ph I Study: Maximum Tolerated Dose (MTD) Dasatinib
NCT01498445 (4) [back to overview]	Duration of Response
NCT01498445 (4) [back to overview]	Number of Participants With Hematologic Responses During First 3 Months of Treatment
NCT01498445 (4) [back to overview]	Overall Survival
NCT01546038 (70) [back to overview]	Serum Levels of Circulating Protein Analytes at Phase 1B - Induction Cycle 1/Day 3
NCT01546038 (70) [back to overview]	Ratios of mRNA Levels Associated With Best Overall Response at Phase 2 Unfit
NCT01546038 (70) [back to overview]	AUCtau of Daunorubicin and Daunorubicinol in Participants Receiving Glasdegib and Cytarabine/Daunorubicin at Phase 1B on Induction Cycle 1/Day 3
NCT01546038 (70) [back to overview]	AUCtau of Cytarabine and Ara-U in Participants Receiving Glasdegib and Cytarabine/Daunorubicin at Phase 1B on Induction Cycle 1/Day 3
NCT01546038 (70) [back to overview]	AUCinf of Decitabine in Participants Receiving Glasdegib and Decitabine at Phase 1B on Cycle 1/Day 1 and Cycle 1/Day 2
NCT01546038 (70) [back to overview]	Area Under the Plasma Concentration-time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of LDAC and Ara-U in Participants Receiving Glasdegib and LDAC at Phase 1B on Cycle 1/Day 2 and Cycle 1/Day 10
NCT01546038 (70) [back to overview]	Area Under the Plasma Concentration-time Profile From Time 0 to Infinity (AUCinf) of LDAC in Participants Receiving Glasdegib and LDAC at Phase 1B on Cycle 1/Day 2 and Cycle 1/Day 10
NCT01546038 (70) [back to overview]	Area Under the Plasma Concentration-time Profile From Time 0 to Dosing Interval (AUCtau) of Glasdegib in Participants Receiving Glasdegib and LDAC at Phase 1B on Cycle 1/Day 10 and Cycle 1/Day 21
NCT01546038 (70) [back to overview]	Tmax of Glasdegib in Participants Receiving Glasdegib and LDAC at Phase 2 Unfit on Cycle 1/Day 10
NCT01546038 (70) [back to overview]	Serum Levels of Circulating Protein Analytes at Phase 2 Unfit - Cycle 1/Day 1
NCT01546038 (70) [back to overview]	Cmax of Glasdegib in Participants Receiving Glasdegib and Cytarabine/Daunorubicin at Phase 1B on Induction Cycle 1/Day 3 and Day 10
NCT01546038 (70) [back to overview]	AUCtau of Glasdegib in Participants Receiving Glasdegib and LDAC at Phase 2 Unfit on Cycle 1/Day 10
NCT01546038 (70) [back to overview]	Baseline Levels of Serum Circulating Protein Analytes Associated With Best Overall Response at Phase 1B
NCT01546038 (70) [back to overview]	Baseline Levels of Serum Circulating Protein Analytes Associated With Best Overall Response at Phase 2 Fit
NCT01546038 (70) [back to overview]	Baseline mRNA Levels Associated With Best Overall Response at Phase 2 Fit
NCT01546038 (70) [back to overview]	Cmax of Glasdegib in Participants Receiving Glasdegib and LDAC at Phase 2 Unfit on Cycle 1/Day 10
NCT01546038 (70) [back to overview]	Number of Participants With Dose-limiting Toxicities (DLTs) at Phase 1B
NCT01546038 (70) [back to overview]	Overall Survival (OS) at Phase 2 Unfit
NCT01546038 (70) [back to overview]	Percentage of Participants With Complete Response (CR) at Phase 2 Unfit
NCT01546038 (70) [back to overview]	Percentage of Participants With CR / Complete Response With Incomplete Blood Count Recovery (CRi) at Phase 1B
NCT01546038 (70) [back to overview]	Post-baseline Levels of Serum Circulating Protein Analytes Associated With Best Overall Response at Phase 1B - Induction Cycle 1/Day 3
NCT01546038 (70) [back to overview]	Post-baseline Levels of Serum Circulating Protein Analytes Associated With Best Overall Response at Phase 1B - Induction Cycle 1/Lead-In
NCT01546038 (70) [back to overview]	Post-baseline Levels of Serum Circulating Protein Analytes Associated With Best Overall Response at Phase 2 Fit - Induction Cycle 1/Day 10
NCT01546038 (70) [back to overview]	Post-baseline Levels of Serum Circulating Protein Analytes Associated With Best Overall Response at Phase 2 Fit - Induction Cycle 1/Day 3
NCT01546038 (70) [back to overview]	Post-baseline Levels of Serum Circulating Protein Analytes Associated With Best Overall Response at Phase 2 Unfit - End of Treatment
NCT01546038 (70) [back to overview]	Tmax of LDAC and Ara-U in Participants Receiving Glasdegib and LDAC at Phase 1B on Cycle 1/Day 2 and Cycle 1/Day 10
NCT01546038 (70) [back to overview]	Tmax of Glasdegib in Participants Receiving Glasdegib and Decitabine at Phase 1B on Cycle 1/Day 10 and Cycle 2/Day 1
NCT01546038 (70) [back to overview]	Tmax of Glasdegib in Participants Receiving Glasdegib and Cytarabine/Daunorubicin at Phase 1B on Induction Cycle 1/Day 3 and Day 10
NCT01546038 (70) [back to overview]	Tmax of Decitabine in Participants Receiving Glasdegib and Decitabine at Phase 1B on Cycle 1/Day 1 and Cycle 1/Day 2
NCT01546038 (70) [back to overview]	Tmax of Daunorubicin and Daunorubicinol in Participants Receiving Glasdegib and Cytarabine/Daunorubicin at Phase 1B on Induction Cycle 1/Day 3
NCT01546038 (70) [back to overview]	Time to Cmax (Tmax) of Glasdegib in Participants Receiving Glasdegib and LDAC at Phase 1B on Cycle 1/Day 10 and Cycle 1/Day 21
NCT01546038 (70) [back to overview]	Serum Levels of Circulating Protein Analytes at Phase 2 Unfit - Cycle 1/Day 10
NCT01546038 (70) [back to overview]	Serum Levels of Circulating Protein Analytes at Phase 2 Fit - Induction Cycle 1/Day 3
NCT01546038 (70) [back to overview]	Serum Levels of Circulating Protein Analytes at Phase 2 Fit - Induction Cycle 1/Day 10
NCT01546038 (70) [back to overview]	Serum Levels of Circulating Protein Analytes at Phase 2 Fit - End of Treatment
NCT01546038 (70) [back to overview]	Serum Levels of Circulating Protein Analytes at Phase 2 Fit - Consolidation Cycle 1/Day 10
NCT01546038 (70) [back to overview]	Serum Levels of Circulating Protein Analytes at Phase 2 Fit - Consolidation Cycle 1/Day 1
NCT01546038 (70) [back to overview]	Serum Levels of Circulating Protein Analytes at Phase 1B - Induction Cycle 1/Day 10
NCT01546038 (70) [back to overview]	Serum Levels of Circulating Protein Analytes at Phase 1B - Baseline
NCT01546038 (70) [back to overview]	Ratios of mRNA Levels to Baseline at Phase 2 Unfit - End of Treatment
NCT01546038 (70) [back to overview]	Ratios of mRNA Levels to Baseline at Phase 2 Fit - Induction Cycle 1/Day 3
NCT01546038 (70) [back to overview]	Ratios of mRNA Levels to Baseline at Phase 2 Fit - End of Treatment
NCT01546038 (70) [back to overview]	Ratios of mRNA Levels to Baseline Associated With Best Overall Response at Phase 2 Fit
NCT01546038 (70) [back to overview]	Post-baseline Levels of Serum Circulating Protein Analytes Associated With Best Overall Response at Phase 2 Unfit - Cycle 1/Day 1
NCT01546038 (70) [back to overview]	Post-baseline Levels of Serum Circulating Protein Analytes Associated With Best Overall Response at Phase 2 Fit - End of Treatment
NCT01546038 (70) [back to overview]	Percentage of Participants With Disease-specific Efficacy for Myelodysplastic Syndrome (MDS) at Phase 2 Fit and Unfit
NCT01546038 (70) [back to overview]	Percentage of Participants With Disease-specific Efficacy for Acute Myeloid Leukemia (AML) at Phase 2 Fit and Unfit
NCT01546038 (70) [back to overview]	Percentage of Participants With Complete Response (CR) at Phase 2 Fit
NCT01546038 (70) [back to overview]	Overall Survival (OS) at Phase 2 Fit
NCT01546038 (70) [back to overview]	Number of Participants With Treatment-emergent AEs Categorized by Seriousness at Phase 2 Fit and Unfit
NCT01546038 (70) [back to overview]	Number of Participants With Treatment-emergent AEs Categorized by Seriousness at Phase 1B
NCT01546038 (70) [back to overview]	Number of Participants With Treatment-emergent AEs at Phase 2 Fit and Unfit (Treatment-related)
NCT01546038 (70) [back to overview]	Number of Participants With Treatment-emergent AEs at Phase 2 Fit and Unfit (All Causality)
NCT01546038 (70) [back to overview]	Number of Participants With Treatment-emergent AEs at Phase 1B (Treatment-related)
NCT01546038 (70) [back to overview]	Number of Participants With Treatment-emergent Adverse Events (AEs) at Phase 1B (All Causality)
NCT01546038 (70) [back to overview]	Number of Participants With Disease-related Gene Mutations at Phase 2 Fit and Unfit
NCT01546038 (70) [back to overview]	Number of Participants With Disease-related Gene Mutations at Phase 1B
NCT01546038 (70) [back to overview]	Number of Participants With Corrected QT Interval Using Fridericia's Formula (QTcF) Values Meeting Predefined Criteria at Phase 2 Fit and Unfit
NCT01546038 (70) [back to overview]	Number of Participants With Corrected QT Interval Using Fridericia's Formula (QTcF) Values Meeting Predefined Criteria at Phase 1B
NCT01546038 (70) [back to overview]	Maximum Observed Plasma Concentration (Cmax) of Glasdegib in Participants Receiving Glasdegib and LDAC at Phase 1B on Cycle 1/Day 10 and Cycle 1/Day 21
NCT01546038 (70) [back to overview]	Cmax of LDAC and Ara-U in Participants Receiving Glasdegib and LDAC at Phase 1B on Cycle 1/Day 2 and Cycle 1/Day 10
NCT01546038 (70) [back to overview]	Cmax of Glasdegib in Participants Receiving Glasdegib and Decitabine at Phase 1B on Cycle 1/Day 10 and Cycle 2/Day 1
NCT01546038 (70) [back to overview]	Overall Survival (OS) at Phase 1B
NCT01546038 (70) [back to overview]	Cmax of Decitabine in Participants Receiving Glasdegib and Decitabine at Phase 1B on Cycle 1/Day 1 and Cycle 1/Day 2
NCT01546038 (70) [back to overview]	Cmax of Daunorubicin and Daunorubicinol in Participants Receiving Glasdegib and Cytarabine/Daunorubicin at Phase 1B on Induction Cycle 1/Day 3
NCT01546038 (70) [back to overview]	Baseline mRNA Levels Associated With Best Overall Response at Phase 2 Unfit
NCT01546038 (70) [back to overview]	Baseline Levels of Serum Circulating Protein Analytes Associated With Best Overall Response at Phase 2 Unfit
NCT01546038 (70) [back to overview]	AUCtau of Glasdegib in Participants Receiving Glasdegib and Decitabine at Phase 1B on Cycle 1/Day 10 and Cycle 2/Day 1
NCT01546038 (70) [back to overview]	AUCtau of Glasdegib in Participants Receiving Glasdegib and Cytarabine/Daunorubicin at Phase 1B on Induction Cycle 1/Day 3 and Day 10
NCT01546038 (70) [back to overview]	Pre-dose Plasma Concentration (Ctrough) of Glasdegib in Phase 2 Fit on Induction Cycle 1/Day 10
NCT01593670 (5) [back to overview]	Number of Patients Who Became Transfusion Independent
NCT01593670 (5) [back to overview]	Overall Survival
NCT01593670 (5) [back to overview]	Number of Patients Who Had Natural Killer (NK) Cell Expansion
NCT01593670 (5) [back to overview]	Number of Patients Who Experienced Grade 3 or Higher Non-hematologic Adverse Events
NCT01593670 (5) [back to overview]	The Number of Patients Who Achieved a Clinical Response
NCT01607645 (13) [back to overview]	CRiMRD+ Defined as Meeting All Criteria for a CRi But With Evidence of Minimal Residual Disease by Flow Cytometry, Cytogenetics, or Other Known Molecular Biomarkers
NCT01607645 (13) [back to overview]	CRMRD- Defined as Morphologic CR Without Evidence of Minimal Residual Disease by Flow Cytometry, Cytogenetics, or Other Known Molecular Biomarkers
NCT01607645 (13) [back to overview]	CRMRD+ Defined as a Morphologic CR But With Minimal Residual Disease by Flow Cytometry, Cytogenetics, or Other Known Molecular Biomarkers
NCT01607645 (13) [back to overview]	Cytogenetic Response Defined as no Detectable Cytogenetic Abnormality in a Subsequent BM Specimen After Induction or Re-induction
NCT01607645 (13) [back to overview]	Duration of Moderate Neutropenia Defined as an ANC Less Than 1000
NCT01607645 (13) [back to overview]	Duration of Severe Neutropenia Defined as an ANC Less Than 500
NCT01607645 (13) [back to overview]	Duration of Thrombocytopenia Defined as Platelet Count Less Than 100,000
NCT01607645 (13) [back to overview]	Resistant Disease Defined as Patient Survives at Least 14 Days After Completion of the Last Dose of Induction or Re-induction But Has Persistent Leukemia in Peripheral Blood (PB) or BM
NCT01607645 (13) [back to overview]	CRi Defined as Meeting All Criteria for a Morphologic CR But ANC Remains Less Than 1,000/μL and/or Platelet Count Less Than 100,000/μL
NCT01607645 (13) [back to overview]	Severe Prolonged Aplasia
NCT01607645 (13) [back to overview]	TRM With Each Course of Decitabine-priming, Idarubicin, and Cytarabine
NCT01607645 (13) [back to overview]	Frequency and Severity of Grade 3, 4, and 5 Toxicities With Each Course of Decitabine-priming, Idarubicin, and Cytarabine According to NCI Common Terminology Criteria for Adverse Events Version (CTCAE) 4.0
NCT01607645 (13) [back to overview]	Number of Participants Who Achieved Morphologic CR
NCT01687400 (5) [back to overview]	Change in Bone Marrow Methylcytosine
NCT01687400 (5) [back to overview]	Compare Outcomes of a 10-day Decitabine Per Cycle Regimen to a 5-day Regimen (Historical Controls)
NCT01687400 (5) [back to overview]	Peripheral Blood Decitabine Plasma Levels
NCT01687400 (5) [back to overview]	Correlation of Patient Specific Mutations With Overall Response Rate
NCT01687400 (5) [back to overview]	Rate of Mutation Clearance During Treatment
NCT01707004 (8) [back to overview]	Time to Neutrophil Recovery
NCT01707004 (8) [back to overview]	Overall Survival (OS)
NCT01707004 (8) [back to overview]	Number of Participants With Primary Graft Failure
NCT01707004 (8) [back to overview]	Number of Participants With Complete Remission After Transplantation
NCT01707004 (8) [back to overview]	Cumulative Incidence of Grade III-IV Acute GVHD
NCT01707004 (8) [back to overview]	Cumulative Incidence of Chronic GVHD According to BMTCTN
NCT01707004 (8) [back to overview]	Progression Free Survival
NCT01707004 (8) [back to overview]	Percentage of Participants With Platelet Recovery by Day 30
NCT01720225 (2) [back to overview]	Participants With a Response
NCT01720225 (2) [back to overview]	Number of Participants Who Became Transfusion Independent
NCT01729845 (4) [back to overview]	Overall Survival
NCT01729845 (4) [back to overview]	Remission Rate Including CR and CRp
NCT01729845 (4) [back to overview]	Duration of Relapse-free Survival (for Patients Achieving CR or CRp)
NCT01729845 (4) [back to overview]	Most Efficacious and Tolerated Dosage of Decitabine (Period 1)
NCT01751867 (7) [back to overview]	Mean Change From Baseline to End of Treatment in Scores of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ C-30) Physical Functioning Scale
NCT01751867 (7) [back to overview]	Mean Percentage of Duration of Hospitalization (Relative to Days on Study Treatment)
NCT01751867 (7) [back to overview]	Cytogenetic Response Rate: Percentage of Participants Who Achieved Cytogenetic Response (Complete+Partial) by Status of Clinical Overall Response - International Working Group (IWG) 2006 Response Criteria
NCT01751867 (7) [back to overview]	Overall Survival Rate: Percentage of Participants Who Survived During 6 Months and 12 Months of Treatment.
NCT01751867 (7) [back to overview]	Transfusion Independence: Number of Participants Who Were Transfusion Independent
NCT01751867 (7) [back to overview]	Hematological Improvement Rate: Number of Participants Who Achieved Complete Remission (CR), Partial Remission (PR) and Hematologic Improvement (HI) - International Working Group (IWG) 2006 Response Criteria
NCT01751867 (7) [back to overview]	Overall Response Rate (ORR): Number of Participants Who Achieved Either Complete Remission (CR), Partial Remission (PR), or Marrow Complete Remission (mCR) - International Working Group (IWG) 2006 Response Criteria
NCT01786343 (3) [back to overview]	Overall Survival
NCT01786343 (3) [back to overview]	Participants With a Response
NCT01786343 (3) [back to overview]	Response Duration
NCT01794702 (4) [back to overview]	Maximum Tolerated Dose (MTD) of Clofarabine
NCT01794702 (4) [back to overview]	Number of Participants With a Response
NCT01794702 (4) [back to overview]	Overall Survival
NCT01794702 (4) [back to overview]	To Determine the Disease-free Survival (DFS).
NCT01829503 (12) [back to overview]	Overall Survival (OS) in Participants Who Experienced Complete Response or Complete Response With Incomplete Count Recovery
NCT01829503 (12) [back to overview]	Overall Survival (OS) in Participants Who Experienced Complete Response, Complete Response With Incomplete Count Recovery, or Partial Response
NCT01829503 (12) [back to overview]	Overall Survival (OS)
NCT01829503 (12) [back to overview]	Overall Survival (OS) in Participants Who Experienced Complete Response
NCT01829503 (12) [back to overview]	Relapse-Free Survival in Participants With Complete Response or Complete Response With Incomplete Count Recovery.
NCT01829503 (12) [back to overview]	Relapse-Free Survival in Participants With Complete Response, Complete Response With Incomplete Count Recovery or Partial Response, and Received Maintenance Therapy
NCT01829503 (12) [back to overview]	Demographic Characteristics and Clinical Measures as Potential Predictors of Overall Survival (OS)
NCT01829503 (12) [back to overview]	Functional Assessment of Cancer Therapy: Health-related Quality of Life (HRQOL) Measure
NCT01829503 (12) [back to overview]	Number of Participants by Best Clinical Response Experienced
NCT01829503 (12) [back to overview]	Numbers of Patients (Out of 44) Experiencing Adverse Events With CTCAE Grade ≥ 3 or Adverse Events Grade ≥ 4
NCT01829503 (12) [back to overview]	Proportion of Participants With Survival to Four and Eight Weeks and One Year
NCT01829503 (12) [back to overview]	Proportion of Participants With Clinical Response (CR)
NCT01846624 (5) [back to overview]	Complete Remission (CR) Rate
NCT01846624 (5) [back to overview]	Median Duration of Response (DoR)
NCT01846624 (5) [back to overview]	Overall Survival (OS)
NCT01846624 (5) [back to overview]	Progression-free Survival (PFS)
NCT01846624 (5) [back to overview]	Overall Response Rate (ORR)
NCT01853228 (13) [back to overview]	Phase 2: Percentage of Participants Who Achieved CR or CRi at Cycle 1 Day 28
NCT01853228 (13) [back to overview]	Phase 2: Percentage of Participants Who Achieved CR or CRi at Cycle 2 Day 28
NCT01853228 (13) [back to overview]	Phase 2: Percentage of Participants Who Achieved CR or CRi at End of Study Treatment
NCT01853228 (13) [back to overview]	Phase 1 and 2: Area Under the Plasma Concentration-Time Curve (AUC) of Decitabine
NCT01853228 (13) [back to overview]	Phase 1 and 2: Total Clearance of Decitabine
NCT01853228 (13) [back to overview]	Phase 2: Duration of Response
NCT01853228 (13) [back to overview]	Phase 1 and 2: Volume of Distribution at Steady-State (Vss) of Decitabine
NCT01853228 (13) [back to overview]	Phase 2: Overall Response Rate
NCT01853228 (13) [back to overview]	Phase 1 and 2: Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs)
NCT01853228 (13) [back to overview]	Phase 1 and 2: Event-Free Survival
NCT01853228 (13) [back to overview]	Phase 1 and 2: Maximum Plasma Concentration (Cmax) of Decitabine
NCT01853228 (13) [back to overview]	Phase 1 and 2: Overall Survival (OS)
NCT01853228 (13) [back to overview]	Phase 1: Maximum Tolerated Dose (MTD) of Cytarabine
NCT01893320 (2) [back to overview]	Participants With a Response
NCT01893320 (2) [back to overview]	Maximum Tolerated Dose (MTD) of Vosaroxin in Combination With Decitabine
NCT02003573 (2) [back to overview]	Determination of the Maximum Tolerated Dose (MTD) Based on the Occurrence of Dose-limiting Toxicity (DLT) in Cycle 1
NCT02003573 (2) [back to overview]	Number of Subjects With Dose Limiting Toxicities (DLT) in Cycle 1
NCT02010645 (1) [back to overview]	Overall Response Rate (ORR)
NCT02029417 (1) [back to overview]	Frequency of Adverse Events, Graded According to NCI CTCAE v4.0
NCT02085408 (4) [back to overview]	Proportion of Patients With Complete Remission
NCT02085408 (4) [back to overview]	Overall Survival by Donor Status
NCT02085408 (4) [back to overview]	Overall Survival
NCT02085408 (4) [back to overview]	Disease-free Survival for Maintenance
NCT02103478 (17) [back to overview]	Number of Participants With Transfusion Independence
NCT02103478 (17) [back to overview]	Number of Participants With Adverse Events
NCT02103478 (17) [back to overview]	Maximum Observed Plasma Concentration (Cmax) of Decitabine
NCT02103478 (17) [back to overview]	Maximum Observed Plasma Concentration (Cmax) of Cedazuridine (E7727) and Cedazuridine-epimer
NCT02103478 (17) [back to overview]	Area Under the Concentration Versus Time Curve of Cedazuridine (E7727) and Cedazuridine-epimer
NCT02103478 (17) [back to overview]	Time to Maximum Observed Plasma Concentration (Tmax) of Decitabine in Phase 2
NCT02103478 (17) [back to overview]	Duration of Complete Response in Phase 2 - Kaplan-Meier Estimate
NCT02103478 (17) [back to overview]	Duration of Complete Response in Phase 1
NCT02103478 (17) [back to overview]	Number of Participants With Overall Response in Phase 1
NCT02103478 (17) [back to overview]	Number of Participants With Hematological Improvement
NCT02103478 (17) [back to overview]	Time to Maximum Observed Plasma Concentration (Tmax) of Cedazuridine (E7727) and Cedazuridine-epimer
NCT02103478 (17) [back to overview]	Number of Participants With Dose-limiting Toxicity in Phase 1
NCT02103478 (17) [back to overview]	Mean Decitabine Area Under the Plasma Concentration Versus Time Curve Ratio (5-day AUC0-t) in Phase 2
NCT02103478 (17) [back to overview]	Mean Decitabine Area Under the Concentration Versus Time Curve (AUC0-t) on Day 5 by Cohort in Phase 1
NCT02103478 (17) [back to overview]	Number of Participants With Overall Response in Phase 2
NCT02103478 (17) [back to overview]	Mean Maximum %LINE Demethylation in Phase 1
NCT02103478 (17) [back to overview]	Mean Maximum %LINE Demethylation in Phase 2
NCT02109744 (3) [back to overview]	Median Overall Survival
NCT02109744 (3) [back to overview]	Mean Change in Blast Percentage in Marrow
NCT02109744 (3) [back to overview]	Blast Percentage in Peripheral Blood
NCT02121418 (2) [back to overview]	Overall Survival of Patients Over Age 60 With Newly Diagnosed AML/High Risk MDS
NCT02121418 (2) [back to overview]	Response Rate
NCT02257138 (4) [back to overview]	Number of Participants With Post-MPN Acute Myeloid Leukemia (AML) With JAK2 Mutations (Phase 2)
NCT02257138 (4) [back to overview]	Maximum Tolerated Dose of Ruxolitinib Phosphate (Phase I)
NCT02257138 (4) [back to overview]	Number of Participants With a Response (Complete Response [CR] + CR With Incomplete Blood Count Recovery) (Phase 2)
NCT02257138 (4) [back to overview]	Number of JAK2 Positive+ and JAK2 Negative- Participants With a Response (Phase 2)
NCT02332889 (1) [back to overview]	Tolerability (Number of Participants Without Adverse Events)
NCT02343939 (9) [back to overview]	Percentage of Participants Who Experienced Laboratory Abnormalities
NCT02343939 (9) [back to overview]	Percentage of Participants With Overall Response at the End of Induction
NCT02343939 (9) [back to overview]	Percentage of Participants Experiencing Treatment-Emergent Adverse Events
NCT02343939 (9) [back to overview]	Percentage of Participants With Morphologic Complete Remission (CR) at the End of Induction
NCT02343939 (9) [back to overview]	Percentage of Participants With Composite Complete Remission at the End of Induction
NCT02343939 (9) [back to overview]	Percentage of Participants Experiencing Dose Limiting Toxicities (DLTs)
NCT02343939 (9) [back to overview]	Overall Survival (OS)
NCT02343939 (9) [back to overview]	Event Free Survival (EFS)
NCT02343939 (9) [back to overview]	Duration of Exposure of Entospletinib
NCT02472145 (7) [back to overview]	Part B: Time to Best Response
NCT02472145 (7) [back to overview]	Part B: Percentage of Participants With Complete Response (CR) Plus Minimal Residual Disease (MRD) Negative Complete Response With Incomplete Recovery (CRi)
NCT02472145 (7) [back to overview]	Part B: Percentage of Participants Who Achieved CR and CRi (Overall Response Rate)
NCT02472145 (7) [back to overview]	Part B: Percentage of Participants Who Achieved Complete Response (Complete Response Rate) Based on Investigator Assessment
NCT02472145 (7) [back to overview]	Part B: Event-free Survival (EFS) Based on Investigator Assessment
NCT02472145 (7) [back to overview]	Part B: Duration of Response (DOR) Based on Investigator Assessment
NCT02472145 (7) [back to overview]	Part B: Overall Survival
NCT02487563 (2) [back to overview]	Number of Participants With Platelet Count Recovery
NCT02487563 (2) [back to overview]	Megakaryocyte Count
NCT02532010 (7) [back to overview]	Remission Duration
NCT02532010 (7) [back to overview]	Overall Survival
NCT02532010 (7) [back to overview]	Complete Remission Rate
NCT02532010 (7) [back to overview]	Overall Remission Rate
NCT02532010 (7) [back to overview]	Event-free Survival
NCT02532010 (7) [back to overview]	Time to Complete Response
NCT02532010 (7) [back to overview]	Relapse-free Survival
NCT02608268 (46) [back to overview]	Phase I-Ib and Dose Ranging Part: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) During the On-treatment Period
NCT02608268 (46) [back to overview]	Phase I-Ib and Dose Ranging Part: Number of Participants With Dose Reductions and Dose Interruptions of Sabatolimab
NCT02608268 (46) [back to overview]	Phase Ib: Number of Participants With Dose Reductions and Dose Interruptions of Spartalizumab
NCT02608268 (46) [back to overview]	Phase II: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) During the On-treatment Period
NCT02608268 (46) [back to overview]	Phase II: Number of Participants With Dose Reductions and Dose Interruptions of Sabatolimab
NCT02608268 (46) [back to overview]	Phase II: Number of Participants With Dose Reductions and Dose Interruptions of Spartalizumab
NCT02608268 (46) [back to overview]	Time to Reach Maximum Serum Concentration (Tmax) of Sabatolimab
NCT02608268 (46) [back to overview]	Time to Reach Maximum Serum Concentration (Tmax) of Sabatolimab
NCT02608268 (46) [back to overview]	Time to Reach Maximum Serum Concentration (Tmax) of Spartalizumab
NCT02608268 (46) [back to overview]	Time to Reach Maximum Serum Concentration (Tmax) of Spartalizumab
NCT02608268 (46) [back to overview]	Duration of Response (DOR) Per RECIST v1.1
NCT02608268 (46) [back to overview]	Overall Response Rate (ORR) Per irRC
NCT02608268 (46) [back to overview]	Overall Survival (OS)
NCT02608268 (46) [back to overview]	Percentage Change From Baseline of Tumor Infiltrating Lymphocytes (TILs) Count
NCT02608268 (46) [back to overview]	Phase I-Ib and Dose Ranging Part: Dose Intensity of Sabatolimab
NCT02608268 (46) [back to overview]	Phase I-Ib: Number of Participants With Dose-Limiting Toxicities (DLTs)
NCT02608268 (46) [back to overview]	Phase Ib: Dose Intensity of Spartalizumab
NCT02608268 (46) [back to overview]	Phase II: Dose Intensity of Sabatolimab
NCT02608268 (46) [back to overview]	Phase II: Dose Intensity of Spartalizumab
NCT02608268 (46) [back to overview]	Phase II: Overall Response Rate (ORR) Per RECIST v1.1
NCT02608268 (46) [back to overview]	Progression-Free Survival (PFS) Per irRC
NCT02608268 (46) [back to overview]	Progression-Free Survival (PFS) Per RECIST v1.1
NCT02608268 (46) [back to overview]	Terminal Elimination Half-life (T1/2) of Sabatolimab
NCT02608268 (46) [back to overview]	Terminal Elimination Half-life (T1/2) of Spartalizumab
NCT02608268 (46) [back to overview]	All-Collected Deaths
NCT02608268 (46) [back to overview]	All-Collected Deaths
NCT02608268 (46) [back to overview]	Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Sabatolimab
NCT02608268 (46) [back to overview]	Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Sabatolimab
NCT02608268 (46) [back to overview]	Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Spartalizumab
NCT02608268 (46) [back to overview]	Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Spartalizumab
NCT02608268 (46) [back to overview]	Baseline Expression of CD163
NCT02608268 (46) [back to overview]	Baseline Expression of CD163
NCT02608268 (46) [back to overview]	Baseline Expression of CD8+
NCT02608268 (46) [back to overview]	Baseline Expression of CD8+
NCT02608268 (46) [back to overview]	Baseline Expression of CD8+
NCT02608268 (46) [back to overview]	Baseline Expression of LAG-3
NCT02608268 (46) [back to overview]	Baseline Expression of LAG-3
NCT02608268 (46) [back to overview]	Baseline Expression of PD-L1
NCT02608268 (46) [back to overview]	Baseline Expression of PD-L1
NCT02608268 (46) [back to overview]	Baseline Expression of TIM-3
NCT02608268 (46) [back to overview]	Baseline Expression of TIM-3
NCT02608268 (46) [back to overview]	Maximum Observed Serum Concentration (Cmax) of Sabatolimab
NCT02608268 (46) [back to overview]	Maximum Observed Serum Concentration (Cmax) of Sabatolimab
NCT02608268 (46) [back to overview]	Maximum Observed Serum Concentration (Cmax) of Spartalizumab
NCT02608268 (46) [back to overview]	Number of Participants With Anti-sabatolimab Antibodies
NCT02608268 (46) [back to overview]	Number of Participants With Anti-spartalizumab Antibodies
NCT02650986 (2) [back to overview]	Number of Participants With Dose Limiting Toxicities
NCT02650986 (2) [back to overview]	Number of Participants With Feasibility Concerns in Manufacturing of NY-ESO-1/ dnTGFbetaRII Engineered Cells
NCT02664181 (2) [back to overview]	Overall Survival
NCT02664181 (2) [back to overview]	Time-to-Progression
NCT02785900 (10) [back to overview]	Minimal Residual Disease (MRD)-Negative Composite Complete Remission Rate
NCT02785900 (10) [back to overview]	Mortality Rates at Day 30 and Day 60
NCT02785900 (10) [back to overview]	Type, Incidence, Severity, Seriousness, and Relatedness of Adverse Events
NCT02785900 (10) [back to overview]	Composite Complete Remission (CRc) Rate
NCT02785900 (10) [back to overview]	Duration of Remission
NCT02785900 (10) [back to overview]	Event-free Survival
NCT02785900 (10) [back to overview]	Leukemia-free Survival
NCT02785900 (10) [back to overview]	Overall Survival
NCT02785900 (10) [back to overview]	Time to Complete Remission
NCT02785900 (10) [back to overview]	Incidence of Grade 3 or Higher Laboratory Abnormalities
NCT02878785 (1) [back to overview]	Phase 1 - Dose Finding
NCT02921061 (6) [back to overview]	Number of Participants With Minimal Residual Disease Negative (MRDneg) Complete Remission (Phase II)
NCT02921061 (6) [back to overview]	Number of Participants With Overall Survival
NCT02921061 (6) [back to overview]	Number of Participants With Relapse-free Survival
NCT02921061 (6) [back to overview]	Number of Participants With Event-free Survival
NCT02921061 (6) [back to overview]	Number of Participants Experiencing Dose Limiting Toxicities (DLTs) at the Maximum Tolerated Dose (MTD) for Decitabine When Given Together With G-CLAM Toxicities (DLTs) (Phase I)
NCT02921061 (6) [back to overview]	Number of Participants Who Achieved Remission (Complete Remission [CR]/CR With Incomplete Peripheral Blood Count Recovery [CRi])
NCT02954653 (9) [back to overview]	Progression Free Survival [Part 1]
NCT02954653 (9) [back to overview]	Number of Participants With Chemistry Laboratory Abnormalities by Type and Maximum National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE) Grade [Part 1]
NCT02954653 (9) [back to overview]	Objective Response Rate (ORR) - Percentage of Participants With Objective Response [Part 1]
NCT02954653 (9) [back to overview]	Number of Participants With Dose-Limiting Toxicities (DLTs) [Part 1]
NCT02954653 (9) [back to overview]	Duration of Objective Response Rate (ORR) [Part 1]
NCT02954653 (9) [back to overview]	Number of Participants With Hematology Laboratory Abnormalities by Type and Maximum National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE) Grade [Part 1]
NCT02954653 (9) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (AEs) by Maximum National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE) Grade [Part 1]
NCT02954653 (9) [back to overview]	Incidence of Anti-Drug Antibodies (ADA) Against PF-06747143 [Part 1]
NCT02954653 (9) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) [Part 1]
NCT02957968 (7) [back to overview]	Evaluation of Myeloid-derived Suppressor Cells (MDSC) Identified in Blood Samples Post-pembrolizumab Compared to MDSC Found in Blood Samples Collected at Baseline.
NCT02957968 (7) [back to overview]	Evaluation of Myeloid-derived Suppressor Cells (MDSC) Identified in Blood Samples Post-decitabine Compared to MDSC Found in Blood Samples Collected at Baseline.
NCT02957968 (7) [back to overview]	Evaluation of Expression of Protein Programmed Death-Ligand 1 (PD-L1) Within Tumor, Stroma, and Infiltrating Immune Cells Combined, at Baseline and Following Immunotherapy.
NCT02957968 (7) [back to overview]	Number of Patients With Pathologic Complete Response (pCR) in the Breast and Post-therapy Lymph Nodes.
NCT02957968 (7) [back to overview]	Number of Patients Meeting Criteria for Lymphocyte-predominant Breast Cancer (LPBC) Following Treatment With Decitabine and Pembrolizumab
NCT02957968 (7) [back to overview]	Number of Adverse Events (AEs) Reported During and After Immune Treatment (ie, Decitabine and Pembrolizumab)
NCT02957968 (7) [back to overview]	The Percentage of Increase in Tumor and Stroma With Infiltrating Lymphocytes (TIL) From Baseline Pre-treatment Biopsy to Post-immunotherapy Biopsy Following Administration of Decitabine Followed by Pembrolizumab.
NCT02996474 (6) [back to overview]	Overall Survival
NCT02996474 (6) [back to overview]	Median Duration (Days) of Response From Initial Achievement of Response to Loss of Response (mCR, mCRi, CR, CRi, PR, or SD)
NCT02996474 (6) [back to overview]	Median Duration (Days) of Best Response From Initial Achievement of Best Response to Loss of Best Response (by the Order of mCR, mCRi, CR, CRi, PR, or SD)
NCT02996474 (6) [back to overview]	Median Days to Best Response From Start of Study to Initial Achievement of Best Response (by the Order of mCR, mCRi, CR, CRi, PR, or SD)
NCT02996474 (6) [back to overview]	Median Days to First Response From Start of Study to Initial Achievement of First Response (mCR, mCRi, CR, CRi, PR, or SD)
NCT02996474 (6) [back to overview]	Feasibility of a Novel Combination of Pembrolizumab and Decitabine in Relapsed/Refractory Acute Myeloid Leukemia Participants
NCT03063203 (13) [back to overview]	Response Compared Between Patients With Presence of Cytogenetic Abnormalities in Addition to TP53 Mutations Versus Patients With Absence of Cytogenetic Abnormalities in Addition to TP53 Mutations
NCT03063203 (13) [back to overview]	Survival Compared Between Patients With Morphologically Evident Disease Versus Patients With Molecularly Detected Disease at the Time of Enrollment
NCT03063203 (13) [back to overview]	Survival Compared Between Patients With Presence of Cytogenetic Abnormalities in Addition to TP53 Mutations Versus Patients With Absence of Cytogenetic Abnormalities in Addition to TP53 Mutations
NCT03063203 (13) [back to overview]	Time to Stem Cell Transplant Among Participants Who Are Suitable Candidates for Transplant and Have an Identified Donor
NCT03063203 (13) [back to overview]	Event-free Survival (EFS)
NCT03063203 (13) [back to overview]	Response Compared Between Patients With de Novo AML Versus Patients With Secondary AML Versus Patients With Treatment-related AML
NCT03063203 (13) [back to overview]	Response Compared Between Patients With Morphologically Evident Disease Versus Patients With Molecularly Detected Disease at the Time of Enrollment
NCT03063203 (13) [back to overview]	Percentage of Responding TP53 Mutated Patients (CR, CRi)
NCT03063203 (13) [back to overview]	Overall Survival of Participants With TP53 Mutation
NCT03063203 (13) [back to overview]	Median Time to Leukemia Relapse (TTLR) in Non-transplant Patients
NCT03063203 (13) [back to overview]	Median Number of Hospital Stays
NCT03063203 (13) [back to overview]	Average Number of Hospital Days
NCT03063203 (13) [back to overview]	Survival Compared Between Patients With de Novo AML Versus Patients With Secondary AML Versus Patients With Treatment-related AML
NCT03233724 (5) [back to overview]	Overall Response Rate
NCT03233724 (5) [back to overview]	Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)
NCT03233724 (5) [back to overview]	Number of Participants With a Dose Limiting Hematologic Toxicity (DLT)
NCT03233724 (5) [back to overview]	Maximum Tolerated Dose (MTD) of Tetrahydrouridine
NCT03233724 (5) [back to overview]	Maximum Tolerated Dose (MTD) of Decitabine
NCT03303339 (13) [back to overview]	Phase 2: Number of Participants Who Achieved a Complete Response (CR)
NCT03303339 (13) [back to overview]	Pharmacokinetic Parameter: Time to Reach the Maximum Observed Plasma Concentration (Tmax) for Onvansertib
NCT03303339 (13) [back to overview]	Number of Participants With Change From Baseline in Eastern Co-operative Oncology Group (ECOG) Performance Status
NCT03303339 (13) [back to overview]	Number of Participants Who Experienced Dose Limiting Toxicities (DLT)
NCT03303339 (13) [back to overview]	Phase 2: Overall Survival (OS)
NCT03303339 (13) [back to overview]	Number of Participants With Adverse Events (AEs)
NCT03303339 (13) [back to overview]	Pharmacokinetic Parameter: Area Under the Curve Over the First 24 Hours AUC(0-24) for Onvansertib
NCT03303339 (13) [back to overview]	Pharmacokinetic Parameter: Maximum Observed Plasma Concentration (Cmax) for Onvansertib
NCT03303339 (13) [back to overview]	Pharmacokinetic Parameter: Plasma Terminal Elimination Half-life (t1/2) for Onvansertib
NCT03303339 (13) [back to overview]	Phase 2: Number of Participants With Partial Response (PR)
NCT03303339 (13) [back to overview]	Phase 2: Number of Participants Who Achieved a Morphologic Leukemia-free (MLF) State
NCT03303339 (13) [back to overview]	Phase 2: Event-free Survival (EFS)
NCT03303339 (13) [back to overview]	Phase 2: Duration of Response (DOR)
NCT03593915 (1) [back to overview]	Number of Participants With Adverse Events and Serious Adverse Events
NCT03941964 (4) [back to overview]	Percentage of Participants With Post-baseline Transfusion Independence
NCT03941964 (4) [back to overview]	Percentage of Participants With Complete Remission or Complete Remission With Incomplete Blood Count Recovery (CR + CRi)
NCT03941964 (4) [back to overview]	Percentage of Participants With Complete Remission (CR)
NCT03941964 (4) [back to overview]	Percentage of Participants With Complete Remission With Incomplete Blood Count Recovery (CRi)
NCT04055844 (12) [back to overview]	Relapse
NCT04055844 (12) [back to overview]	Progression Free Survival (PFS)
NCT04055844 (12) [back to overview]	Progression Free Survival (PFS)
NCT04055844 (12) [back to overview]	Percentage of Participants With Grade II-IV Acute Graft-versus-host Disease (aGVHD II-IV)
NCT04055844 (12) [back to overview]	Non-Relapse Mortality (NRM)
NCT04055844 (12) [back to overview]	Relapse
NCT04055844 (12) [back to overview]	Non-Relapse Mortality (NRM)
NCT04055844 (12) [back to overview]	Efficacy of Combined Modality Treatment (Ruxolitinib, Decitabine, and DLI) for Relapsed AML or MDS Post Allo-HCT: Rate of Overall Survival (OS)
NCT04055844 (12) [back to overview]	Efficacy of Combined Modality Treatment (Ruxolitinib, Decitabine, and DLI) for Relapsed AML or MDS Post Allo-HCT: Rate of Overall Survival (OS)
NCT04055844 (12) [back to overview]	Complete Remission (CR)
NCT04055844 (12) [back to overview]	Complete Remission (CR)
NCT04055844 (12) [back to overview]	Best Response
NCT04146038 (2) [back to overview]	Number of Participants With Complete or Partial Response
NCT04146038 (2) [back to overview]	Number of Participants Experiencing Adverse Events Incidence With of Salicylate + Venetoclax + Decitabine

Participant Responses

Objective responses by International Working Group criteria: 'Complete Response' (CR) defined as Normalization of the peripheral blood and bone marrow with <5% bone marrow blasts, a peripheral blood granulocyte count > (1.0 x 109/ L, and a platelet count > 100 x 109/L); 'Other Response' including Partial Remission (PR) defined as above, except for the presence of 6-15% marrow blasts, or 50% reduction if <15% at start of treatment combined with participants who meet all criteria for CR except for platelet recovery to >100 x 109/L; and 'No Response'. (NCT00067808)
Timeframe: Response to treatment after 8 weeks of therapy

Intervention	Participants (Number)
	Complete Response	Other Response	No Response
Decitabine 10 mg/m2 IV	4	6	7
Decitabine 20 mg/m2 IV	47	21	25
Decitabine 20 mg/m2 SQ	4	4	6

Intervention	percentage of participants (Number)
	Grade 1, Nausea	Grade 1, Fatigue	Grade 1, Oral Mucositis	Grade 1, Pharyngolaryngeal pain	Grade 1, Decreased white blood cell	Grade 2, Fatigue	Grade 2, Decreased white blood cell	Grade 2, Neutrophil count decreased	Grade 2, Lymphocyte count decreased	Grade 3, Decreased white blood cell	Grade 3, Neutrophil count decreased	Grade 3, Febrile neutropenia	Grade 3, Infections	Grade 3, respiratory disorders	Grade 4, Decreased white blood cell	Grade 5
Treatment	42	33	25	25	25	25	25	16	16	42	25	8	8	8	58	0

Intervention	Participants (Number)
	Overall Improvement	Complete Remission (CR)	Marrow Complete Remission (mCR)	Partial Remission (PR)	Hematologic Improvement (HI)
Decitabine 20 mg/m2 Intravenous	51	17	16	0	18

Intervention	months (Median)
Cytarabine or Supportive Care	5.0
Dacogen (Decitabine) Only	7.7

Intervention	percentage of participants (Number)
Cytarabine or Supportive Care	7.8
Dacogen (Decitabine) Only	17.8

Intervention	Participants (Number)
Romiplostim (AMG 531) Placebo Plus Azacitidine	1
Romiplostim (AMG 531) 500 mcg Plus Azacitidine	1
Romiplostim (AMG 531) 750 mcg Plus Azacitidine	0
Romiplostim (AMG 531) Placebo Plus Decitabine	0
Romiplostim (AMG 531) 750 mcg Plus Decitabine	0

Intervention	Percentage of Participants (Number)
	Complete Remission (CR)	Complete Remission Without Platelet Recovery (CRi)	Partial Remission (PD)
Decitabine	22	6	0
Decitabine + Valproic Acid	29	9	1

Intervention	percentage of participants (Number)
Refractory or Relapsed AML, Concurrent	7.1
Refractory or Relapsed AML, Sequential	0.0

Intervention	percentage of participants (Number)
Untreated AML or Intermediate, Concurrent	35.0
Untreated AML or Intermediate, Sequential	13.6

Intervention	participants (Number)
Concurrent, Vorinostat 400mg qd x 7d/4wk + Decitabine	0
Concurrent, Vorinostat 400mg qd x 7d/2wk + Decitabine	0
Concurrent, Vorinostat 400mg qd x 14d/4wk + Decitabine (MTD)	0
Sequential, Vorinostat 400mg qd x 7d/4wk + Decitabine	0
Sequential, Vorinostat 400mg qd x 10d/4wk + Decitabine	0
Sequential, Vorinostat 400mg qd x 14d/4wk + Decitabine (MTD)	1

Intervention	delta delta CT values (Median)
	Expression levels of MiR-29b	Expression levels of DNMT3a
Non Responder	0.0024305	0.000341819
Responders	0.0056394	0.000196066

Intervention	Percentage of Participants (Number)
	Overall Improvement Rate	Complete Response	Marrow Complete Response	Partial Response	Hematologic Improvement
Schedule A: SQ 3 Consecutive Days	23.3	16.3	0	0	7.0
Schedule B: SQ Once Every 7 Days	22.7	0	4.5	4.5	13.6

Intervention	participants (Number)
	Anemia	Platelet count decreased	Neutrophil count decreased	Leukopenia	Alkaline Phosphatase Increased	Ascites	Clostridial Infection	Hyperglycemia
Decitabine	3	1	2	1	1	1	1	1

Intervention	percentage of participants (Number)
	Fatigue	Febrile neutropenia	Diarrhea	Nausea
Level 1-Phase II (All Patients Enrolled)	88	76	75	69

Intervention	percentage of participants (Number)
Dose Level 1:DAC (Decitabine) 0.075 mg/kg + TMZ (Temozolomide)	0
Dose Level 2:DAC (Decitabine) 0.15 mg/kg + TMZ (Temozolomide)	17

Intervention	Percentage of participants (Number)
	Cycle 1: HI-E	Cycle 1: HI-P	Cycle 1: HI-N	Cycle 2: HI-E	Cycle 2: HI-P	Cycle 2: HI-N	Cycle 3: HI-E	Cycle 3: HI-P	Cycle 3: HI-N	Cycle 4: HI-E	Cycle 4: HI-P	Cycle 4: HI-N	Cycle 5: HI-E	Cycle 5: HI-P	Cycle 5: HI-N	Cycle 6: HI-E	Cycle 6: HI-P	Cycle 6: HI-N	Cycle 7: HI-E	Cycle 7: HI-P	Cycle 7: HI-N	Cycle 8: HI-E	Cycle 8: HI-P	Cycle 8: HI-N	End of treatment: HI-E	End of treatment: HI-P	End of treatment: HI-N
Decitabine	5.9	8.8	2.9	17.2	27.6	6.9	28.6	39.3	17.9	37.0	33.3	7.4	40.9	40.9	13.6	52.4	61.9	19.1	47.1	52.9	5.9	43.8	56.3	12.5	27.6	34.5	6.9

Intervention	Unit on a scale (Mean)
	Baseline, Q29	Baseline, Q30	End of treatment, Q29	End of treatment, Q30
Decitabine	4.4	4.9	4.3	4.5

Intervention	Percentage of participants (Number)
	Cycle 2, Complete Response (n=18)	Cycle 2, Partial Response (n=18)	Cycle 4, Complete Response (n=20)	Cycle 4, Partial Response (n=20)	Cycle 6, Complete Response (n=11)	Cycle 6, Partial Response (n=11)	Cycle 8, Complete Response (n=6)	Cycle 8, Partial Response (n=6)	End of treatment, Complete Response (n=17)	End of treatment, Partial Response (n=17)
Decitabine	22.2	0.0	20.0	25.0	18.2	27.3	0.0	0.0	11.8	5.9

Intervention	Events (Number)
	Infection	Transfusion	Acute choleycystitis	Allergic transfusion reaction	Dyspnoea with right pleural effusion	Febrile neutropenia	Fever	For Decitabine	MDS hematuria	Paronychia, pneumonia, heart failure	PAA,pancytopenia,fluctuated neutropenia fever	Right dorsal foot cellulitis	Rt Lw lung pneumonia with impending resp. failure	SAE+Schedule hospitalization for Decitabine	Septic shock	Not available
Decitabine	10	4	1	1	4	16	4	33	2	1	1	1	1	4	1	36

Intervention	Days (Mean)
	Cycle 1 (n=37)	Cycle 2 (n=30)	Cycle 3 (n=28)	Cycle 4 (n=28)	Cycle 5 (n=22)	Cycle 6 (n=21)	Cycle 7 (n=17)	Cycle 8 (n=16)
Decitabine	9.0	15.4	13.3	27.1	22.5	7.5	33.3	5.0

Intervention	Months (Median)
	Overall Survival	Overall Survival among Responders ((n=86)
Clofarabine + Cytarabine + Decitabine	11.1	21.1

decitabine

Cross-References

Synonyms (125)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Drug Classes (1)

Pathways (3)

Protein Targets (30)

Potency Measurements

Inhibition Measurements

Biological Processes (209)

Molecular Functions (72)

Ceullar Components (44)

Bioassays (101)

Research

Studies (3,733)

Market Indicators

Research Demand Index: 67.14

Study Types

Clinical Trials (399)

Trial Overview

Trial Outcomes

Participant Responses

Frequency of Adverse Events According to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0

Restoration of Radioiodine Uptake in Metastatic Lesions as Demonstrated by Diagnostic Whole-body Scanning After Decitabine Administration

Incidence of Toxicities, Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v3.0

CD34+ Cells

CXCR4

CD34+ Cells

Response Rate (Complete Response, Partial Response, or Hematologic Improvement.

CXCR4

Hemoglobin F

Hemoglobin F

Hemoglobin F

CD34+ Cells

Hemoglobin F

Hemoglobin F

Hemoglobin F

CD34+ Cells

CXCR4

CXCR4

CXCR4

CXCR4

CD34+ Cells

CD34+ Cells

Overall Response

Best Response and Overall Improvement

Number of Participants Who Achieved Overall Response

Overall Survival in Patients 65 Years or Older Who Have Newly Diagnosed de Novo or Secondary AML.

Percentage of Participants With Complete Remission (CR) Plus Complete Remission With Incomplete Platelet Recovery (CRp)

Hypomethylating Agent Dose Reduction and Delay Due to Thrombocytopenia

Occurrence of a Clinically Significant Thrombocytopenic Event

Platelet Transfusion

Achieving an Overall Response (Complete or Partial Response, CR or PR) at the End of the Treatment Period

Complete Response = Morphologic Complete Remission (mCR)

Number of Participants With Relapse-Free Response at 1 Year

Response Duration

Participant Response Rates to Decitabine With or Without Valproic Acid in MDS and AML

Overall Survival Rate

Number of Participants Who Completed Maintenance Decitabine.

Disease-free Survival (DFS) Rate at 1 Year

Phase I: Maximum Tolerated Dose (MTD) for Use in Phase II

Phase II: Percent of Patients With Objective Response, CA125 Response or Stable Disease > 3 Months

Phase II: Progression Free Survival

Phase II: Percent of Patients With Objective Response

Objective Response Rate in Participants Treated With Vorinostat + Decitabine With Refractory or Relapse Acute Myelogenous Leukemia (AML)

Objective Response Rate in Participants Treated With Vorinostat + Decitabine With Intermediate-high Risk Myelodysplastic Syndrome (MDS) or Untreated Acute Myelogenous Leukemia (AML)

Number of Participants Experiencing Dose Limiting Toxicity (DLT) Events

Rate of Complete Remission

Measurement of DNMT Protein in Peripheral Blood or Bone Marrow Cells

The Overall Improvement Rate

Number of Patients With an Unacceptable Toxicity

Intervention	Participants (Number)
	CR	CRp/CRi
Induction Clofarabine + Cytarabine + Decitabine	60	9
Re-Induction	12	4

Intervention	ng/mL (Mean)
	Day 1	Day 5
Phase I: 15 mg/m2	151.7	142.0
Phase I: 20 mg/m2	166.4	190.6

Intervention	ng*h/mL (Mean)
	AUC Last - Day 1	AUC Last - Day 5	AUC Infinity - Day 1	AUC Infinity - Day 5
Phase I: 15 mg/m2	149.0	136.0	150.0	136.9
Phase I: 20 mg/m2	155.2	152.0	156.1	151.2

Intervention	Participants (Number)
	Major/Complete	Minor/Partial	No response	Not estimable
Phase II: 20 mg/m2	6	1	10	3

Intervention	Participants (Count of Participants)
	Progressive Disease (PD)	Stable Disease (SD)
Phase II:Decitabine 0.2 mg/kg +Panobinostat 30mg +Temozolomide	12	5

Intervention	Participants (Count of Participants)
	Cohort 1: Experienced DLT	Cohort 2: Experienced DLT	Cohort 3: Experienced DLT	Cohort 4: Experienced DLT
Phase I Dose Escalation	0	0	0	0

Intervention	participants (Number)
	complete cytogenetic remission	partial cytogenetic remission	no cytogenetic remission
Arm I: Decitabine 0.2mg/kg	5	2	4

Intervention	participants (Number)
	Hematologic Improvement	Complete Remission	Partial Remission	Stable Disease	Disease Progression
Arm I: Decitabine 0.2mg/kg	7	4	0	9	5

Intervention	days (Median)
Treatment A: Decitabine + Induction Chemotherapy	43.0
Treatment B: Induction Chemotherapy Only	37.0

Intervention	days (Median)
Treatment A: Decitabine + Induction Chemotherapy	26.0
Treatment B: Induction Chemotherapy Only	18.0